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 Gene therapy has become an important strategy to treat several human diseases, 
including cancer, viral infections and inherited disorders. In response to this growing trend, a 
number of gene delivery vectors have been manufactured both to facilitate nucleic acid 
uptake by target cells and also to promote the transport of genetic materials into the nucleus. 
The success of gene therapy however depends on the efficient delivery of therapeutic genes 
into target cells both in vitro and in vivo. Cationic liposomes represent a class of non-viral 
vectors that have shown the ability to bind and deliver DNA cargo to defective cells 
efficiently. This study has focused on the development of a novel folate-targeted cationic 
liposome-mediated gene delivery system. This receptor is overexpressed on numerous cancer 
cell types and offers a convenient docking point for subsequent cellular uptake of folate 
decorated liposome-DNA complexes by receptor mediation.  
 
 In this study, a total of six cationic liposome preparations comprising either cationic 
cholesterol cytofectin N,N-dimethylpropylamidosuccinylcholesterylformylhydrazide (MSO9) 
or  3β[N(N1,N1-dimethlaminopropylsuccinamidoethane)-carbamoyl]-cholesterol (SGO4) 
were formulated by mixing the fusogenic neutral helper lipid, 
dioleoylphosphatidylethanolamine (DOPE) as a common constituent. DSPE-PEG2000 was 
also used in formulations for possible in vivo development of PEGylated, targeted liposomes. 
The targeting ligand folate was appended to the distal end of liposome-anchored DSPE-
PEG2000, for prominent display and optimal receptor recognition. 
 
 Transmission electron micrographs revealed liposomes to be unilamellar, spherical 
shaped vesicles with a narrow size range (50 - 80 nm in diameter). Agarose gel retardation 
studies demonstrated complex formation between cationic liposomes and plasmid DNA, 
whilst serum nuclease protection assays showed that the liposome formulations were capable 
of protecting the complexed DNA in lipoplexes against serum nuclease digestion. Ethidium 
bromide dye displacement studies yielded information on the compaction or condensation 
efficacy of the liposomes with respect to the cargo plasmid. In addition, particle sizes 
determined by dynamic light scattering confirmed the suitability of lipoplexes for future in 
vivo applications in which extravasation is essential. Importantly, these liposome:DNA 
complexes were found to exhibit minimal growth inhibition levels in HEK293, HeLa and KB 




complexes in the folate receptor-positive cell lines (HeLa and KB). The plasmid containing 
the transgene firefly luciferase (pCMV-luc) was used in transfection studies. Results showed 
that folate targeted liposomes, irrespective of cytofectins MSO9 or SGO4 achieved highest 
transfection activities in vitro, specifically via receptor mediation. Lower transfection activity 
was observed for by untargeted PEGylated and unPEGylated liposomes compared to that of 
the folate targeted liposomes, strongly implicating folate receptor-mediation in the uptake of 
ligand-displaying lipoplexes. This was further confirmed by flow cytometry analysis. 
Furthermore, zeta potential values obtained for targeted complexes revealed low negative 
surface charge, thus minimizing the possibility of electrostatic interaction between lipoplexes 
and target cells. The cytofectin, MSO9, achieved 10 fold greater transfection activity than the 
cytofectin SGO4 although they are closely related, differing only in their spacer lengths. 
Competition assays using free folate (200 µM) to confirm folate receptor mediated lipoplex 
uptake in the HeLa, and KB cells revealed a dramatic decline in transfection activity due to 
the excess free folate binding to and blocking access to the folate receptors on the cell 
membrane. The two novel PEGylated lipoplexes designed for folate receptor-mediated 
uptake by transformed mammalian cells display very favourable physicochemical 
characteristics, low cytotoxicity and promising transfection profiles in vitro. Therefore further 
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1. Gene Therapy - Principle 
Gene therapy presents a unique approach to medicine as it can be adapted for the 
treatment of both genetic and acquired diseases such as cancer, cardiovascular diseases, AIDS, 
neurodegenerative disorders (Lasic, 1997) and urological diseases (Goins et al., 2009). Gene 
delivery depends upon the binding or encapsulation of a gene of interest, which is then 
preferably delivered to target cells. After uptake, the DNA has to be released into the cell so that 
transcription and translation may take place to afford the protein of interest. To accomplish 
effective gene delivery, a number of barriers must be overcome at every step of this process in 
order to enhance gene activity. Although the objectives and principles of gene therapy have been 
well-defined over the last decades, its application as a versatile, therapeutically efficacious 
approach has not yet met all expectations. Nowadays, it is clear that gene therapy may not only 
lead to its key goal of supplanting a deficient gene, but it could also lead to a modulation of the 
expression of genes acting on the physiology of malicious cells (Swartz et al., 2012). Moreover, 
by means of gene therapy, new functions might be integrated into cells, hence serving a 
therapeutic purpose (Hughes, 2005). Thus in a modern concept and broader sense, gene therapy 
addresses the potential use of nucleic acids, which includes plasmid DNA, antisense 
oligonucleotides  siRNA or miRNA, to modify the expression of genes in cells for therapeutic 
purposes (Cornford et al., 2009). 
 
The ‘naked’ plasmid DNA is unstable under in vivo circumstances due to rapid 
degradation by serum nucleases. Therefore, improvement of the stability of gene delivery vectors 
plays an important role in gene therapy. Carriers or ‘vectors’ are essential to provide effective 
DNA condensation and to protect the DNA or RNA from degradation and finally facilitating 
their uptake into specific cells (Luo et al., 2000; Lechardeur et al., 2005). 
 
The primary challenge for gene therapy is to develop a method that delivers a therapeutic 




Gene delivery may be affected by viral and non-viral procedures. An ideal gene delivery vector 
needs to meet three major criteria: (i) it should protect the transgene against degradation by 
nucleases in the blood system and intercellular matrices, (ii) it should transport the transgene 
safely across the plasma membrane and into the nucleus of target cells, and (iii) it should have no 
detrimental effects to the cells.  
 
1.1. Gene Therapy Approaches  
 Gene therapy can be accomplished ex vivo or in vivo. In ex vivo gene therapy, cells are 
removed from the host organism, inoculated with the therapeutic gene and then reintroduced into 
the organism (Antonio et al.; 2006). With the recent advances in this field, DNA can be easily 
injected directly into the nucleus while siRNA is transferred to the cytoplasm (Yoichi et al., 
2008; Atul et al., 2009). The ability to specifically deliver nucleic acids to the desired cell is 
clearly gainful. However, this method is not without limitations. Only cells that can be removed 
and efficiently reintroduced in a functional way can be preserved using ex vivo gene therapy. To 
date, nearly all ex vivo gene therapy studies address diseases of the circulatory system 
(Cavazzana-Calvo et al., 2000; Youngren et al., 2013). Due to the nature of ex vivo gene therapy, 
most diseases cannot be treated in this way.  
 
 In contrast, in vivo gene therapy involves treatment of cells in their natural environment, 
in a living organism, and is applicable to nearly all diseases. Nucleic acids (most frequently 
complexed to a vector) are administered either topically, by direct injection into a tissue, or by 
systemic intravenous injection (Amiji, 2005). The nucleic acids must then effectively reach the 
desired cells by crossing the cell membrane, and upon reaching the desired cellular compartment, 
effectively unpack from the vector before they can exhibit a therapeutic effect. Although this 
method of gene therapy is broadly applicable and therapeutic nucleic acids have been established 
and tested, the lack of a safe and efficient delivery vector has limited in vivo gene therapy 
successes. 
 
1.2. Gene Therapy in Cancer  
Cancer gene therapy is the best studied application of gene therapy. During the past two 




which were in the area of cancer treatment (Breyer et al., 2001; Yang et al., 2011; Li et al., 
2013). The transformation of normal cells into neoplastic ones involves multiple alterations at 
their genetic level (Bertram, 2000). Due to the complex nature of cancer, cancer gene therapy 
includes many therapeutic approaches, which fall into two main groups (Figure 1.1).  
 
Cancer Gene Therapy













Figure 1.1: Molecular and immunologic therapies. 
 
Up regulation or down regulation of some genes is the basis of tumour initiation and 
progression. Oncogenes and tumour suppressor genes are two gene groups that counter-balance 
each other and play a key role in cancer development. While tumour suppressor genes prompt 
apoptosis (programmed cell death), oncogenes enhance cell proliferation. The biological activity 
of oncogenes can be modulated and suppressed using anti-oncogenes, such as oligonucleotides, 
that can bind to a precise sequence of the RNA (antisense oligonucleotides) or the DNA 
(antigene oligonucleotides). The main representative of the tumour suppressor gene family is the 
p53 gene which is responsible for detection of DNA damage followed by repair initiation or 
apoptosis induction (Wynand and Bernd, 2006). As mutational alterations in the p53 gene occur 
in almost 40% of all tumours, successful transfection of p53 into cancerous cells can result in 




and gene therapy is another molecular approach in cancer gene therapy. This strategy relies on 
the conversion of a non-toxic prodrug into its active cytotoxic metabolite within cancerous cells. 
 
The conversion is facilitated by non-mammalian enzymes which are overexpressed in 
neoplastic cells as a result of effective transfection with their genes. Other molecular approaches 
in cancer gene therapy are, inhibition of angiogenic inducers (vascular endothelial growth factor 
and angiopoietine), introduction of angiogenic inhibitors (angiostatin, endostatin) or transferring 
of multiple drug resistance genes and thereby overcoming the dose limiting toxicity of traditional 
chemotherapy (El-Aneed, 2004).  
 
Cancer cells are immunogenic in nature, with cancer antigens being intracellular 
molecules. However regular immune response is not enough to destroy tumour cells. The 
capability of cancer cells to escape the resistant system is associated with the secretion of 
immunosuppressive factors, down-regulation of antigen expression or major histocompatibility 
complex molecules and the deficiency of co-stimulation. Genetic immunotherapy can be 
employed mainly to boost T-cell mediated immune response against cancer. The most frequently 
used approach to do so, involves the transfer of the genes of immune stimulant molecules such as 
cytokines and more specifically interleukin-12 (Barajas et al., 2001). The production of 
interleukin-12 by tumour cells facilitates the immune response by the activation of many 
components in the immune system, in particular cytotoxic T lymphocytes and natural killer cells. 
An alternative method to induce the desired immune reaction against cancer cells is direct 
genetic vaccination by antigen encoding genes. Injected intravenously or intramuscularly, the 
DNA enters the local cells (fibroblasts, myocytes) which then produce and secrete the antigen. 
Antigen presenting cells capture the new antigen and migrate to lymphoid organs, initiating the 
desired immune response. Cell vaccines on the other hand are produced by in vitro engineering 
of antigen presenting cells in a way that enables them to actively present tumour antigens. The 
success of gene therapy largely depends on the efficiency of delivery of the DNA to its target 
cell/tissue. The therapeutic gene of interest must form stable complexes with vector of choice 
(viral or non-viral), be relatively non-toxic to the cells and be efficient in gene transfer and 





1.3. Gene Transfer Vectors – An Overview 
Since the sequencing of the human genome use of gene products as a medicine for 
inherited and acquired diseases has gained importance in biomedical research. The ‘Human 
genome project’ has provided a vast amount of information about the human genome and at the 
same time predicted a plethora of genes with therapeutic potential (Taylor et al., 2010). Yet, 
mere identification and isolation of the therapeutic gene need not necessarily lead to successful 
gene therapy. Reliable delivery of the genetic material into eukaryotic cells followed by suitable 
expression of the desired gene is a bottleneck for gene transfer even in in vitro systems (van Gaal 
et al., 2011). Delivery is even more problematic in vivo where targeting and safety of the gene 
vectors, as well as prompt elimination from circulation present additional challenges for 
successful gene transfer. Accordingly, intensive research efforts have focused on creating safe, 
efficient, and reliable strategies to convey nucleic acids into eukaryotic cells (Amiji, 2005; Lee et 
al., 2005).  
 
1.3.1. Bacterial Gene Delivery Systems 
The use of bacteria as gene transfer vectors has been exploited in tumour gene therapy. 
The hypoxic microenvironment in tumours can facilitate colonization by anaerobic bacteria 
(Theys et al., 2001). Auxotrophic bacteria have also been tested in vitro, but require tumour-
specific nutrition factors for their replication (Li et al., 2001). To confirm the maximum safety 
with these therapeutic bacterial vectors the transgene expression should be as specific as 
possible. One approach to reach this safety level is the use of a radiation induced promoter and 
thereby exploiting the natural conflict to irradiation. The therapeutic gene that is under control of 
the radiation-inducible promoter is only expressed in bacteria that colonize irradiated tissues 
(Nuyts et al., 2001). 
 
1.3.2. Viral Gene Delivery Carriers 
Viruses are the most effective gene delivery vectors known today due to their capacity to 
transfer and protect foreign genes, cross the cellular membrane, escape endosomes, and to 
achieve efficient gene expression (Walther, 2000). Due to their natural ability to infect cells 
efficiently in terms of the number of transfected cells, several viruses, such as retroviruses, 




viral facilitated gene delivery. For example, retroviral vectors can introduce genes permanently 
into somatic cells by integration into the cell's chromosomal DNA. Retroviruses only infect 
replicating cells, though the resultant permanent integration of therapeutic genes minimizes the 
ability to modify or to terminate therapy in response to any contrary side effects or to cure the 
disease. In addition, the permanent integration of genes into host chromosomes may result in 
activation of oncogenes or inactivation of tumour suppressor genes (Arnold and Anna, 2010). In 
contrast, adenoviruses efficiently infect non-dividing cells and do not integrate genes into the 
host genome (Forde et al., 2015; Tomlinson, 1996; Young et al., 2006). Different mechanisms 
exist for the interaction of viruses with cells, depending on the type of virus. The protein capsid 
of a virus is able to bind to proteins in the cellular membrane, gain entry by internalization, and 
recycle its membrane proteins. Other viruses have a protein-lipid capsid that can fuse and enable 
the virus to pass through the cell membrane (Amir et al., 2011). Viruses have inherent 
mechanisms to avoid lysosomal trafficking, by promoting the fusion of the viral envelope with 
the endosomal membrane and therefore, causing the release of the virus into the cytoplasm (Sun 
and Zhang, 2010). These unique abilities of viruses led to the first clinical trial in gene therapy in 
1990, where retroviral vectors were used to introduce the adenosine deaminase gene into the 
white blood cells of patients suffering from severe combined immunodeficiency (SCID) 
(Tomlinson, 1996; Te-Lang and Dongming, 2011). Viral vectors are able to mediate gene 
transfer with high efficiency of up to 90% with the possibility of long term as well as stable gene 
expression, satisfying two out of three criteria described above. However, acute immune 
response, immunogenicity, and insertional mutagenesis especially after repeated applications in 
clinical trials have raised serious safety concerns about some commonly used viral vectors. 
 
1.3.3. Non-Viral Gene Delivery 
The development of a safe and efficient non-viral gene delivery system remains a hurdle 
toward the successful application of gene therapy to treat human disease (Rettig and Rice, 2007). 
Although viral delivery systems are much more efficient in the delivery of genetic material, there 
are concerns regarding toxicity, high costs of producing therapeutic doses, immunogenicity and 
possible integration of viral genetic material into the human genome (Mancheno-Corvo, 2006). 
Chemically defined non-viral vectors can potentially avoid these drawbacks of viral delivery and 




discovery of RNA interference has expanded the scope of gene therapy to include applications 
for knocking down or otherwise modulating gene expression (Julian et al., 2012). Protein 
regulation by RNAs and antigen expression by DNA vaccines are two additional applications of 
gene therapy that hold great promise if the delivery of oligonucleotides to nucleus can be 
successfully achieved. 
 
Non-viral vector systems, including cationic lipids, polymers, dendrimers, and peptides, 
all offer potential routes for compacting DNA for systemic delivery. However, unlike viral 
analogues that have an evolved means to overcome cellular barriers and immune defense 
mechanisms, non-viral gene carriers consistently exhibit significantly reduced transfection 
efficiency as they are hindered by numerous extra and intracellular obstacles (Liu et al., 2011). 
However, biocompatibility and potential for large scale production makes these compounds 
increasingly attractive for gene therapy (Meredith and Eric, 2009). As a result, a significant 
amount of research in the past decade has focused on designing cationic compounds that can 
form complexes with DNA and can avoid both in vitro and in vivo barriers for gene delivery 
(Meredith et al., 2009).  
 
1.3.3.1.  Non-Viral Physical Gene Delivery Methods 
Several physical methods have been developed to enhance DNA delivery efficiency, 
including electroporation, pressurized intravascular delivery, sonoporation, laser irradiation, and 
magnetofection (Mehier-Humbert et al., 2005a; Mehier-Humbert and Guy, 2005b). 
Electroporation increases the permeability of cell membranes to plasmid DNA by exposing the 
target cells to a series of electrical pulses. Pressurized intravascular delivery has been used to 
successfully transfect cells in a variety of tissue types including liver and skeletal muscle. 
Sonoporation, which usually involves the use of a low-dose ultrasound or laser irradiation leads 
to transient formation of small pores in the cell membrane, enhancing permeability to the nucleic 
acid. Magnetofection involves the application of a magnetic field to enhance the uptake of 
plasmid DNA coupled with magnetic nanoparticles. Most of these physical methods enhance the 
entry of DNA into cells by overcoming barriers posed by the cell membrane, but are often 
associated with significant cytotoxicity. Furthermore, the challenges associated with intracellular 




1.3.3.2. Cationic Polymers 
Cationic polymers have a common chemical characteristic, a polyamine, which is 
positively charged at physiological pH due to its high pKa. These positive charges are 
neutralized upon condensation of DNA into the appropriate form for cellular uptake. The use of 
cationic polymers for gene transfer was pioneered with the use of poly-L- Lysine (PLL) and it is 
still widely investigated as conjugates with targeting ligands and other functional peptides 
(Kerbel and Hawley., 1995; Lakshmi and Cato, 2007; Trinchieri, 2003; Taylor, 1982; 
Vandercappellen et al., 2008). 
 
However, a number of substantial limitations of PLL based systems are difficult to 
overcome, which has led to the search of alternative cationic polymers. These include 
polyethyleneimine (PEI), chitosan, poly (2-dimethylamino) ethyl methacrylate (pDMAEMA), 
polyamidoamine (pAMAM) dendrimer, poly [α-(4-aminobutyl)-L-glycolic acid] (PAGA). In 
particular, PEI is the most efficient polymeric gene delivery carrier due to its buffering effect in 
the endosome compartment, and presents as a possible alternative to cationic liposomes despite 
its rigid structure and high tendency for aggregation (Defu et al., 2013; Raugi and Lovett, 1987).  
 
1.3.3.2.1.  PEI 
Polyethylenimine (PEI) is a stable, easy to handle, inexpensive cationic polymer 
(Lungwitz et al., 2005). It has gained significant attention as a non-viral gene delivery system 
through condensation of DNA into compact particles, uptake into the cells, release from the 
endosomal compartment into the cytoplasm, and uptake of the DNA into the nucleus (Kircheis 
et al., 2001). PEI mediated gene delivery is based on the electrostatic interactions of the 
polycation with the negatively charged phosphate groups of DNA. The DNA condensation is 
therefore a function of the cation-to-anion ratio, i.e. the PEI nitrogen-to-DNA phosphate (N/P) 
ratio. Condensation protects the DNA from degradation by nucleases, and the compact particles 
can be taken up by cells via natural processes such as adsorptive endocytosis, pinocytosis and 
phagocytosis (Forrest et al., 2004). The complexation and condensation performance is 
dependent on several polymer characteristics, such as molecular weight, number and charge 
density, in addition to the composition of the complexes, e.g. the ratio of polymer to DNA. The 




hydrodynamic diameter, surface charges and the stability of the PEI: DNA complexes may be 
important factors to be considered to achieve a higher transfection efficiency of the polycation 
vectors.  
 
 1.3.3.2.2.   pAMAM dendrimer 
The polyamidoamine (pAMAM) dendrimers with extremely branched spherical 
structures were tested as gene delivery carriers, but initially low/poor gene transfection activities 
were achieved with these vectors. pAMAM dendrimers were developed further to improve 
stability at physiological pH. They have shown good transfection efficiency in vitro (Christine et 
al., 2005; Rak et al., 1996). In recent in vivo studies, a pAMAM dendrimer was coupled with the 
Epstein Barr virus (EBV) based plasmid vector and investigated for its potential to deliver the 
herpes simplex virus thymidine kinase (HSV-tk) suicide gene into Ewing's sarcoma bearing mice 
(Yin et al., 2012). The EBV/dendrimer system significantly suppressed tumour growth and 
prolonged the survival of mice. 
 
1.3.3.2.3. Chitosan 
Chitosan is a natural cationic polysaccharide, consisting of D-glucosamine and N-acetyl-
D-glycosamine. Chitosan is nontoxic and biodegradable, and is therefore a good candidate for a 
non-viral gene delivery vector. In particular, chitosan:DNA complexes were reported to be 
efficient in transfecting intestinal epithelial cells, most likely due to the nucleo adhesive 
properties of chitosan. In a recent study, oral administration of the chitosanyl dominant peanut 
allergen gene (pCMV-Arah2) complexes, substantially reduced the peanut antigen induced 
murine anaphylatic responses, which was associated with reduced levels of plasma histidine, IgE 
and vascular leakage (Folkman, 2007; Leong, 2004). 
 
1.3.3.2.4. pDMAEMA 
Poly (2-dimethylamino)ethyl methacrylate (pDMAEMA) is a water soluble cationic 
polymer containing tertiary amine groups. Like those of PEI, these tertiary amines act as a proton 
sponge in the acidic endosome compartment, inducing the osmotic swelling and endosome 
rupture (Sutapa et al., 2011). This endosomolytic property of pDMAEMA resulted in high 




pDMAEMA/DNA complexes were found to be quite stable in physiological buffer solution over 
a period of ten months (Car et al., 2014). 
 
1.3.3.2.5. PAGA 
Unlike other synthetic cationic polymers, poly[α-(4-aminobutyl)-L-glycolic acid] 
(PAGA), a biodegradable analogue of PLL, is rapidly degraded in aqueous solution to give L-
Oxylysine as a final product (Marie et al., 2008). PAGA is being studied as a cytokine gene 
delivery carrier for the treatment of diabetes and cancer. When PAGA interleukin-10 gene 
complexes were systemically administrated into NOD mice, the insulitis was markedly reduced, 
compared to the use of the naked gene (Gasparini and Harris, 1995). Also PAGA was found to 
efficiently delivery another cytokine gene encoding interleukin-12 into subcutaneous tumour 
bearing mice significantly reducing the tumour growth (Ellis and Fidler, 1995; Maheshwari et 
al., 2002). 
 
1.3.3.3. Cationic Peptides 
Cationic peptides employed for gene transfer are amphiphilic peptides which can undergo 
conformational changes in acidic environments, escaping the endosomal/lysosomal pathways. 
They contain the positively charged amino acids (histidine, lysine and/or arginine) such that they 
can effectively condense DNA. The helical KALA peptide (derived from the influenza HA-2 
subunit, which enables the virus to infuse into the cell membrane) is one of the early cationic 
peptides used successfully for gene delivery in cultured cells (Hongtao et al., 2010). In spite of 
the cationic amino acids of lysine (7 AA) present in the KALA peptide (30 AA), it was 
corroborated that the arginine residues with 4 cationic amino acids in another α-helical peptide 
(16 AA residues) were enough to condense DNA and deliver it to the cytoplasm (Bhawna  et al., 
2005). The efficiency of the peptide vector also depends upon the hydrophobic portion that plays 
a major role in aggregation and endosomal escape (Haines et al., 2001; Raj et al., 2012). The 
relationship between peptide aggregation and efficient gene delivery is not well understood. 
DNA release into the cytoplasm can also be enhanced by the introduction of cysteine moieties 
into the peptide backbone, resulting in the formation of reducible disulphide bonds within the 




the delivery complex. As with other vector systems receptor mediated gene transfer can be 
achieved through ligand attachment (Niidome et al., 2000). 
 
              Peptide gene carriers have been mainly explored in vitro (Kim et al., 2003; Eric et al., 
2008). Their in vivo behaviour is still under investigation. Recently successful transfection in the 
lungs using a peptide vector was obtained after intravenous administration into mice. It was, 
however, 10–40 folds less efficient than liposomes and PEI vectors (Rittner et al., 2002; Baoum 
et al., 2012; Letoha et al., 2013). 
 
1.3.3.4. Cationic Lipids 
Cationic lipids are especially attractive as they can be easily prepared and extensively 
characterized. Further, each of their constituent parts can be modified, thereby facilitating the 
elucidation of structure-activity relationships. A great number and an impressive variety of 
synthetic vectors have been prepared and their transfection efficiency evaluated not only in 
experimental studies, but also in clinical trials for treatment of diseases such as cancer (Montier 
et al., 2008; Roth and Cristiano, 1997) and cystic fibrosis (Martin et al., 2005; Michael et al., 
2001). To date although some positive results have been attained, the overall outcome indicates a 
need for further research (Niidome and Huang, 2002; Parvizi et al., 2013; Tagalakis et al., 2013). 
There are possible correlations between the length, saturation, type of hydrophobic moiety and 
transfection efficiency. Intracellular DNA release strategies that can be triggered as a function of 
the incorporation of cellular environmentally sensitive groups (pH, redox and enzyme sensitive) 
within the linker moiety are also under investigation. 
 
The length and type of the aliphatic chains incorporated into cationic lipids significantly 
affect their transfection efficiency. Vectors are often prepared in a series differing in their 
hydrophobic domain. The hydrophobic domain has also been functionally modified by the 
inclusion of highly fluorinated alkyl chains which are both hydrophobic and lipophobic, a 
characteristic which may better protect the lipoplex from unwanted interactions. At first, a series 
of closely related fluorinated analogues of DOGS (with either both chains fluorinated to varying 




prepared in order to chart the effect of the hydrophobic/lipophobic balance on the transfection 
efficiency (Vierling et al., 2001).  
 
A cationic lipid is a positively charged amphiphile, which generally contains the 
following structural domains: i) a hydrophilic head group which is positively charged, usually 
via the protonation of one (monovalent lipid) or several (multivalent lipid) amino groups; ii) a 
hydrophobic portion composed of a steroid or of alkyl chains (saturated or unsaturated); iii) a 
linker (connecting the cationic head group with the hydrophobic anchor) whose nature and 
length may impact on the stability and the bio-degradability of the vector; and iv) spacer (Figure 
1.2). Modifications of the hydrophobic domain have shown that optimal vector structure is often 
dependent on this moiety, which can fall into various structural classes and variants. Finally, 
labile linkers have been introduced which are sensitive to various biological stimuli, inducing 
DNA release at defined time points during the intracellular trafficking of the lipoplex (Hasegawa 





































































1.3.3.4.1. Cationic Head groups in Liposomal Formulations 
DNA binding by the vector requires a head group which is capable of sustaining a 
positive charge at physiological pH. The charge is most often located on amino groups, as was 
the case for the ‘early’ vectors. The vast majority of cationic lipids for gene delivery rely on the 
charge accommodated on a nitrogen atom, as there appears to be a relationship between the 
hydration of such mono-ammonium head groups and the transfection activity. In essence, the 
greater the imbalance between the cross sectional area of the head group (small end) and the 
hydrophobic moiety (large end) i.e., the more cone shaped the cationic lipid and the more 
unstable the resulting lipid assembly. Hence there is a greater likelihood of undergoing fusion 
with anionic vesicles. Lipoplex instability is presumed to result in improved transfection, as 
fusion, between the cationic lipoplex and the endosomal membrane leads to DNA release into 
the cytoplasm (Xu and Szoka, 1996; Joanna et al., 2004; Gao and Huang, 1995).  
 
1.3.3.4.1.1. Multivalent Head Groups 
As multivalent cationic lipids may form liposomes with a greater surface charge density 
than their monovalent counterparts, they are generally expected to be better at DNA binding and 
delivery. One such approach was the incorporation of natural polyamines e.g. spermidine and 
spermine that have the ability to interact with the inner groove of B-DNA (Schmid and Behr, 
1991). Triaminespermidine in cholesteryl spermidine (Zonghua et al., 2010), and 
tetraaminespermine in the lipid DOGS (Behr, 1993) are early representative examples. The 
presence of protonation sites with different pKa values in DOGS may actually result in buffering 
of the endosomal acidification, thereby protecting the DNA from degradation and facilitating its 
escape from the endosome. The results suggested that the tetra methylene portion of spermine 
might be able to bridge between the complementary strands of DNA, whereas a polyamine with 
a trimethylene central spacer would only interact with adjacent phosphate groups on the same 
DNA strand. As these branched structures have the advantage of avoiding the folding problems 
of linear polyamine chains, they can include additional protonation sites without affecting DNA 
binding. Importantly, with more protonation sites per molecule, the resulting lipoplexes can thus 
achieve the same charge density with lesser amounts of the cationic lipid in the formulation. This 
may lessen the drawback of cationic lipid associated cytotoxicity. Indeed, as cationic lipids may 




expression and acceptable toxicity need to be found (Darya et al., 2009; Sunil et al., 2004; 
Loeffler and Behr, 1993). 
 
The hydrophobic and hydrophilic moieties of cationic lipids are commonly linked using 
carbamate, amide, ester or ether bonds. The linker bond mediates the stability of the cationic 
amphiphile. Although no particular bond emerges as consistently optimal in structure-activity 
studies across different vector types, ether linked vectors seem to be more stable (Ghosh et al., 
2000). However they are more toxic than ester linked lipids which may also be more easily 
cleaved within the cell (Bora et al., 2012). Carbamates are thought to achieve a reasonable 
balance between stability and toxicity and are therefore more frequently used (Gao and Huang, 
1991). 
 
1.3.3.4.2. Cationic Lipid Mediated Gene Transfection - Basic Principles 
Cationic lipids were first introduced by Felgner et al., (1987), following early attempts to 
transfer DNA via encapsulation in liposomes (Nicolau and Sene, 1982; Pezzoli and Candiani, 
2013). Thus, the first reported lipid was DOTMA, which consists of a quaternary amine 
connected to two unsaturated aliphatic hydrocarbon chains via ether groups. Synthesis of the 
multivalent lipopolyamine DOGS was reported soon afterwards (Osama et al., 2006) and DC-
Chol (3-(N-(N’, N’-dimethylaminoethyl)carbamoyl)cholesterol) with cholesterol as the 
hydrophobic portion closely following (Gao and Huang, 1991). The transfection activity of 
cationic lipids (especially those which cannot form bilayers alone) can be increased by their 
formulation as stable liposomes with the neutral co-lipid DOPE. Inclusion of DOPE is presumed 
to enhance endosomal escape of the lipoplexes into the cytoplasm as DOPE is thought to have 
fusogenic properties important for endosomal membrane disruption (Vidal and Hoekstra, 1995). 
The use of these initial lipids demonstrated the transfection ability of cationic lipids. However, 
this ‘proof of principle’ stage has been followed by a highly challenging period. Indeed, progress 
in improving the level of transfection efficiency up to that required for therapeutic use has been 
slow. This is possibly linked to an unclear structure-activity relationship in vector design, and to 
the related incomplete understanding of the highly complex series of steps involved in 
transfection. Thus, the development of novel lipids is justified, a novel cationic lipid being not 




steps. Accordingly, numerous novel vectors were developed, representing a wide variety in 
structures and thus numerous potential mechanisms by which better transfection levels might be 
obtained. 
 
1.3.3.4.3. Lipids in Liposome Formulations 
1.3.3.4.3.1. Phospholipids (PLs) 
Phospholipids (PLs) classically found in high amounts in cell membranes of living 
matter, are important components in liposome formulations. PLs comprises of two fatty acids 
connected to a polar head group, with either glycerol (Figure 1.3) or sphingomyelin as the back 
bone. PLs are amphipathic molecules, and have both hydrophobic and hydrophilic groups. The 
two hydrocarbon chains constitute the hydrophobic tails, while the phosphate group and its polar 
attachment constitute the hydrophilic group (Cooper and Hausman, 2009). PLs can consist of 
different head and tail groups that affect the surface charge and bilayer permeability of liposomes 
















Saturated fatty acid, e.g. myristic acid
Unsaturated fatty acid, e.g. Oleic acid
 
Figure 1.3: Structure of a glycerophospholipid. 
 
Phosphatidylcholine (PC) is a common phospholipid employed in liposomes, and can be 
obtained from both natural and synthetic sources. PC is zwitterionic and consists of a hydrophilic 
head group with a quaternary ammonium moiety choline, which is linked to a glycerol via a 
phosphoric ester (Brandl, 2001). 
 
The rigidity of the liposome membrane depends on the packing of the hydrocarbon 
chains of the lipid molecules. The hydrocarbon chain length and degree of saturation of the acyl 




transforms from a fully extended and closely packed ‘gel phase’ to a liquid crystalline disordered 
‘fluid phase’. In general, fluid membranes are more permeable to solutes than rigid bilayers 
(Brandl, 2001). 
 
The charge of the lipid used in liposome formulation dictates the surface charge of the 
liposomes. The surface charge of liposomes can be designed by replacing phosphatidylcholine 
(PC) partly with negatively or positively charged phospholipids, which induces electrostatic 
repulsion and stabilization against liposome fusion (Ogihara et al., 2010). The surface features of 
liposomes may also be restructured by modifying lipids with hydrophilic moieties e.g. 
polyethylene glycol (PEG), to membrane bilayers (Brandl, 2001). 
 
1.3.3.4.3.2. Cholesterol (Chol) and Other Lipids 
Cholesterol (Chol) is also commonly used in liposome formulations, and its incorporation 
into the lipid bilayer has a major influence on the liposome properties. The presence of Chol in 
the lipid bilayer enhances its stability and leads to the formation of highly ordered rigid 
membranes with fluid like characteristics (Lee and Lee, 2005). 
 
The molecular structure of cholesterol (Figure 1.4) with the four hydrocarbon rings 
reveals its strongly hydrophobic character. The presence of the hydroxyl group (OH) attached to 
position 3 makes that part of the molecule weakly hydrophilic (Cooper and Hausman, 2009). 
Chol can be incorporated into lipid bilayers at concentrations of up to 50 mole %, without 
forming a bilayer on its own. Due to its amphipathic properties, Chol inserts itself into the 
bilayer with its OH-group orientated towards the aqueous environment, and the rigid 













Figure 1.4: General structure of cholesterol (Chol). 
 
1,2-Di-oleyl-3-trimethyl-ammonium-propane (DOTAP) is another example of a lipid 
used in liposome formation. DOTAP is a cationic lipid with two unsaturated fatty acyl chains. It 








Figure 1.5: General structure of DOTAP.  
 
1.3.3.4.4. Classification of Liposomes 
Classifications of liposomes can be based upon their size and lamellarity or charge. 
Different sizes of liposomes depend on their composition and their method of 
preparation. Liposomes based on size can be categorized into three main types. 
 Small unilamellar vesicles (SUVs) are vesicles consisting of a single bilayer, and can 




administration compared to multilamellar vesicles (MLVs) because of their size 
homogeneity. Their small size results in lower amount of encapsulation of hydrophilic 
drugs. 
 Large unilamellar vesicles (LUVs) are vesicles with size in the order of 100 nm, 
consisting of one single lamella. They can entrap a higher amount of hydrophilic drugs 
due to their larger aqueous core compared to SUVs (Perrie et al., 2010). 
 MLVs: These are vesicles having a size range from 100 nm to several micrometers, 
depending on the method of preparation. They consist of a large number of concentric 
lamella. Due to their lamellarity they are more suited for the incorporation of lipophilic 
molecules compared to hydrophilic substances. 
  
Liposomes are generally classified according to their charge; 
 
1.3.3.4.5. Cationic Liposomes 
The positive charge on the liposomal surface ensures their binding to the negatively 
charged cellular membranes. Cationic liposomes react spontaneously with the negatively 
charged DNA molecules (self-assembling system), forming complexes with almost all DNA 
molecules participating in the reaction. It has been shown that two processes are involved in the 
complex formation. A fast exothermic process, attributed to the electrostatic binding of DNA to 
the liposome surface. A subsequent slower endothermic reaction which is likely to be due to the 
fusion of the two components and their rearrangement into a new structure (Pector et al., 2000). 
Incorporation of small amounts of anionic lipid into liposomes leads to DNA association with 
the inner surface of the liposomal membrane, which protects DNA against enzymatic 
degradation (Zhdanov et al., 2002).  
 
1.3.3.4.6. Anionic and Neutral Liposomes 
Due to the toxicity issues of the early cationic lipids, there has been exploration into the 
feasibility of anionic or zwitterionic lipids as potentially safe nucleic acid delivery vectors 
(Mozafari and Omri, 2007). The nucleic acid entrapment and delivery efficiency with these 
lipids on their own, however, is debatable due to the absence of complexation-enhancing 




negatively charged and the lipids are either anionic or neutral in nature. Therefore, such delivery 
systems require a third moiety to achieve intense association to form lipoplexes. Foged et al., 
(2007) attempted preparing siRNA associated anionic liposomes without utilizing a bridging 
agent. Consequently, the prepared formulations showed poor encapsulation efficiency (7–9 %) 
with no activity in HeLa cells. Halder et al., (2006) prepared neutral liposome (DOPC) 
associated lipoplexes that indicated efficient knockdown of the focal adhesion kinase gene in an 
ovarian tumour mice model. The tumour growth inhibition was observed for 4 days with overall 
reduction in tumour weight by 72 %. Although in this case, neutral liposomes were efficient, 
there may be potential issues with their long-term colloidal stability due to the absence of the 
repulsive forces between the particles. 
 
1.3.3.4.7. Production of Liposomes 
As liposomes are formed by the spontaneous interaction between phospholipids and 
water (with agitation of some form – Torchilin, 2007), the importance when producing 
liposomes lies in the ability to form vesicles of the right size and structure with the highest 
entrapment efficiency (New, 1990). A wide variety of methods have been employed to produce 
liposomes which include mechanical dispersion techniques, dried-reconstituted vesicles, and 
solvent dispersion techniques (ethanol/ether injection vesicles and reverse phase evaporation 
vesicles). Most methods of producing liposomes can be said to consist of three stages, which 
include the drying down of lipids from organic solvents, dispersion of the lipids in aqueous 
media and subsequent purification of the resultant liposomes.  
  
1.3.3.4.7.1. Thin Film Hydration 
The thin film hydration method involves using a lipid solution in an organic solvent such 
as chloroform. The lipid solution is then subjected to rotary evaporation to remove the solvent 
and produce a thin lipid film deposited on the side of the flask. Any residual solvent can then be 
removed by drying the film under a stream of nitrogen. The film is then rehydrated with an 
aqueous buffer that is above the Tm of the lipid mixture. The flask is then agitated through hand 
shaking (sometimes glass beads are used) and/or vortexing, which displaces the thin film from 
the walls of the flask causing the production of liposomes. The liposomal suspension produced 




that includes sonication and extrusion can then be completed to produce a more homogenous 
formulation with a specific size range (SUVs, LUVs etc) (Sriram and Rhodes, 1995). 
 
1.3.3.4.7.2. Sonicated Vesicles 
To produce a homogenous SUV liposomal sample, it is necessary to use a method which 
imparts energy at a high level on the lipid suspension (New, 1990). Initially, Huang, (1969) 
produced SUVs with an approximate diameter of 25 nm by using a probe sonication method 
whilst Schroeder et al., (2009) produced similar SUVs using an ultrasonic bath for a prolonged 
period of time (1–1.5 h). 
 
Probe sonication can be used when suspensions require high energy in a small volume 
e.g. high concentration of lipid or the use of a viscous aqueous phase. As a consequence of this 
process, heat is given off and therefore it is essential that the suspension is maintained at a 
constant temperature by the use of a cooling bath to prevent any lipid degradation. A further 
issue that may arise through probe sonication is the possible contamination of the sample through 
the degradation of the probe, suspending Ti particles within the sample. Subsequent 
centrifugation or gel permeation chromatography can be used to separate any small MLVs that 
remain in the SUV population.  
 
The ultrasonic bath method is more suitable to dilute lipid concentrations of a higher 
volume and as there is a lower energy input, there is subsequently a lower risk of lipid 
degradation due to heat. The risk of contaminants entering the solution is reduced as the 
formulation can be maintained in a sealed container throughout the sonication process. The main 
drawbacks of the bath sonication method include the need for prolonged sonication time and the 
final liposome size may not be entirely homogenous. Thus there may be a requirement for 
centrifugation (Samad et al., 2007). 
 
1.3.3.4.7.3. Membrane Extrusion 
The use of membrane filters to reduce the size of liposomes has been investigated 
extensively with two main methods having evolved. The first method uses what is described as a 




which leads to specific channels through which liposomes are forced. The channel or pore size is 
controlled by the density of the fibers used in the membrane manufacture. The drawback of this 
method is that larger liposomes can become stuck within the membrane channels and this 
therefore blocks the filter. The more widely used method is that of the nucleopore membrane 
which consists of uniform pores through a thin sheet of polymer. A variety of membranes can be 
obtained, with pore sizes ranging from 50 μm to 10-3 µm. Liposomes which exceed the 
membrane pore size will be broken down into smaller vesicles when extruded through the 
membrane. The liposomes which are only marginally larger than the pore size may be able to 
change their conformation and squeeze through the pore. Hence, despite a number of extrusions 
a small percentage of the liposomes will be larger than the pore size itself (Takeuchi et al., 2001, 
2005). 
 
1.3.3.4.8. The Role of Liposome/Lipoplex Size 
The rate of the opsonisation and clearance of injected liposomes from the blood 
circulation by the reticulo endothelial system (RES) is dependent on the composition and size of 
the complexes (Silva et al., 2014). The RES is part of the immune system and its main function 
is to eliminate foreign materials from the body (Kevin and Helen, 2007; Perrie and Rades, 2010). 
The RES is made up of cells such as blood monocytes and Kupffer cells, reticular cells (lymph 
node, bone marrow, and spleen). Shortly after intravenous injection, liposomes become coated 
by serum proteins called opsonins. Once they are opsonised, they will rapidly be phagocyted by 
the RES cells, but a major component of the injected liposomes will accumulate in the liver and 
spleen (Maurer et al., 2001). 
 
Generally large liposomes (>200 nm in diameter) are rapidly opsonised and taken up by 
the RES, and disappear from the blood circulation within a short period, primarily ending up in 
the spleen. Opsonisation decreases with a decrease in liposome size. Small liposomes have a 
relatively larger surface area, and will have a lower density of opsonins on the membrane surface 
which results in lower uptake by macrophages (Younsoo et al., 2005). Liposomes with a size of 
70 to 200 nm will have a greater chance to escape from the RES and remain in the circulation 
longer enabling them to reach their target. Due to extravasations through the fenestrated capillary 




structure and architecture of the blood capillary walls vary in different organs and tissues. There 
are structural differences between healthy and tumour capillaries, and blood supply to the organs 
and tissues is somewhat different (Brandl, 2001). 
 
1.3.3.4.9. The Role of Surface Charge and Membrane Characteristics 
The organization of lipids in the liposome membrane plays a major role in the physical 
membrane properties such as permeability, elasticity, surface charge, binding properties of 
proteins, and is as important as liposome size in their clearance (Sok et al., 2012).. 
 
Neutrally-charged liposomes with tightly packed membranes tend to remain longer in the 
circulation and exhibit increased drug retention, compared to charged systems. Protein 
opsonisation onto the liposome surface is reduced due to the tightly packed and rigid membrane. 
The presence of Chol liposome formulations may change the packing of the phospholipids to a 
more stably ordered and rigid membrane which may avoid drug leakage. Moreover, this could 
also reduce binding of opsonins on the liposomes and improve stability and retention of 
liposomes in vivo (Dan et al., 2007). Certain plasma proteins have an affinity for liposomes, 
which is enhanced if the liposome is charged. In particular, cationic systems are expected to 
quickly interact with various components in systemic circulation, resulting in a shorter half-life 
in vivo (Maeda et al., 2009). It is also known that anionic liposomes containing negatively-
charged lipids such as phosphatidylserine (PS), phosphatidic acid (PA) and phosphatidylglycerol 
(PG) are quickly taken up by macrophages and thus disappear from the circulation within a short 
time (Ichihara et al., 2014; Massing and Fuxius, 2000). 
 
1.3.3.4.10. Long Circulating/Stealth Liposomes 
In order to avoid rapid clearance by the RES after intravenous injection and to enable 
liposomes to remain in circulation for prolonged periods, the attachment of polyethylene glycol 
(PEG) on the liposome surface has been employed. PEG is a ‘hydrophilic’ polymer varying in 
molecular weight depending on the number of monomer repeat units. The polymer creates a 
steric barrier with the flexible chains forming ‘mushroom’ (an array of macromolecular chains 
attached to a surface or tethered polymers) which extends out from the surface (Figure 1.6), 




commonly known as ‘stealth liposomes’, and have good solubility properties in aqueous media 
(Torchilin, 2007 & 2012). PEG is non-biodegradable; it does not form any metabolites, has a 
very low toxicity profile and does not accumulate in the RES (Perrie and Rades, 2010). 
 
 




1.3.3.4.11. Cationic Liposome:DNA interaction 
The first step in the preparation of vector/DNA aggregates suitable for gene transfer is the 
condensation of the DNA, which is driven by an electrostatic interaction between the cationic 
liposome and the polyanionic DNA (Banerjee et al., 2004). Spontaneous self-assembly into 
nanometer scale particles (lipoplexes, nanobioparticles) result, leading to shielding of the DNA 
from the nucleases of the extracellular medium. Use of an excess of cationic amphiphile 
(quantified by the lipid/DNA ratio resulting in a mean theoretical charge ratio of the lipoplex (+/-
) gives the lipoplex surface a positive charge, which is presumed to mediate subsequent cellular 
uptake by interaction with negative cell surface structures such as heparin sulphate (Zhi et al., 
2010). As a result of non-specific endocytosis, the lipoplex is encapsulated in intracellular 
vesicles, although fusion based cellular uptake is not totally excluded. The DNA must then avoid 
degradation in the late endosome/lysosome compartment by escaping from the (early) endosome 
into the cytoplasm (Sahay et al., 2010). Trafficking of the DNA through the cytoplasm precedes 
uptake by the nucleus of the target cell, followed by transgene expression (Figure 1.7). In the 




suggested that gene expression does not occur if the DNA remains condensed in lipoplexes (Al-
Dosari and Gao, 2009). The efficiency of cationic lipids for gene transfection can be evaluated in 
terms of gene delivery (percentage of transfected cells) or gene expression (amount of transgene 
protein produced). The efficiency of any transfection reagent also strongly depends on the cell 
system chosen for its evaluation (transformed cell lines or primary cells in vitro, in vivo 
administration) (Kiefer et al., 2004). Efficiency gains in vitro do not automatically lead to higher 
efficiencies in vivo. To determine the relative efficiency of compared cationic lipids is crucial, 
and so quantifying the efficiency of cationic lipid systems needs to take into account their 





Figure 1.7: Representation of cellular delivery of DNA with surfactant vectors. Cellular internalization is 
     an important step in gene delivery. As shown, internalization is achieved   here through        










1.4. Targeted Gene Delivery 
1.4.1. Active vs Passive Targeting 
The term passive targeting is usually defined as a method to deliver drugs based on the 
ability of the drug carrier to circulate for longer times in the blood stream and accumulate in 
pathological tissues. ‘Active targeting’ is also called ligand based targeting, which is based on 
the ligand-receptor recognition enabling the binding of ligand-conjugated carriers to the target 
tissues. In the case of cancer therapy, the delivery of gene materials with non-targeted agents 
(passive targeting) is achieved mainly by the enhanced permeability and retention (EPR) effect 
(Figure 1.8). The endothelial cells of tumour neo-vasculature are poorly organized with large 
fenestrations, causing macromolecules to leak extensively into the tumour tissue. Additionally, 
macromolecules are retained easily in the tumours because of the low venous return in the 
tumour and poor lymphatic clearance (Cabral et al., 2011). This preferential accumulation 
through the EPR effect is the so-called ‘passive targeting’, which is characteristic of non-targeted 
agents. On the other hand, active targeting describes the active binding of the drug or gene 
delivery vectors to the cell surface through receptor-mediated endocytosis, facilitating the 
retention and cellular uptake (Figure 1.9). The introduction of targeting ligands should enhance 
the tissue, cell, or sub-cellular specific delivery efficiency through active targeting, when 
compared to its corresponding non-targeted counterpart agents. To achieve the cell specific 
active targeting, several ligand based systems have been designed to target specific cancer cells 
(Shi et al., 2011). This is particularly important for intracellular delivery to facilitate bioactivity.  
 
            The successful targeting requires at first the identification of the structures on the cell 
surface which could provide a selective uptake into the cell. Secondly, for active targeting, gene 
delivery agents are coupled with a ligand which is expected to interact with a specific target on 
the cell surface (Merkel et al., 2011). Folate as a ligand has been used as a targeting moiety for 
lung tissue (Brannon-Peppas and Blanchette, 2012). The pulmonary epithelium is a key point of 
the administration of bio-macromolecules and could prove to be an attractive approach for local 















                          
 
Figure 1.9: Passive vs active targeting. (A) Non-targeted NPs (B) The presence of targeting ligands on               
                   the surface of NPs (C) Targeted NPs. Adapted from Farokhzad and Langer, (2009). 
 




1.4.2. Conjugates of Targeting Moieties and Lipids 
Targeted gene delivery systems have attracted great attention due to their potential in 
directing the therapeutic genes to the specific target cells. They may also help minimize adverse 
effects such as cytotoxicity or immune reactions, as well as maximizing the efficacy of the 
therapeutic response. The targeted delivery of the lipoplexes may be achieved through the 
incorporation of targeting moieties (e.g. ligands) into liposomes by direct formulation, with no 
covalent bond to any lipid (Seol et al., 2000); conjugated to the helper lipid (Dauty et al., 2002), 
or connected directly to the cationic lipids (Kawakami et al., 2000a; Gaucheron et al., 2001a). 
For lipoplexes modified with a targeting moiety such as folate (Dauty et al., 2002), galactose 
(Singh et al., 2007; Kawakami et al., 2000a; Gaucheron et al., 2001a), mannose (Kawakami et 
al., 2000b), antibodies (Duan et al., 2008) and transferrin (Seol et al., 2000; Sakaguchi et al., 
2008; Singh and Ariatti, 2006a; Singh et al., 2006b) the uptake can be receptor mediated and 
enhanced (Zhang et al., 2010). 
 
1.4.3. Folic acid, as a Ligand for the Selective Targeting into Tumour Cells 
Targeting of the folate receptor (FR) has received much attention over the years, since the 
folate receptor is a tumour marker that is over expressed in many cancer cells, including cancers 
of the ovary, kidney, uterus, testis, brain and colon. In addition, folic acid is a relatively small 
molecule (MW ∼ 441 Da), and has the advantages of being stable and non-immunogenic 
compared to monoclonal antibodies (Siti et al., 2010), while retaining a relatively high receptor 
affinity. Reddy and co-workers (2002) showed that a folate moiety attached to a lipid membrane 
anchor via a cysteinyl-PEG3400 spacer, greatly increased specific cellular uptake to FR 
overexpressing cancer cells and transfection efficiency compared to the unmodified cationic 
liposome. Recently, Yoshizawa et al., (2008) developed a folate-linked nanoparticle (NP-F), 
composed of cholesteryl-3β-carboxyamidoethylene-N-hydroxyethylamine, Tween 80 and folate-
poly(ethylene glycol)-distearoyl-phosphatidylethanolamine conjugate (F-PEG2000-DSPE), which 
delivered synthetic siRNA with high transfection efficiency and selectivity into nasopharyngeal 






Folic acid (Figure 1.10) is a vitamin essential for one-carbon transfer reactions in several 
metabolic pathways. Folic acid is vital for the biosynthesis of nucleotide bases with the vitamin 
being consumed in higher quantities by dividing cells. Normal cells transport biological folates 
across the plasma membrane using two membrane associated proteins, the reduced folate carrier 
(RFC) or the folate receptor (FR). The RFC is found in almost all cells and establishes the 
primary pathway responsible for uptake of physiological folates. The FR is found predominantly 
on polarized epithelial cells and activated macrophages (Gordon and Martinez, 2010; Martinez et 
al., 2009) and preferentially binds and internalizes oxidized folates via receptor-mediated 
endocytosis (Leamon and Reddy, 2004). Although low concentrations of RFCs are sufficient to 
source the folate requirements of most normal cells, the FR is frequently overexpressed on 
cancer cells, facilitating the malignant cell to compete successfully for the vitamin when supplies 














Figure 1.10: Structure of folic acid. 
  
 In humans, three genes encoding functional folate receptors termed FRα, FRβ, and FRγ 
(also known as FOLR1, FOLR2, and FOLR3, respectively) were identified (Kelemen 2006; 
Gabizon et al., 2004; Gabizon et al., 2006; Gabizon et al., 2010; Gabizon et al., 2012). FRα and 
FRβ are anchored at the plasma membrane via GPI anchor, whereas FRγ is secreted due to the 
lack of a signal sequence for GPI anchor attachment (Lu and Low, 2012; Hala et al., 2009; 
Salazar and Ratnam, 2007). FRα is generally exposed on the apical surface of polarized 




(Kamen and Smith, 2004). FRβ is expressed in normal myelopoiesis, in the placenta, spleen, and 
thymus (Wibowo et al., 2007). FRγ is secreted from lymphoid cells in the spleen, bone marrow 
and thymus. FRα is involved in folate transcytosis in the kidney and transfer into the central 
nervous system (CNS); however, the biological functions of FRβ and FRγ remain unclear. FRβ, 
however, has the ability to deliver folate and folate derived molecules into activated 
macrophages or leukemic cells. Moreover, FR targeted therapies are likely to be effective in the 
treatment of various types of cancer and inflammatory diseases due to high levels of FRα or FRβ 
in disease affecting cells. In particular, FRα is constantly overexpressed in non-mucinous 
adenocarcinomas of ovary, breast, kidney, uterus, cervix, colon, and malignant pleural 
mesothelioma, ependymal brain tumours, testicular choriocarcinoma, and nonfunctioning 
pituitary adenocarcinoma. FRβ expression is increased in certain leukemia, and is most 
commonly seen in acute myelogenous leukemia and chronic myelogenous leukemia as well as in 
activated synovial macrophage cells involved in the pathogenesis of rheumatoid arthritis and 
other inflammatory diseases like Crohn’s disease and psoriasis (Felicia et al., 2005).   
 
 As the FRs aid as markers for diseased cells in cancers and inflammatory disease, the 
development of three different types of FR targeted therapeutics based on antibodies, folate-
conjugates, and anti-folates are being pursued. Monoclonal antibodies against FRα and FRβ can 
promote the clearance of folate receptor positive cells by the immune system. Folate conjugates 
used to deliver cytotoxic cargo or imaging agents or DNA therapeutics to FR positive cells, and 
FR targeted anti-folates would possibly eliminate cytotoxic side effects of current anti-folates 
transported to normal cells via reduced folate carriers (RFC) (Low and Kularatne, 2009).   
 
 While overexpression of FR on many cancer cells recognises the receptor as a potential 
target for a variety of ligand and antibody directed cancer therapeutics (Peer et al., 2007), the FR 
is further qualified as a tumour specific target, since it generally becomes accessible to 
intravenous drugs only after malignant transformation. This is, because the FR is selectively 
expressed on the apical membrane surface of certain epithelial cells, making it inaccessible to 
blood borne substances and thus protected from FR directed therapeutics delivered in plasma. 
Conversely, upon epithelial cell transformation, cell polarity is lost and the FR becomes 




tumour specificity, folic acid has become a popular molecule for targeting therapeutics to cancer 
cells. The desirability of folate was further enhanced by its high binding affinity (Kd∼10−10 M), 
low immunogenicity, ease of modification, small size (MW ∼ 441.4), compatibility with a 
variety of organic and aqueous solvents, low cost, stability during storage, and availability (Park 
et al., 2005). To date, many chemical and biological therapeutic agents have been successfully 
conjugated to folic acid, most of which have shown enhanced delivery to FR-positive tumour 
cells both in in vitro and in vivo (Kamaly et al., 2009).  
 
1.4.3.1. FR Targeted Liposomal Delivery  
 Along with efforts to develop folate conjugated anticancer targeted gene therapy agents, 
progress has been made in the field of folate targeted gene therapy, where both viral (retro and 
adeno) and non-viral (liposomal or polylysine based) vectors have been examined (Li et al., 
2001). As might be expected, when liposomal vectors are used for targeted gene delivery, they 
encounter the same obstacles as drug encapsulating liposomes, including problems such as serum 
stability, tumour penetration, vector internalization, and endosomal escape following tumour cell 
uptake. The solutions to these problems, however, are very different from those for targeted 
liposome encapsulated anti-cancer agents. Firstly, encapsulation of bulky, negatively charged 
polynucleotides require a very different set of components and methods than those used with low 
molecular weight drugs. Secondly, unloading of liposome-entrapped genes following cell surface 
binding and endocytosis requires formation of pores much larger than those needed for escape of 
small molecules. And lastly, genes (unlike many drugs) must gain access to the nucleus before 
their therapeutic activities can be expressed. As a result, folate targeted liposomal vectors must 
also include features that enable transfer of the genetic material from the cytoplasm into the 
nucleus. Unlike low molecular weight drugs which can be encapsulated in liposomes of virtually 
any size, naked DNA is much too bulky to be encapsulated into the small liposomes. This size 
limitation is crucial, as the well characterized routes for particle endocytosis generally have size 
limits of 100-200 nm (Liu et al., 2010). As a result, DNA condensation becomes necessary for its 
delivery into cells through receptor-mediated endocytosis. DNA condensation is generally 
attained by complexation with high molecular weight polycations (polylysine, polyethylenimine, 
and polyamidoamine dendrimers), or liposomes in ratios that can allow retention of the 




found useful for encapsulation of DNA:polylysine particles into folate-targeted anionic 
liposomes (Lu et al., 2012; Medina-Kauwe et al., 2005). The net anionic character of the 
complex has been shown to reduce non-specific binding to mammalian cell surfaces, thereby 
allowing transgene expression to be determined primarily by the distribution of the FR. 
 
 Endosomal escape mechanisms have also contributed significantly to the efficiency of 
folate targeted gene therapy. Unlike cationic liposomes and lipoplexes, which can fuse with most 
plasma membranes and release their contents directly into the cytoplasm, FR-targeted vectors 
enter endosomal compartments from which they must escape for transfection to occur. For this 
purpose, mixtures of DOPE and cholesterol hemisuccinate (CHEMS) have proven useful in 
formulating liposomes that are stable at neutral or basic pH, but fusogenic at acidic or endosomal 
pH values (Khalil et al., 2006). Folate-targeted liposomal vectors constructed from these 
fusogenic components transfect cells in orders of magnitude better than non-fusogenic lipids of 
similar composition. Similarly  the use of a ‘‘caged’’ pH-sensitive lipid, N-citraconyl-
dioleoylphosphatidyl-ethanolamine (CDOPE), that releases its head group at endosomal pH 
values and thereby becomes a fusogenic DOPE, also augments folate mediated gene expression 
(Yoo and Park, 2004). Since an improvement in folate-targeted gene therapy is also seen after 
incorporation of a pH dependent fusogenic peptide into liposomal vectors (Reddy and Low, 
2000), it can be concluded that some type of pH triggered endosomal unloading mechanism must 
be included to enhance the efficiency of folate targeted gene therapy (Xi and Grandis, 2003). 
Finally, incorporation of a nuclear localization sequence into the encapsulated polynucleotide 
can also modestly increase the transfection activity of an FR-directed vector, suggesting that 
facilitated transport of the genetic material from the cytoplasm into the nucleus may also 
contribute to the efficiency of targeted gene therapy (Reddy et al., 1999). 
 
Although some targeted liposomes do not display greater tumour accumulation than non-
targeted liposomes, folate targeted gene therapy vectors have been found to promote much 
higher levels of tumour specific gene expression than non-targeted vectors. Presumably, as noted 
above, the folate derivatization enhances vector internalization, without significantly affecting 
deposition or retention of the large particles in the tumour (Xu et al., 2013). Not only was 




observed to express the gene. Furthermore, systemic delivery of a folate targeted p53 cationic 
gene therapy vector was found to greatly improve the therapeutic efficacy of conventional chemo 
and radio-therapeutic agents against FR-positive human tumour xenografts, yielding complete 
cures of subcutaneous cancers of the breast, prostate, and head and neck where the chemo and 
radio therapeutic agents alone exerted little effect. As expected from studies with other cationic 
liposomes, the major limitation associated with the PEG coating method was proposed where the 
pre-condensed DNA-cationic lipid structure could be protected by a layer of PEG, with folic acid 
at the distal ends of the PEG to facilitate tumour cell targeting (Jennifer and Robert, 2000). 
Leamon et al., (2003) have also observed significantly improved tumour-specific transgene 
expression following derivatization of their liposomal vectors with a PEG–tethered folic acid. 
Not only was tumour expression greatly enhanced, but with one particular vector composition, 
gene expression in other target tissues was either low or absent. Although many variables were 
examined in these latter studies, vector size and charge emerged as the most critical parameters 
to optimize for folate mediated gene expression. 
 
1.5. Receptor Mediated Endocytosis 
 Targeting is usually achieved by conjugating a high affinity ligand to the carrier that 
provides preferential accumulation of the latter for instance, in a tumour bearing organ, in the 
tumour itself, in individual cancer cells or intracellular organelles. The overexpression of 
receptors or antigens in many human cancers lends itself to efficient drug/gene uptake via 
receptor mediated endocytosis (Figure 1.11). Folate and transferrin are widely applied ligands for 
liposome targeting because their cognate receptors are frequently overexpressed in a range of 
tumour cells (Kakudo et al., 2004; Hilgenbrink and Low, 2005). Liposomes tagged with various 
monoclonal antibodies have also been delivered to many targets such as the colon, prostate, brain 
and breast cancer tissues (Park et al., 2001). 
 
 The performance of non-viral vectors could be optimized by targeting them to distinct 
cellular internalization pathways, considering that not every pathway may be equally effective in 
releasing a therapeutic biomolecule in the cytosol. This step is critical for nucleic acid delivery, 
to increase the possibility of nuclear transport and the ultimate expression of the delivered genes 







Figure 1.11: Diagramatic representation of the folate receptor mediated endocytosis pathway. Covalent 
conjugates of drugs, macromolecules, or imaging agents linked to folic acid via the 
vitamin’s g-carboxyl group bind to the folate receptor with equal affinity to free folic acid 
(K/50 DpM). Following endocytosis and vesicular trafficking, much of the material is 
released into the cell cytoplasm. The unbound folate receptor may then recycle to the cell 
surface. Adapted from Wang and Low, (1998). 
  
1.6. In vitro Liposomal Targeting 
 In vitro liposomal targeting is a commonly used method for targeting specific cells as it 
offers more assertion and is also more easily regulated than in the in vivo applications. It can be 
challenging as it needs specialization in culture techniques, as well as requiring a mitotic cell 
population. The in vitro targeting provides the advantages of working with cells in a culture 
environment and liposomes can be effectively delivered to the target cells (Singh, 1998). These 
in vitro methods are very useful for developing and improving techniques in vivo (Poste et al., 
1984).  
 
1.7. In vivo Liposomal Targeting 
 Successful liposomal targeting in vivo is an enviable aim. In vivo, gene transfer requires 




specificity to the tumour tissue, and should only enter cells through selective targeting. The 
therapeutic candidates (drug/DNA) must escape degradation by nucleases and the complex must 
be internalized into the cell for successful unloading of the therapeutic gene/drug. Furthermore, 
the vector must not be toxic to the cells and the DNA should be preserved for transcription and 
eventual expression of the protein (Lesage et al., 2002). However, there are some other obstacles 
that the vector system must overcome for successful in vivo therapeutic transfer into the tumours 
(Nishikawa and Huang, 2001). In the case of systemic administration, the vector complex must 
avoid the reticulo endothelial system (RES) and should be able to escape from circulation with 
minimal interaction with anionic serum proteins. Thereafter, the vector complex should finally 
bind and enter the target cell and deliver the therapeutic material into the cell nucleus. 
Lipoplexes that are injected intravenously are mainly internalized by the spleen, liver, and 
macrophages of the RES (Singh, 1998). 
 
 Accessibility of the ligand-carrying lipoplexes is one of the main obstacles of the specific 
target tissue (Cavallia et al., 2013). Nevertheless, there have been prominent reports on liposome 
mediated targeting in vivo. One of the first in vivo studies carried out by Wu and Wu, (1988) 
showed that the DNA delivery by asialoglycoprotein-poly-L-Lysine conjugate was established in 
mammalian hepatocytes via the asialogylcoprotein receptor. Lonez et al., (2008) also reported 
the use of cationic liposomes into targeted tissues in animals.  
 
1.8. Lipofection – Barriers and Carriers 
In order to be expressed in a eukaryotic cell, foreign DNA has to reach the nucleus where 
the transcription machinery is located. Successful lipofection depends upon overcoming the 
barriers posed by the extracellular environment and intracellular structures (Zuhorn et al., 2002; 
Chou et al., 2011; Atul et al., 2009; Belting et al., 2005). Overcoming these barriers by cunning 
lipoplex design based on lipoplex structure-function relationships is the cornerstone of research 
to enhance lipofection efficiency (Zuhorn et al., 2002; Chesnoy and Huang, 2000; Elouahabi and 
Ruysschaert, 2005). In this section barriers to lipofection as well as structural and functional 






1.8.1.  Extracellular Barriers 
The extracellular environment is hostile to lipofection both in vitro and in vivo. When 
complexed with cationic liposomes DNA is fairly well protected from action of degrading 
enzymes (Sania et al., 2004; Dash et al., 2011) and nucleases (Bhattacharya and Mandal, 1998) 
as it is condensed and enveloped by a lipid layer (Daniel et al., 2005; Vladimir and Klemen, 
2011; Sternberg et al., 1994). However, cell culture medium contains a number of serum 
proteins, e.g. albumin, lipoproteins, and macroglobulins, which could interfere with interaction 
between lipoplexes and cells thus causing reduced transfection (Masottid et al., 2009; Tandia et 
al., 2003). Interaction with serum components prior to encounter with cells has been shown to 
influence lipoplex structure diverting its intracellular processing (Zuhorn et al., 2002). Serum 
effects on lipofection efficiency seem to be dependent on the chemical structure of the cationic 
lipid, liposome formulation, and cationic lipid/DNA ratio of the lipoplexes (Masottid et al., 2009; 
Simberg et al., 2003; Tandia et al., 2005). However a detailed understanding of lipoplex serum 
interactions is yet to be completely elucidated. 
 
The number of in vivo extracellular barriers for liposome mediated transgene delivery is 
multiplied as physiological processes, such as complement activation and the reticulo endothelial 
system rapidly clear lipoplexes from the circulation (Kaul and Amiji, 2005; Dass, 2004). 
Targeting lipoplexes into desired tissues instead of nonspecific transfection in liver or lungs 
(Jafari et al., 2012; Thomas and Klibanov, 2003) presents an additional challenge for in vivo 
lipofection. The most popular strategy to prolong circulation times of lipoplexes and 
simultaneously incorporate targeting molecules onto the surface of the gene delivery complex, 
involves the coating of lipoplexes by lipids with a conjugated PEG moiety (Wanga and Thanou, 
2010; Tam et al., 2000). A major drawback of these "stabilized plasmid-lipid particles" is their 
low transfection efficiency in vitro due to the stabilizing PEG-coating. However, lipofection 
efficiency could be at least partly recovered by introducing a positively charged moiety to the 
distal end of the PEG chain (Chen et al., 2000). 
 
1.8.2. The Plasma Membrane 
The plasma membrane is the main barrier of a eukaryotic cell through which the lipoplex 




driven by a net positive charge of the lipoplex and occurs most likely via electrostatic binding to 
proteoglycans of the external leaflet of plasma membrane (Mislick and Baldeschwieler, 1996; 
Eliyahu et al., 2005; Rehman et al., 2013; Mounkes et al., 1998). Essentially, the cytotoxicity of 
the lipoplex may be related to the charge ratio of the lipoplex and may arise when cationic 
amphiphiles mix with lipids of the cellular membrane (Zuhorn et al., 2002; Dass, 2004). Initially 
it was suggested that internalization of lipoplexes proceeds through direct fusion with the plasma 
membrane (Lechardeur and Lukacs, 2002). Currently, a wealth of data indicates that endocytosis 
is the most vital internalization route for lipoplexes (Rehman et al., 2012; Jones et al., 2013). 
 
More specifically, it has been suggested that small lipoplexes with diameter < 200 nm 
enter cells via clathrin-dependent endocytosis while larger complexes prefer the caveolae-
mediated route (Hoekstra et al., 2007). It has been further shown that the former pathway is the 
one that leads to a more efficient lipofection (Zuhorn et al., 2007). However, considering great 
variability in the chemical structures of cationic lipids and diversity of eukaryotic cells it is likely 
that details of the endocytotic pathway may vary markedly depending on the cell type. 
 
1.8.3. Cytoplasm and Endosomal Escape 
Internalized plasmid DNA has to find its way to the nucleus from the cytoplasm. After 
endocytosis the cargo entrapped in liposomes trafficks to the endosomes and eventually locates 
in the lysosomes whose environment is detrimental for the DNA (Xia and Low, 2010; Torchilin, 
2006). Hence, escape of the DNA from the endosomal compartment is absolutely required for 
successful gene delivery. It has been shown that anionic lipids present in the endosomal 
membranes readily mix with the cationic lipids of lipoplexes resulting in interlipidic ion-pairing 
and subsequent release of nucleic acid from the complex (Walter and Tejraj, 2010; Ikramy et al., 
2006; Zelphati and Szoka, 1996). Moreover, formation of membrane destabilizing hexagonal 
inverted (HII) instead of lamellar (Lα) phases (Figure 1.12) correlates with efficient lipofection 
(Mok and Cullis, 1997; Munoz-Ubeda et al., 2012). Consistent with the above, most efficient 
lipoplex formulations contain HII-phase forming lipids, such as dioleylphosphatidylethanolamine 
(DOPE) (Zuhorn et al., 2007) or diacylglycerol (DAG) (Balazs and Godbey et al., 2011). 
Cationic lipids with effective shape favouring the HII-phase are more effective in lipofection than 






Figure 1.12: Schematic illustration of lamellar Lα (Panel A) and inverted hexagonal HII (Panel B) phases  
          of lipoplexes. Ribbons depict DNA complexed with cationic lipid membrane. Adapted   
          from Koltover et al., (1998). 
 
Endosomal escape is often the result of the destabilizing action of lipids of the lipoplex 
on the endosomal membrane. Interestingly, when mixed in nearly isoelectric stoichiometry, 
pairing of cationic and anionic lipids result in a lamellar to hexagonal phase transition even 
though both of the lipids adopt a lamellar phase in isolation (Lewis and McElhaney, 2000). This 
suggests that mixing of anionic and cationic lipids could induce endosomal membrane 
destabilization by stimulating the HII phase (Hafez et al., 2001). To enhance endosomal escape 
lipoplexes have been designed that disrupt the endosomal membrane and release DNA due to the 
low pH of the endosomes by virtue of pH dependent transitions (Budker et al., 1996; Fielden et 
al., 2001). However, despite promising preliminary results, pH-sensitive lipoplexes have so far 
demonstrated only limited success in lipofection efficiency in practice. 
 
1.8.4. The Nuclear Membrane 
The nuclear membrane is the last and probably the most challenging barrier for 
successful gene expression. Data on nuclear entry of the plasmid DNA is somewhat controversial 
but some basic principles are known. DNA complexed with cationic lipid is not expressed if it is 
directly injected into nucleus thus suggesting that DNA has to be released from lipoplex 
somewhere in the cytoplasm, e.g. after fusion with intracellular membrane structures (Mehier-
Humbert and Guy, 2005; Zhao and Yung, 2008; Sanna et al., 2014). However, the half-life of 




narrow time-window for nuclear entry of the plasmid after dissociation from the lipoplex. A 
close correlation between onset of transgene expression and mitosis in synchronized cell cultures 
has been established (Mortimer et al., 1999; Merdan et al., 2002) revealing fragmentation of the 
nuclear membrane during mitosis to facilitate DNA entry into the nucleus. However, non-
dividing cells can be transfected by lipoplexes albeit with low efficiency indicating that mitosis 
is not absolutely required for nuclear entry (Zuhorn et al., 2002). Injection of highly condensed 
DNA complexed with polyethyleneimine (PEI) into cytoplasm results in efficient transgene 
expression suggesting that properly packed DNA particles can access the nucleus (Zhao and 
Yung 2008; Suh et al., 2003). Furthermore, condensation and subsequent conformational 
changes of DNA induced by cationic liposomes could be significant not only for protection of 
DNA in the extracellular space but also for nuclear entry and transcriptional activity of the 
nucleic acid (Vladimir and Klemen, 2011; Braun et al., 2003; Gelbart et al., 2000; Akao, 1996).  
 
1.9. Advantages of Cationic Liposomes 
 Cationic liposomes which may resemble traditional pharmaceuticals (Hirko et al., 2003; 
Chen and Haung, 2005) shows low immunogenicity (Goncalves et al., 2004). They also contain a 
wide diversity of both hydrophobic and hydrophilic diagnostic or therapeutic agents, provide a 
larger drug payload per particle, protect encapsulated agents from metabolic processes, and allow 
for a high degree of cooperative binding to target cell antigens. The lipid composition of the 
bilayer can be further modified to obtain other desirable properties, including prolonging 
circulatory half-life, the ability to complex with nucleic acids to mediate gene delivery or genetic 
regulation, and the capacity to deliver encapsulated contents to the cytosol through the 
endosome/lysosome pathway (Spragg et al., 1997). Furthermore, enhanced formulations may 
prevent them from being cleared by the complement and repeated administrations in vivo may be 
accomplished without adverse consequences (Templeton, 2002). 
 
1.10. Disadvantages of Cationic Liposomes  
 Disadvantages may include low transfection efficiency and cell toxicity in some cases 
(Torchilin, 2012; Hirko et al., 2003). Another limitation is that cationic liposomes form 
aggregates with serum proteins bearing negative charges (Singh and Ariatti, 2003). Binding of 




intemalisation (Zuhorn and Hoekstra, 2000). This inhibitory consequence of serum on liposome 
mediated gene delivery (lipofection) can be overcome by using lipoplexes with high lipid:DNA 
charge ratios. Nanoparticles of DNA condensed with biocompatible polycations prior to mixing 
with the cationic liposomes have been shown to render the DNA resistant to DNAse activities 
and to enhance the transfection efficiencies of cationic liposomes in various cell lines (Karmali 
and Chaudhuri, 2007). 
 
1.11. OUTLINE OF THESIS          
           The aim of the study was to investigate a novel cationic liposome based approach for 
folate targeted delivery of nucleic acids to human carcinoma cell lines overexpressing the folate 
receptor. 
 
          In this thesis, the in vitro delivery of plasmid DNA complexed to novel cationic liposomes 
prepared with cationic cholesterol cytofectins N, N-dimethylpropylamidosuccinylcholesteryl 
formylhydrazide (MSO9) or 3β[N(N1,N1-dimethylaminopropylsuccinamidoethane)-carbamoyl]-
cholesterol (SGO4), and with the co-lipid DOPE was investigated. Cationic liposomes were also 
coated with poly ethylene glycol (PEG) which is said to provide stealth capability and protects 
liposomes from non-specific opsonization as well as to increase circulation time in the blood 
system in vivo. PEGylated liposomes all contained 2 mole percent PEG. The vitamin, folic acid 
(also known as vitamin B9) was appended to DSPE-PEG2000 and formulated into FR-targeted 
liposomes. All liposome preparations including their lipoplexes were characterized using 
transmission electron microscopy and zeta-sizing. Examination of the ability of cationic 
liposomes to bind and condense the plasmid DNA was carried out by band shift assays using 
agarose gel electrophoresis and ethidium bromide intercalation assays respectively. Nuclease 
protection assays were performed to assess the ability of the cationic liposomes to effectively 
bind and protect the plasmid DNA from serum nuclease degradation. Cytotoxicity and 
transfection studies were carried out in the receptor negative HEK293 (human embryonic 
kidney), and the receptor positive HeLa (human cervical carcinoma) and KB (human 
nasopharyngeal) cell lines. The protocols for these assays are outlined in chapter two. Cell 
viability studies were conducted using the MTT assay which is based on the mitochondrial 




luciferase reporter gene assay. Competition assays using free folate ligand was performed to 
confirm receptor mediated gene transfection by folate-targeted cationic lipoplexes. Quantitative 
lipoplex uptake was examined by flow cytometry in FR-positive cell lines. 
  
 Briefly, chapter two looks at all the materials and methods utilized in this study. 
Chapter three details all the results obtained, followed by a detailed discussion of these results. 
Lastly, chapter four provides a short conclusion for this study. 
 
1.12. Aims and Objectives  
 Aim 
The aim of this study was to synthesize novel cationic liposomes with and without a 
targeting ligand foic acid, and to evaluate the effects of this targeted cationic liposome vectors in 
vitro culture system. 
 
 Objectives 
 To synthesize novel cationic cholesterol derivatives for incorporation into cationic 
liposomes. 
 To prepare unPEGylated and PEGylated liposomes with DSPE-PEG2000 (2 mole 
percentage).  
  To formulate folic acid-labelled moiety for incorporating into cationic liposomes to   
establish targeting aspect. 
  Liposome and lipoplex characterization using electron microscopy and zeta 
measurements. 
 To examine the nucleic acid binding, interaction and protection abilities of the liposomes 
by using band shift assays, ethidium bromide dye displacement assays and nuclease 
protection assays. 
 To examine the effect of cytotoxicity of complexes in vitro. 
 To study the gene expression phenomenon using luciferase reporter gene assays in vitro. 







MATERIALS AND METHODS 
 
2.  Materials 
Dioleoylphosphatidylethanolamine (DOPE), folic acid and Bicinchonimic acid (BCA) 
assay reagents were purchased from the Sigma-Aldrich Co., St. Louis, USA. 
Distearoylphosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000) and DSPE-
PEG2000 NH2 were purchased from Avanti Polar Lipids, Alabaster, USA. 
Cholesterylchloroformate, 3-dimethylaminopropylamine; 2-[4-(2-hydoxyethyl)-1–piperazinyl]-
ethanesulphonic acid (HEPES) and ethidium bromide were purchased from Merck, Damstadt, 
Germany. Cationic cytofectins MSO9, N,N-dimethylpropylamidosuccinylcholesteryl-formyl-
hydrazide, SGO4 and 3β[N(N1,N1-dimethlaminopropylsuccinamidoethane)-carbamoyl]-chole-
sterol were synthesized according to reported procedures (Singh and Ariatti, 2006a). Ultra-pure 
DNA grade agarose was obtained from Bio-Rad Laboratories, Richmond, USA. The pCMV-luc 
DNA and pCMV-luc GFP were obtained from Plasmid Factory, Bielefield, Germany. HEK293 
cells were obtained from the University of the Witwatersrand Medical School, HeLa cells were 
purchased from Highveld Biological (Pty) Ltd. (Lyndhurst, RSA) and, KB cells were obtained 
from the Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei, Taiwan. Eagles 
Minimum Essential Medium (EMEM) containing Earle’s salts and L-glutamine, trypsin-versene 
and penicillin (5000 units/mL)/streptomycin (5000 μg/mL) were purchased from Lonza 
BioWhittaker, Walkersville, USA. The Luciferase Assay kit was purchased from the Promega 
Corporation, Madison, USA. All tissue culture plastic consumables were purchased from 
Corning Incorporated, New York, USA. All other reagents were of analytical grade. 
 
2.1. Methods 
2.1.1. Synthesis of Cationic Cholesterol Derivatives 
2.1.1.1.  Preparation of Cationic Cholesterol Derivative MSO9 
MSO9 was synthesized in four steps beginning with the preparation of cholesteryl-
formylhydrazide. All four steps described previously by Singh and Ariatti (2006a) are discussed 




2.1.1.1.1. Preparation of Cholesterylformylhydrazide MSO4 
To a solution of hydrazine (240 mg, 7.5 mmol) in chloroform: methanol (3:0.6 mL) was 
added a solution of cholesterylchloroformate (1.13 g, 2.5 mmol) in chloroform. This was carried 
out with stirring at 0 ºC. Following 24 h at room temperature, the solution was concentrated in 
vacuo, followed by recrystallization of the resulting crystalline mass from chloroform: methanol 
(4:1 v/v) to yield the product. 
 
2.1.1.1.2. Preparation of Cholesterylformylhydrazidehemisuccinate (MSO8) 
MSO4 (89 mg, 0.2 mmol) and succinic anhydride (20 mg, 0.2 mmol) were dissolved in 2 
mL DMF: pyridine (1:1 v/v) and the reaction was continued overnight at room temperature. The 
solvent was removed by rotary evaporation in a Büchii Rotavapor-R to yield the product of white 
crystals from absolute ethanol. 
 
2.1.1.1.3. Preparation of N-hydroxysuccinimide ester of cholesterylformylhydrazide-
hemisuccinate 
MSO8 (82 mg, 0.15 mmol), dicyclohexylcarbodimide (DCC) (62 mg, 0.3 mmol) and N-
hydroxysuccinimide (NHS) (35 mg, 0.3 mmol) were dissolved in 1 mL of dimethylformamide 
(DMF). The reaction was monitored by TLC (results not shown). After 48 h, the 
dicyclohexylurea crystals were removed by filtration. The solvent was then removed by 
evaporation and the resulting crude product was dissolved in chloroform: water mixture (1:1 v/v). 
The water layer, containing excess N-hydroxysuccinimide, was removed. The chloroform layer 
was extracted with water (10 mL) and concentrated to dryness in vacuo. The residue was 
extracted with petroleum ether (60-80 °C, 10 mL) to remove excess DCC. The product was 
obtained as white crystals. 
 
2.1.1.1.4. N, N-dimethylpropylamidosuccinylcholesterylformylhydrazide (MSO9) 
The N-hydroxysuccinimide ester of cholesterylformylhydrazidehemisuccinate (MSO8) 
(53 mg, 0.083 mmol) and dimethylaminopropylamine (DMAPA) (36 mg, 0.35 mmol) were 
dissolved in 15 mL water: pyridine: DMF (13: 7: 10 v/v/v) and TLC was used to monitor the 
reaction (results not shown). Purification of the product was carried out on silica gel 60 F254 TLC 













































N,N-Dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MSO9)  
Figure 2.1: Scheme for the synthesis of cationic cholesterol derivative N, N-dimethylpropylamino- 




2.1.1.2. Synthesis of Cationic Cholesterol Derivative 3β[N(N1,N1-dimethylaminopropyl-- 
succinamido-ethane)-carbamoyl]cholesterol (SGO4) 
SGO4 was synthesized in three steps, as discussed below. The reactions involved in the 
synthesis of cytofectin SGO4 are outlined in Figure 2.2. 
 
2.1.1.2.1. Preparation of 3β[N(2-aminoethyl)-carbamoyl]cholesterol (SGO1) 
To ethylene diamine (2.25 g, 37.5 mmol) in dry CH2Cl2 (40 mL) was added a solution of 
cholesterylchloroformate (2.0 g, 4.45 mmol) dropwise over 5 minutes. After 48h at room 
temperature the reaction mixture was extracted with 3 × 150 mL H2O. The CH2Cl2 layer was 
dried over anhydrous Na2SO4 and evaporated to a white powder. Thereafter, the product was 
recrystallized from cyclohexane. The product was purified further by column chromatography on 
a silica gel 60 column (2.2 × 23 cm). The column was initially eluted with chloroform (50 mL) 
and then with CHCl3: MeOH: Con.NH4OH (95:4:1) (100 mL) followed finally with 
CHCl3:MeOH:Conc.NH4OH (90:10:1). Product fractions were evaporated and the title 
compound was obtained in a crystalline form from cyclohexane.  
  
Yield: 67% (705 mg); Mp: 168−170 °C; 1H NMR (400MHZ, CDCl3):δ 0.67 (s, 3H, 
H−18'), 0.86 (d, 6H, J = 7 Hz, overlapping 2 Hz, H−26', H−27'), 0.91 (d, 3H, J = 6.5 Hz, H−21'), 
1.00 (s, 3H, H−19'), 1.0−2.1 (m, 28H, cholesteryl), 2.35 (m, 2H, H−4'), 2.85 (m, 2H, H2NCH2), 
3.25 (q, 2H, J = 5.7 Hz, H2NCH2CH2), 4.49 (m, 1H, H−3'), 5.37 (d, 1H, J = 4.9 Hz, H−6') ppm. 
13CNMR (100MHZ, CDCl3): 11.9 (C−18'), 18.7 (C−21'), 19.3 (C−19'), 21.0 (C−11'), 22.6 
(C−26'), 22.8 (C−27'), 23.9 (C−23'), 24.3 (C−15'), 28.0, 28.2 (C−2', C−16', C−25' overlapping), 
31.9 (C−7', C−8' overlapping), 35.8 (C−20'), 36.2 (C−22'), 36.6 (C−1, C−10'), 37.0 (C−1'), 38.6 
(C−24'), 39.5, 39.7 (C−4', C−12'), 42.3 (C−13'), 50.0 (C−9'), 56.2 (C−17'), 56.7 (C−14'), 74.4 
(C−3'), 122.5 (C−6'), 156.5 (NHCOO), 139.8 (C−5'). HR-MS (ESI−QTOF +ve): Anal. Calcd. for 
C30H53O2N2: (M+H) 473.4113, Found 473.4290. 
 
2.1.1.2.2. Preparation of 3β[N(hemisuccinamidoethane)-carbamoyl]cholesterol (SGO2) 
3β[N(2-aminoethane)-carbamoyl]cholesterol (237 mg, 0.5 mmol) in CH2Cl2 (5  mL) was 
added dropwise to a solution of succinic anhydride (60 mg, 0.6 mmol) in pyridine (1 mL). After 




and 1 mL of DMF was added to obtain a clear solution. After 24 h a quantitative yield of product 
was obtained. The product was recrystallized from ethanol.  
 
Yield: 84% (165 mg ); Mp: 168-170 °C; 1H NMR (400MHZ, C5D5N): δ 0.67 (s, 3H, 
H−18'), 0.90 (d, 6H, J = 6.6 Hz, H−26', H−27'), 1.0−2.1 (m, 28H, cholesteryl), 2.56 (m, 2H, 
H−4'), 2.85 (t, 2H, J = 6.9 Hz, H−2), 3.06 (t, 2H, J = 6.8Hz, H−1), 3.68 (t, 2H, J = 6.5 Hz, H−5), 
3.74 (t, 2H, J = 5.5 Hz, H−6), 4.82 (m, 1H, H−3'), 5.38 (bs, 1H, H−6'). 13C NMR (100MHZ, 
C5D5N): 12.0 (C−18'), 19.0 (C−21'), 19.4 (C−19'), 21.3 (C−11'), 22.7 (C−27'), 23.0 (C−26'), 
28.2, 28.5, 28.7 (C−2', C−16', C−25'), 31.5 (C−5), 32.1, 32.2 (C−7', C−8'), 36.1 (C−22'), 36.5 
(C−10'), 36.8 (C−1'), 39.2 (C−1), 39.7, 39.9 (C−4', C−12'), 42.5 (C−13'), 50.3 (C−9'), 56.4 
(C−17'), 56.8 (C−14'), 74.1 (C−3'), 122.6 (C−6), 140.4 (C−5), 157.3 (NHCOO), 172.7 (C−4), 
175.5 (C−7). HR-MS (ESI−QTOF +ve): Anal. Calcd. for C34H57N2O5 (M+H) 573.4273, Found 
573.4338.  
 
2.1.1.2.3. Preparation of 3β[N(N1,N1-dimethylaminopropylsuccinamidoethane)-carbamoyl]- 
     cholesterol (SGO4) 
To a solution of 3β[N(hemisuccinamidoethane)-carbamoyl]cholesterol (114 mg, 0.2 
mmol) and N-hydroxysuccinamide (32 mg, 0.28 mmol) in pyridine (2 mL) was added a solution 
of dicyclohexylcarbodiamide (55 mg, 0.26 mmol) in pyridine (0.8 mL). A catalytic amount of 4-
dimethylaminopyridine (2.4 mg, 0.02 mmol) was also included in the reaction mixture. After 24 
h, 3-dimethylaminopropylamine (51 mg, 0.5 mmol) was added to the mixture which was stored 
in the dark at room temperature for 24 hours. Dicyclohexylurea crystals were removed by 
filtration. The filtrate was concentrated and the product was purified by silica gel 60 column 
(2.0×17.0 cm) chromatography. Equilibration and elution were performed using CHCl3: 
MeOH:Con. NH4OH (43:7:1).  
 
Yield: 61% (90 mg); Mp: 216−218 °C; 1H NMR (400MHZ, CDCl3):δ 0.68 (s, 3H, 
H−18'), 0.86 (d, 6H, J = 6.7 Hz, overlapping 2 Hz, H−26', H−27'), 0.91 (d, 3H, J = 6.5 Hz, 
H−21'), 1.00 (s, 3H, H−19'), 1.00−2.21 (m, 27H, cholesteryl), 2.27 (s, 6H, H−13, H−14), 2.42 (t, 
2H, J = 6.3 Hz, H−4), 2.50 (s, 4H, H−6, H−7), 3.30−3.36 (m, 6H, H−1, H−2, H−9), 4.48 (m, 1H, 




(C−21'), 19.3 (C−19'), 21.0 (C−11'), 22.6 (C−26'), 22.8 (C−27'), 23.8 (C−23'), 24.3 (C−15'), 
28.0, 28.2 (C−2', C−16', C−25' overlapping), 31.8 (C−10), 31.9 (C−7', C−8' overlapping), 35.8 
(C−5'), 36.2 (C−22'), 36.6 (C−1, C−10' overlapping), 37.0 (C−1'), 38.6 (C−24'), 39.5, 39.7 (C−4', 
C−12'), 42.3 (C−13', C−9 overlapping), 45.2 (C−13, C−14 overlapping), 50.0 (C−9'), 56.1 
(C−17'), 56.7 (C−14'), 58.3 (C−11), 74.5 (C−3'), 122.5 (C−6'), 139.8 (C−5'), 156.8 (NHCOO), 
172.1 (C−7), 173.0 (C−4). HRMS (ESI−QTOF +ve): Anal. Calcd. for C39H69N4O4 (M+H) 





































Figure 2.2: Scheme for the synthesis of cationic cholesterol derivative 3β[N(N1,N1-dimethlaminopropyl 





2.1.2. Synthesis of DSPE-PEGFOL for Folate Targeted Liposome 
DSPE-PEGFOL was synthesized (Figure. 2.3) as an adaptation of previously reported 
protocols (Yoshida et al., 2006; Liu et al., 2011). To folic acid (100 mg, 0.226 mmol) dissolved 
in dimethyl sulfoxide (5 mL) were added equimolar amounts of N-hydroxysucciniimide (NHS) 
(28.8 mg, 0.25 mmol), and dicyclohexylcarbodiimide (DCC) (51.5 mg, 0.25 mmol). The reaction 
mixture was incubated overnight at room temperature. The insoluble dicyclohexylurea (DCU) 
was filtered off from the reaction mixture. To a solution (44 µL) of the NHS ester of folic acid 
(NHSF, 2 µmol) was added DSPE-PEG2000NH2 (2.79 mg, 1 µmol). To obtain a solution, 
dimethylsulfoxide (DMSO) (40 µL) and pyridine (40 µL) were added. The solution was left 
overnight and pyridine was removed by rotary evaporation. Water (500 µL) was added to the 
reaction mixture and the solution was centrifuged at 12000 rpm (SANYO MSE) for 5 min at 
room temperature, to remove the trace insolubles. The supernatant was dialyzed (MW cutoff of 
2000 Da) against water (three x 500 mL). The dialyzed product was analyzed by UV-

















































































2.1.3. Preparation of Cationic Liposomes  
Cationic liposomes with or without folate were synthesized by the thin film rehydration 
method adapted from Gao et al., (1991). Six cationic liposomes were prepared with the 
cytofectins MSO9 or SGO4 with the quantities of each lipid component shown in Table 2.1. The 
liposome preparations were made up to a total of 2 µmol of lipid in 0.5 mL of HEPES buffer 
(150 mM Nacl, 20 mM HEPES, pH 7.5) (HBS). The targeting ligand folic acid appended to 
PEG2000 was used in the targeted cationic liposomes. Additionally, distearoylphosphatidyl-
ethanolamine polyethylene-glycol2000 (DSPE-PEG2000) was formulated into liposomes to obtain 
both a folate targeting and stealth capability in liposome formulations. Each lipid was first 
dissolved in chloroform (1 mL) and rotary-evaporated (Rotavapor-R at 25 ºC) to afford a thin 
film deposit on the inner wall of a test tube. The sample was dried further under high vacuum in 
a drying pistol for 20-30 min. Thereafter, the resultant thin lipid film was rehydrated in 0.5 mL 
of sterile HBS and finally the mixture was briefly vortexed and sonicated for 5 minutes using a 
Transonic bath type sonicator at 20 °C. Liposome suspensions were routinely stored at 4 °C. 
 







Molar Ratio (µmole) 








MSO9:DOPE 0.63 --- 0.74 --- --- 1 --- 1 --- --- 
MSO9:DOPE: 
2%PEG2000 

























SGO4:DOPE --- 0.65 0.74 --- --- --- 1 1 --- --- 
SGO4:DOPE: 
2%PEG2000 





























2.1.4. Calculation of Nitrogen to Phosphate (N:P/+:-) Ratio 
The required amounts of cationic liposome and plasmid (pCMV-luc) DNA were 
calculated according to the desired N/P ratio based on previous reports by Zanta et al., (1997). 
The N/P ratio is the ionic balance of the liposome:pDNA in lipoplexes. The positive charge of 
the liposome arises from the liposome amine nitrogen (N). The negative charges in the plasmid 
DNA backbone arises from the phosphate groups of the deoxyribonucleotides. The average 
molecular weight of a nucleotide was assumed to be 350 g/mol. The lipoplexes of plasmid DNA 
and liposome were prepared by mixing of both components leading to complex formation due to 
electrostatic interactions. The lipid:DNA charge ratio was calculated as the molar ratio of lipid 
cytofectin molecule with one positive charge per molecule, to the phosphate of the nucleotide of 
DNA.  
 
2.1.5 Preparation of Lipoplex 
Lipoplexes were prepared by simply mixing the desired liposome suspension with the 
plasmid DNA gently in a final volume of 10 µL of HBS to obtain the desired (+/-) charge ratios 
from 1:1 to 7:1. Thereafter, the lipoplexes were incubated at room temperature for 30 minutes to 
mature. The preparation of complexes was carried out in a class-II bio-hazard hood under sterile 
solutions.  
 
2.1.6 Characterization of Liposomes and Lipoplexes 
The chemical and physical characteristics of liposomes determine their in vivo and in 
vitro behaviour. The quality control of liposomal dispersions is essential since they are used 
extensively as vehicles for gene/ drug delivery and their properties will determine their fate in 
vivo. Two of the most important parameters are particle size and zeta potential. Liposome size is 
important, as it is one factor that determines the uptake of the vector into cells. Also for a 
possible in vivo use, small size has to be ensured to avoid complications such as micro embolism 
in blood vessels. Surface charge of the particles in dispersion is an important parameter as the 
potential of liposomes plays a role, for example in stabilizing liposomes against aggregation or 
fusion and in the interaction between liposomes and charged drugs. It also has an impact on the 
behaviour of liposomes in vivo (Cevc, l993). Any subsequent modification of the liposome 




techniques used for detecting lipoplex formation, and protection of plasmid DNA by cationic 
liposomes are described below. 
 
2.1.6.1. Agarose Gel Electrophoresis 
Cationic liposome:pDNA complexes were formed using pCMV-luc (6.2 kbp) at a final 
DNA concentration of 0.5 μg in 10 μL HBS and at liposome:DNA (+/-) charge ratios from 1:1 to 
7:1 as shown in Table 2.2. The complexes were incubated for 30 min at room temperature for 
lipoplex maturation. Thereafter, 3 µL of gel loading buffer (50% glycerol, 0.5% bromophenol 
blue, 0.5% xylene cyanol in 2X gel buffer) was added to the incubation mixtures which were 
then loaded onto 1% agarose gels containing ethidium bromide (0.5 µg/mL). The gel running 
buffer was composed of 36 mM Tris-HCl, 30 mM sodium phosphate and 10 mM EDTA (pH 
7.5). Electrophoresis was performed at 50V for 90 min and images were captured using the 
VacutecSyngene G: Box gel documentation system (Syngene, Cambridge, UK) at an 800 milli 
second exposure time. 
 
Table 2.2: Liposome:DNA complexes set up for gel retardation studies.  
 
Lipoplex Formulation (+/-) Well Number 
 1 2 3 4 5 6 7 8 
MSO9:DOPE 0 1:1 2:1 3:1 4:1 5:1 6:1 7:1 
MSO9:DOPE:2%PEG2000 0 1:1 2:1 3:1 4:1 5:1 6:1 7:1 
MSO9:DOPE:2%PEG2000:DSPEPEG2000FOL 0 1:1 2:1 3:1 4:1 5:1 6:1 7:1 
SGO4:DOPE 0 1:1 2:1 3:1 4:1 5:1 6:1 7:1 
SGO4:DOPE:2%PEG2000 0 1:1 2:1 3:1 4:1 5:1 6:1 7:1 
SGO4:DOPE:2%PEG2000:DSPEPEG2000FOL 0 1:1 2:1 3:1 4:1 5:1 6:1 7:1 
pCMV-luc (µg) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 







2.1.6.2. Serum Nuclease Protection Assay 
Lipoplexes were analysed to determine the protection offered to the DNA against 
nuclease attack by the different liposome preparations. Varying amounts of cationic liposomes 
(Table 2.3) were added to a constant amount of pCMV-luc DNA (1 μg). This was made up to a 
final volume of 10 μL with HBS. The samples were allowed to incubate for 30 minutes at room 
temperature. Thereafter, 10% (v/v) foetal bovine serum (FBS) was added to the lipoplexes. Two 
controls were employed, a negative control containing only pCMV-luc DNA and a positive 
control containing pCMV-luc DNA and 10% FBS. The samples were then incubated for 4 h at 
37 °C. After the incubation period, the chelator EDTA was added to the samples to a final 
concentration of 10 mM to stop the nuclease reaction. Sodium dodecyl sulphate (SDS) was then 
added to a final concentration of 0.5% (w/v), to liberate DNA from the complexes for migration 
into the gel. The samples were then incubated for a further 20 minutes at 55°C. Thereafter, the 
samples were subjected to electrophoresis on a 1% agarose gel for 90 min at 50 volts and images 
captured using the VacutecSyngene G: Box gel documentation system as described in 2.1.6.1. 
 
Table 2.3: Nuclease protection assessment by cationic liposomes.  
Cationic Liposome Formulation Liposome:DNA Ratio (+/-) pCMV-luc (µg) 
MSO9:DOPE 2:1 3:1 4:1 1 
MSO9:DOPE:2%PEG2000 1:1 2:1 3:1 1 
MSO9:DOPE:2%PEG2000:DSPEPEG2000FOL 2:1 3:1 1:1 1 
SGO4:DOPE 2:1 3:1 4:1 1 
SGO4:DOPE:2%PEG2000 2:1 3:1 4:1 1 
SGO4:DOPE:2%PEG2000:DSPE-PEG2000FOL 2:1 3:1 4:1 1 
 
2.1.6.3.  Ethidium Bromide Intercalation Assay 
The binding of DNA with the cationic liposomes was further studied using the EtBr 
intercalation assay. EtBr is an intercalating agent, and acts as the fluorescent probe providing 
reproducible and efficient evaluation of lipoplex formation. The displacement of EtBr, upon lipid 
interaction with the DNA, is reflected as a drop in the fluorescence signal, since unbound EtBr 




particularly at the point of endosomal escape for delivery of DNA therapeutic agents (Lasic, 
1997). All fluorescence measurements were carried out using a Glomax multi+ detector system 
(Promega, Biosystems, Sunnyvale, USA). The excitation wavelength was 525 nm and the 
emission wavelength was kept at 580 nm. Initially, 2 µL of ethidium bromide (0.2 µg), from a 
100 µg/mL diluted stock solution, was added to 100 µL of HBS buffer (pH 7.4) in black 96-well 
plates and the baseline fluorescence was determined as 0%. The 100% relative fluorescence was 
achieved by adding 2.4 μL (1.2 μg) of pCMV-luc plasmid DNA to the HBS-ethidium bromide 
mix. Thereafter, liposome (1 μL) preparations were added stepwise to the mixture and readings 
were taken after each addition until a plateau was reached. Contents in the wells were mixed 
thoroughly for even distribution and also to attain the complete DNA compaction or 
condensation. The fluorescence intensity obtained upon each addition of liposome was 
normalized relative to the fluorescence signal of the DNA–EtBr complex, which was taken as 
100%.  
 
2.1.6.4. Cryo-Transmission Electron Microscopy (Cryo-TEM) 
Morphology and size of liposomes as well as lipoplexes were determined by cryo-TEM. 
The cationic liposome suspensions were diluted to a 1:20 ratio, and the lipoplexes were diluted 
1:100 with sterile Hepes buffered saline (HBS). A 1 μL droplet of the diluted cationic liposome 
or lipoplex suspension was deposited onto a copper grid. To this, was added 1 µL of 1% (w/v) 
uranyl acetate and the grid was allowed to dry for 2 minutes. After removing the excess 
suspension with a filter paper, the grid was placed in liquid nitrogen and then transferred into a 
GATAN cryo-holder maintained at -170 °C. This was then introduced into the TEM for 
observation at -150 ºC. Images were obtained under cryogenic conditions and investigated at 100 
kV in a JEOL JEM1010 electron microscope (Tokyo, Japan). The micrographs were captured on 
a MegaViewIII camera, and SIS i-TEM software facilitated measurements of liposomes on 
calibrated images. 
 
2.1.6.5. Photon Correlation Spectroscopy 
Particle size, size distribution as well as the particles surface charge of dispersions can be 
estimated using photon correlation spectroscopy (PCS), also known as dynamic light scattering 




laser light (helium, neon or argon) due to the Brownian motion of particles in 
solution/suspension (Ostrowsky, 1993). Intensity of the stray light fluctuates as the particles in 
dispersion show Brownian motion. Small particles diffuse more rapidly than large particles, and 
the rate of fluctuation of scattered light intensity varies accordingly. Therefore, the 
hydrodynamic diameter of the particles may be deduced. Results of this calculation include two 
parameters: the Z-average as mean calculated hydrodynamic diameter describing the size of 
particles and the polydispersity index (PDI) describing the particle size distribution (Hope et al., 
1986). 
 
The sizes of the liposomes and lipoplexes, size distribution and zeta potential were 
measured in a Malvern Zetasizer Nanoseries (Malvern Inst, Worcestershire, UK) at 25 ºC. The 
cell types chosen for Z-average measurement were a DTS0012 – polystyrene disposable sizing 
cuvette and DTS-1061 for zeta potential measurements. These types of cells allows for 
determination of an appropriate amount of sample in the range of 0.5 to 1 mL. For liposomes, the 
samples were prepared in a 1:20 dilution (50 μL sample + 950 μL) in sterile HBS, and for 
lipoplexes, the samples were prepared in a 1:100 dilution (10 μL of preformed lipoplex sample + 
990μL) in sterile HBS. Three measurements were taken at setting position 4.65 and using run 
time and attenuator (intensity adjustment) around 6-8 as recommended by the analysis software. 
 
2.1.7. Growth and Maintenance of Cells 
2.1.7.1. Propagation of Cells 
HEK293, HeLa and KB cells were grown in EMEM (Lonza) containing 10% FBS and 
penicillin (5000 units/mL)/streptomycin (5000 μg/mL). Cells were monitored on a regular basis 
and medium changed when necessary. Cells were trypsinised and split into desired ratios once 
they had reached confluence. For the trypsinisation procedure, the medium from the cells was 
decanted, and the cells washed with 5 mL phosphate buffered saline (PBS) (150 mM sodium 
chloride, 27 mM potassium chloride, 1 mM potassium dihydrogen phosphate, 6 mM di-sodium 
hydrogen phosphate, pH 7.5). Thereafter, 1 mL trypsin-EDTA mixture (0.25% w/v trypsin, 0.1% 
w/v EDTA) was added and trypsinisation was observed under a Nikon TMS inverted microscope 
(Nikon. Tokyo, Japan) (approximately 1-2 minutes). Once cells had rounded off, approximately 




gently tapped against the palm of the hand in order to dislodge the cells. The cells were split as 
desired into 25 cm3 flasks, containing 4 mL medium. The cells were incubated at 37 °C and 
medium changed at the required intervals. Once cells had reached confluency they were once 
again trypsinised and split as required or cryopreserved and stored in liquid nitrogen or a -81 C 
Biofreezer (Nuaire) for future use. 
 
2.1.7.2. Cryopreservation and Reconstitution of Cells 
Confluent cells were washed with PBS and trypsinised as in 2.2.7.1. The cells were then 
pelleted by centrifugation at 1000 rpm for 3 minutes in a Eppendorf centrifuge. The cells were 
then resuspended in 0.9 mL medium and 0.1 mL dimethylsulfoxide (DMSO). The cell 
suspension was dispensed into a cryogenic ampuole which was placed in a NalgeneMR Frosty 
cryogenic container and in a -80 °C biofreezer for slow freezing, at a rate of 1 °C/minute. The 
ampuoles of frozen cells were then transferred into liquid nitrogen for long term storage or to 
cryoboxes for short term storage in the -81 C biofreezer. 
 
 The cells were reconstituted when required in the following manner. The ampuole 
containing the cells was removed from liquid nitrogen/biofreezer, and immediately placed in a 
37 °C water bath. Directly after thawing, the ampuole was wiped with ethanol, and the cells were 
pelleted by centrifugation (1000 rpm for 3 minutes). The supernatant was discarded into a waste 
bottle, and the cells were resuspended in 1 mL fresh medium (EMEM + 10% FBS + antibiotics). 
The medium was changed after 24 hours, and the cells were monitored with frequent medium 
changes until they reached confluency. 
 
2.1.8. Plasmid DNA Amplification 
The pCMV-luc DNA (Plasmid factory) (Figure. 2.4) was successfully amplified in the 
Department of Biochemistry, University of KwaZulu-Natal according to a standard protocol. The 
DNA purity and concentration were quantified using a Thermo Electron Corporation Biomate 3 
spectrophotometer at 260 and 280 nm and adjusted to 0.5 μg/μL. The isolated DNA was 
analyzed on a 1% agarose gel against a control DNA sample to confirm purity and integrity. 
Moreover, the quality of DNA in terms of three forms of bands, namely, supercoil, circular and 













Figure 2.4: Map of  pCMV-luc control vector showing the SV40 promoter and firefly  luciferase           
(luc) gene (Plasmid Factory, Bielefeld, Germany). 
 
2.1.9. Cell Viability Assay 
The viability of the cells in the presence of varying amounts of cationic liposome was 
evaluated using the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
described by Mosmann, (1983). Cells were seeded at a density of 2.5 x 104 cells/well in 48-well 
plates, and incubated at 37 °C in a humidified atmosphere containing 5% CO2 for 24 h before 
treatment. The liposome:pCMV-luc complexes were prepared as defined in Table 2.4 and 
incubated at room temperature for 20-30 minutes. Thereafter, they were added to each well 
containing 0.3 mL of EMEM medium (containing 10% FBS, streptomycin 100 μg/mL), and 
penicillin (100 U/mL) and incubated for further 48 h at 37 °C. After incubation, the medium was 
discarded and 0.2 mL of fresh complete medium and 0.2 mL of 5 mg/mL MTT solution in 
phosphate buffered saline (PBS) was added to the sample wells and incubated for an additional 4 
h at 37 ºC. Thereafter, the MTT containing medium was aspirated and 200 μL of DMSO was 
added to dissolve the yellow formazan crystals formed by viable cells. The absorbance was 
measured at 570 nm to determine cell viability as percentage of untreated control cells. The data 





Table 2.4: Lipoplex ratios used in cell viability and transfection studies. 
Cationic Liposome Formulation Liposome:DNA Ratio (+/-) 
MSO9:DOPE 2:1 3:1 4:1 
MSO9:DOPE:2%PEG2000 1:1 2:1 3:1 
MSO9:DOPE:2%PEG2000:DSPEPEG2000FOL 2:1 3:1 1:1 
SGO4:DOPE 2:1 3:1 4:1 
SGO4:DOPE:2%PEG2000 2:1 3:1 4:1 
SGO4:DOPE:2%PEG2000:DSPEPEG2000FOL 2:1 3:1 4:1 
 
2.1.10. Transfection Assay 
Cells were trypsinised and 2.5 x 104 cells/well were seeded into a 48-well plate, keeping 
the volumes constant to 0.3 mL complete medium (EMEM + 10% FBS + antibiotics) per well 
and incubated at 37 °C, 5% CO2 for 24 h. Prior to transfection, the medium was removed and 
replenished with fresh complete medium. Transfection mixtures were prepared as indicated in 
Table 2.4 and added to the cells. Two controls were set up and included untreated cells, and cells 
exposed to naked plasmid DNA only. Cells were incubated for a further 48 h at 37 ºC. Each 
transfection experiment was conducted in triplicate. The resulting luciferase expression was 
quantified using the Promega luciferase assay system.  
 
2.1.10.1. Luciferase Assay 
The luciferase assay was carried out using the Promega luciferase assay kit. The 
luciferase assay reagent (20 mM Tricine, 1.1 mM Magnesium carbonate hydroxide pentahydrate, 
2.7 mM Magnesium sulphate, 0.1 mM EDTA, 33.3 mM dithiothreitol, 270 μM coenzyme A, 470 
μM luciferin, 530 μM ATP), was prepared by adding 10 mL of the luciferase assay buffer to one 
vial of lyophilised luciferase assay substrate. The cell culture lysis reagent (5X) (25 mM 
trisphosphate, pH 7.8; 2 mM dithiothreiotol, 2 mM 1,2-diaminocyclohexane–N,N,N',N'-tetra 
aceticacid, 10% (v/v) Glycerol, 1% (v/v) Triton X-100), was diluted with distilled water to obtain 





Initially, cells were prepared by first removing the growth medium and carefully washing 
twice with cold PBS (0.3 mL). Thereafter, 80 μL of 1X cell lysis reagent was added to the wells 
to cover the cells and the multi-well plate was then placed on a Scientific STR 6 platform shaker 
for 15 minutes at 30 rev/min. Thereafter, the cell debris was dislodged from the wells and the 
resultant suspension was centrifuged in Eppendorf microcentrifuge at 12000 x g for 5 seconds to 
pellet the cellular debris. The cell free extracts were collected to measure luciferase activity. This 
was done by adding 50 µL of luciferase assay reagent to 20 µL of cell free extract at room 
temperature, mixing immediately and placing the reaction mixture in a GloMax Multi+ detection 
system (Promega). To produce the most uniform and reproducible data the reaction mixtures 
were completely mixed prior to measurement. The light produced was measured and normalized 
against the protein content in the cell lysates that was determined using the bicinchonimic acid 
(BCA) assay (Sigma). 
 
2.1.11. FA-Competition Studies 
To elucidate and confirm the cellular mechanisms of gene delivery by folic acid 
conjugated lipoplexes, the following experiment was designed. Folate receptor positive KB and 
HeLa cells were cultured in the same conditions as that for the transfection tests. Cells were 
seeded into 48-well plates at 2.5 x 104 cell density per well and incubated for 24 h. Thereafter, 
the medium was changed and excess/free folic acid (200 µM) was added to cells in each well and 
cells incubated for 20 min at 37 ºC to allow the free folic acid to bind to the receptor on the cell 
surfaces. Following this incubation the FA-targeted lipoplexes prepared as in Table 2.5 with 
predetermined ratios were added to the cells containing excess/free folic acid, and incubated at 
37 °C for 48 h in the presence of 5% CO2. Thereafter, the medium was aspirated and the cells 
harvested for luciferase activity measurements. 
 
Table 2.5: Competition assays of lipoplexes. 
Formulation Liposome/DNA Ratio (+/-) 
MSO9:DOPE:2%PEG2000:DSPEPEG2000FOL 2:1 3:1 4:1 





2.1.12. Flow Cytometry 
The quantitative cell uptake of lipoplexes was analyzed further by flow cytometry. Cells 
which are FR-positive (HeLa, KB) were seeded in 12-well plates at a seeding density of 2.5x104 
cells/well and incubated for 24 h under the same culture conditions described in above sections 
(37 °C, 5% CO2). Thereafter, complexes at high transfection N/P ratios as shown in Table 2.6 
were prepared, added to the cells and were incubated for additional 48 h. The pCMV-luc GFP 
DNA (1 µg) was used in this study for complex formation with liposomes. At the end of 
incubation, medium from the wells was discarded and cells were gently washed two times with 
PBS buffer (0.3 mL) to eliminate non-specific binding. Thereafter, cells were treated with 
Trypsin-EDTA (0.1 mL) for 2-5 minutes until every cell had detached from the well, and 
subsequently centrifuged at 1000 rpm for 5 minutes to give cell pellets. The pellets were then 
dispersed in PBS (1 mL) then analyzed using Accuri C6 flow cytometer (BD Biosciences). 
Gating was performed on forward scatter-side scatter plots (FSC-SSC) to eliminate the dead cells 
and cell debris. Fluorescence parameters from at least 10,000 cells were recorded. Data were 
analyzed using FlowJo software program (Tree Star, Inc, Ashland, OR). Fluorescence displayed 
quantitatively as mean fluorescence intensity of the gated cell population in comparison to cells 
not expressing GFP.  
Table 2.6: Flow cytometry assays of lipoplexes. 







MSO9:DOPE 4:1 3:1 
MSO9:DOPE:2%PEG 3:1 3:1 
MSO9:DOPE:2%PEG:DSPEPEG2000FOL 4:1 3:1 
SGO4:DOPE 4:1 2:1 
SGO4:DOPE:2%PEG 2:1 3:1 





2.1.13. Statistical Analysis 
Statistical significance of differences between data was evaluated by one-way ANOVA 























 RESULTS AND DISCUSSION 
 
3. Synthesis of Cationic Cholesterol Derivatives 
Two cationic cholesterol derivatives (CCDs), namely MSO9 and SGO4 were used in this 
study. These two CCDs show similar chemical structural properties which include a cholesterol 
anchor, a carbamoyl linker bond and a dimethylamino head group. The structural difference 
between the two cationic cholesterol derivatives lies in the spacer arm where CCD MSO9 has an 
11 atom spacer arm and SGO4 has a 13 atom spacer length as illustrated in Figures 3.2.1 and 
3.2.2 respectively.  
 
3.1. Synthesis of N, N-dimethylpropylamidosuccinylcholesterylformylhydrazide (MSO9) 
The synthesis of cationic cholesterol derivative MS09 was achieved in four steps (Figure 
2.1). In the first step, cholesterylformylhydrazide (MSO4) was afforded by the reaction of 
cholesteryl chloroformate with hydrazine (N2H4) (electron donor). This may be described as a 
dehydrohalogination reaction.  
 
In the second step, the cholesterylformylhydrazide (MSO4) amino group was treated with 
succinic anhydride (C4H4O3) in the presence of a dimethylformamide:pyridine solvent system 
(1/1 v/v) to yield the intermediate compound cholesterylformylhydrazide hemisuccinate 
(MSO8). This step of MSO8 synthesis involves the expansion of the spacer segment by 
succinylation. MSO8 is more polar due to the presence of peptide and acidic carboxyl 
functionalities.  
 
In step three, the N- hydroxysuccinimide ester of cholesterylformylhydrazidehemi-
succinate (NHS ester of MS08) was prepared by reacting MSO8 with equimolar ratios of 
DCC:NHS (1:1), in preparation for the addition of a cationic head group. The MS08 carboxyl 
group was first activated by DCC, followed by reacting with N-hydroxysuccinimide (NHS) to 
generate the reactive ester of MS08. In step four, the pairing of amine group 




amido link was executed to afford the final compound, MS09, with loss of N-
hydroxysuccinimide.  
 
3.2. Synthesis of 3β[N(N1,N1-dimethlaminopropylsuccinamidoethane)-carbamoyl]-
cholesterol (SGO4) 
Cationic cholesterol derivative SGO4 was obtained in good yield in a convenient three 
step process (Figure 2.2). In the first step, cholesteryl chloroformate was reacted with the 
aliphatic ethylene diamine to afford the compound 3β [N(2-aminoethyl)-carbamoyl]cholesterol 
(SGO1), formed as a result of nucleophilic attack on to the carboxyl group of cholesteryl 
chloroformate. This constituted the first step in the construction of a spacer segment. 
 
The second step was a succinylation reaction. Succinylation aids in lengthening the 
spacer fraction by adding a succinyl group (CO-H2C-H2C-CO) to SGO1. Thereafter SGO1 was 
treated with succinic anhydride (C4H4O3) in the presence of pyridine:DMF (1:1 v/v) to obtain 
3β[N(hemisuccinamidoethane)-carbamoyl]cholesterol (SGO2). SGO2 is more polar than SGO1 
due to the presence of an aliphatic peptide bond, a carbamoyl link and a carboxylic group.  
 
The final step in the reaction entailed the establishment of a cationic head group on to the 
SGO2 intermediate for binding to anionic DNA. The final product, SGO4 was obtained by two 
sub-steps. The reaction between SGO2 and NHS/DCC-DMAPA in a pyridine solvent system 
gave a product SGO4 (61% reaction yield) with a carbamate bond. Every step was monitored by 
TLC, and the final product gave a single spot at Rf=0.07 (CHCl3:MeOH:Conc.NH4OH) (43:7:1 
(v/v/v)) (Figure 3.1) and HRMS 657.55 (M+H) peak. The infrared spectrum was also consistent 





































Figure 3.1: Representative TLC plates showing reaction progress of synthesis of SGO4 cationic 
 cholesterol derivative. A. SGO1 B. SGO2 C. SGO4. Solvent system used was: 










3.3. Synthesis of DSPE-PEG2000FOL for Targeted Liposome Formulation 
Figure 2.3 outlines the synthesis of the targeting moiety wherein, folate was conjugated 
to DSPE-PEG2000, a PEG derivative of phosphatidylethanolamine. The specific ligand-receptor 
interactions are utilized in this study to deliver nucleic acids in a receptor specific manner using 
folate conjugated liposomes. Folate was chosen since the folic acid receptor constitutes a useful 
target for tumour specific delivery, especially in malignancies of the ovary, but also because this 
small size molecule is poorly immunogenic and easily available (Lu et al., 2006; Bharali et al., 
2005). DSPE can be regarded as a buoy intended to be non-covalently entrapped into the nano-
carrier wall. It is often utilized to insert PEG into nanoparticles or liposomes (Wang et al., 2012; 
Liu et al., 2014; Fondell et al., 2011; Xu et al., 2009).  
 
The DSPE-PEGFOL polymer was successfully synthesized in two steps. In the first step 
a reactive intermediate, N-hydroxysuccinamidefolate (NHS-FOL), an active ester was prepared 
by a dehydration reaction. This was achieved by activating the carboxyl group on folic acid with 
N-hydroxysuccinimide (NHS) in the presence of DCC (coupling agent). NHS is water soluble 
and DCC is soluble in petroleum ether, resulting in simplified purification processes for the 
intermediate and final products. 
 
The second step was to attain the intended compound DSPE-PEGFOL by the covalent 
attachment of DSPE-PEG2000 with a distal amine group to the succinate ester NHS-FOL. 
Covalent attachment of folate to PEG was deemed to be advantageous as the ligand would not 
only be prominently displayed, but the spacer, PEG2000 enjoys low cytotoxicity (Gorle et al., 
2014), water solubility (Vinayak et al., 2005) and low immunogenicity (Mohs et al., 2005). 
Moreover, the presence of PEG to form a shell at the outside of the carrier provides functional 
end groups for the attachment of the targeting ligand through a flexible tether (Otsuka et al., 
2012). NHS ester of folate (NHS-FOL) was coupled with amino DSPE-PEG2000 in 
DMSO:pyridine solvent system (1:1 v/v) to yield the final product DSPE-PEGFOL. The 
successful formation of DSPE-PEG-FOL was confirmed using U.V spectrometry (results shown 












Figure 3.2.1:  Structure of cationic cholesterol derivative MSO9.  A. 3D model B. MSO9 displaying the  
















Figure 3.2.2:  Structure of cationic cholesterol derivative SGO4.  A. 3D model B. SGO4 displaying the  









3.4. Preparation of Cationic Liposomes 
3.4.1. Conventional/Untargeted Liposome Preparation 
Liposomes are microscopic sphere-shaped particles (Figure 3.4) in which membranes, 
consisting of one or more lipid bilayers, encapsulate a fraction of the solvent in which they are 
suspended into their interior (Jimenez-Rojo et al., 2014). The cationic liposome preparation was 
achieved by utilizing the method described in section 2.1.3. Liposomes in this study were 
prepared by using two cationic cholesterol cytofectins MSO9 and SGO4. The synthesis of the 
former cytofectin was previously reported by Singh and Ariatti, (2006a) and the latter was newly 
synthesized successfully by adapting the method by Singh and Ariatti, (2006a) with a simple 
modification, using active methylene group containing amine (ethylene diamine) instead of 
hydrazine. The common structural features of these two cationic lipids include a positively 
charged tertiary amino head group, a spacer arm, linker bond and a hydrophobic lipid domain 
(Figure 3.2.1 and Figure 3.2.2). The head group usually contains simple or multiple amine 
groups and is responsible for the interactions between liposome and DNA, and the lipoplex and 
the cell membrane (Lavigne et al., 2004). 
 
Cholesterol (C27H45OH), which is a cell membrane component, can adapt membrane 
fluidity, elasticity and permeability by closing the gaps created by imperfect packing of other 
lipid species when proteins are embedded in the membrane (Bermudez et al., 2002). Cholesterol-
based cationic lipids have been used as the main lipid component of liposomes for the transport 
of genes (Tagami et al., 2007) and chemical drugs (Al-Jamal and Kostarelos, 2007) since they 
are generally less toxic than other lipids (Tomasinsig et al., 2009). Furthermore, cholesterol 
enables the formation of vesicles with reduced aggregation and greater stability (Liang et al., 
2008). The linker bond is responsible for the chemical stability and biodegradability of a cationic 
lipid. The backbone in the cationic lipid acts as a connector between the hydrophobic domain 
and the cationic head group. The chemistry of the actual connector (linker) has most often been 
of the carbamate or amide variety, both of which are chemically stable and biodegradable. The 
connecting moieties can be designed to be ‘tunable’; i.e. they can be stable during formulation, 
storage, administration and initial circulation, but can be degraded rapidly at the desired site, e.g. 
in an endosome (Singh and Ariatti, 2006a & 2006b; Tros de Ilarduya et al., 2010). Obata and co-




unit (Obata et al., 2009). The length of the spacer arm may not be very critical, however, the 
cytotoxicity and transfection potential of the cationic liposome may be influenced by the nature 
and length of the spacer arm (Oh and Park, 2009; Palermo et al., 2012). The fusogenic potential 
between liposomes and biomembranes depends on the nature of the spacer arm (i.e. length and 
hydrophobicity), which plays an important role in intracellular DNA delivery (Obata et al., 
2009). A longer spacer segment in the cationic cytofectin will decrease the steric hindrance 
between hydrophilic head group and the lipophilic cholesterol anchor system which will then 
result in effective interaction of the cationic lipid with the nucleic acid (Singh, 1998). MSO9 and 
SGO4 are monovalent cationic lipids and are able to compact nucleic acids less strongly when 
compared to multivalent cationic lipids. However, it has been said that a high number of positive 
charges in the head group results in an attraction with the nucleic acid that is so strong that the 
release of the nucleic acid is hindered resulting in low transfection efficiency (Miller, 1998; 
Yang et al., 2013; Safari and Hosseinkhani, 2013). 
 
All six cationic liposomes in this study (both PEGylated and unPEGylated) were 
prepared with the neutral co-lipid DOPE as a common component. Cationic lipids are often 
mixed with so-called helper lipids, such as dioleoylphosphatidylethanolamine (DOPE) or 
cholesterol; both lipids potentially promote the conversion of the lamellar lipoplex phase into a 
non-lamellar structure, which presumably rationalizes their ability to improve cationic lipid 
mediated transfection efficiency (Wasungu and Hoekstra, 2006). DOPE is believed to help in 
membrane fusion as well as deterioration of the cellular and endosomal membrane (Resina et al., 
2009). Additionally, DOPE profoundly affects the polymorphic features of lipoplexes in that it 
promotes the transition from a lamellar to a hexagonal phase, and its presence causes 
neutralization of cationic charges by the negative charges on phosphodiester backbone of DNA 
(Vijayanathan et al., 2002; Srinivasan and Burgess, 2009). The presence of DOPE in lipoplexes 
helps in DNA release into the cytoplasm by disrupting the lipid membrane of the endosomes. 
This molecular parameter will thus be important for DNA dissociation and hence eventual 
transfection efficiency (Xu et al., 2013; Gao et al., 2011). Liposomes prepared in the absence of 
DOPE have been shown to have poorer rates of cell internalization and transfection (Xu et al., 





3.4.2. Preparation of PEGylated and Targeted Cationic Liposomes 
The pre-PEGylation of the cationic liposome was achieved using a 2 mole percentage of 
DSPE-PEG2000 and reducing the percentage of DOPE in the relevant liposome preparation to 
maintain a total of 4 mM total lipid. Polyethylene glycol (PEG) is typically conjugated to 
distearoylphosphatidylethanolamine (DSPE) via a carbamate linkage that results in a net 
negative charge on the phosphate moiety (Mora-Huertas et al., 2010). PEG is an inert, 
biocompatible polymer which forms a protective layer over the liposome surface and slows 
down liposome recognition by opsonins and therefore subsequent clearance of liposomes 
(Torchilin, 2005). The repulsive characteristic feature of PEG prevents the liposomes from being 
aggregated and therefore favours the formation of small liposomes (Lin and Thomas, 2003). 
 
Novel targeted liposome formulations were prepared by incorporating the targeting 
moiety, folic acid (0.01 µM). This ligand was intended to specifically target the folate receptor 
(FR) bearing tumour cells (Figure 3.3). To attain better selectivity of PEG shielded liposomes, it 
is advantageous to attach the targeting ligand via a PEG spacer, so that the ligand is appended 
outside of the polymer, which will decrease steric hindrance when binding to the target tissues 
(Torchilin, 2005). The PEG spacer between the lipid and the targeting ligand may position the 
targeting moiety suitably and provide stealth property to the liposome (Hossen et al., 2010). The 
folate receptor is a 38-KDa glycosyl phosphatidylinositol GPI-anchored glycoprotein with highly 
restricted normal tissue distribution and amplified expression in a wide variety of human 
tumours, including over 95% of non-mucinous ovarian carcinomas (Tomassetti et al., 1999). 
Liposomes incorporating a lipophilic folate derivative, such as folate-PEG-DSPE or folate-PEG-
Chol, have been shown to efficiently deliver antitumour agents into FR-bearing tumor cells via 
receptor-mediated endocytosis (Chiu et al., 2006; Wu et al., 2006).Targeting by folic acid has 
been studied by several researchers, showing the use of the ligand as a good targeting molecule 
for gene delivery in vitro and in vivo. Specifically, folate-targeted cationic liposomes have 





Figure 3.3: Graphic representation of the cationic liposome mediated receptor targeted gene delivery used in this study. Cationic liposome 
 interacts with DNA to form the lipoplex via electrostatic interaction. PEGylation was established by the addition of DSPE-PEG2000
 in the liposome formulation, targeting aspect by the conjugation of folic acid to DSPE-PEG. The gene carrying liposome enters


















Figure 3.4: Evolution of liposomes. A. Early traditional phospholipids ‘plain’ liposomes with    
 water soluble drug (a) entrapped into the aqueous liposome interior and water-insoluble 
 drug (b) incorporated into the liposomal membrane. B. Antibody targeted 
 immunolioposome with antibody covalently coupled (c) to the reactive phospholipids in 
 the membrane, or  hydrophobically anchored (d) into the liposomal membrane after 
 preliminary modification with a hydrophobic moiety. C. Long circulating liposome 
 grafted with a protective polymer  (e) such as PEG, which shields the liposome surface 
 from the interaction with opsonizing proteins (f). D. Long circulating immunoliposome 
 simultaneously bearing both protective polymer and antibody, which can be 
 attached to the liposome surface (g) or, preferably, to the distal end of the grafted 
 polymer chain (h). E. New-generation liposome, the surface of which can be modified 
 by different ways. Among these modifications are: the attachment of protective 
 polymer (i) or protective polymer and targeting ligand, such as antibody (j); the 
 attachment/incorporation of the diagnostic label (k); the incorporation of positively 
 charged lipids (l) allowing for the complexation with DNA (m); the 
 incorporation of stimuli-sensitive lipids (n); the attachment of stimuli-sensitive 
 polymer (o); the attachment of cell-penetrating peptide (p); the incorporation of 







3.5. Formation of Liposome:DNA Complex (Lipoplex) 
A lipoplex is a typical complex produced upon the electrostatic interaction of 
negatively charged DNA with the positively charged liposome (Figure 3.5). Lipoplexes were 
prepared by using varying amounts of MS09 and SGO4 cationic liposomes complexed with 
plasmid DNA expressing the luciferase reporter gene (pCMV-luc, 6.2 kb) to obtain a range of 












Figure 3.5: Schematic representation of liposome, DNA complex (lipoplex) formation. DNA is  
 sandwiched between liposomes forming the liposome:DNA complex (lipoplex) via  
 electrostatic interactions.  
 
The phosphate group on the deoxyribose rings of DNA confers a net negative charge 
to the molecule, limiting the potential for electrostatic interaction with the anionic lipids in 
the cell membrane. Accordingly, efficient protection and transportation of DNA into cells is 
required as the DNA is vulnerable to enzyme degradation in serum and would not reach the 
cell nucleus on its own (Sakolvaree et al., 2007). Cationic lipids are highly soluble in aqueous 
solution, forming positively charged micellar structures termed liposomes. Intriguingly, 
cationic carrier molecules can complex with DNA thus neutralizing its electrostatic charge, 
thereby promoting cell-membrane-DNA interaction (Parker et al., 2003). It is postulated that 
two processes are involved in the complex formation. A fast exothermic process attributed to 
the electrostatic binding of DNA to the liposome surface, and a subsequent slower 
endothermic reaction which is likely to be caused by the fusion of the two components and 
their rearrangement into a new structure. During this complex forming process, the 




Immediately after complexation or at low DNA concentrations, multiple liposomes appear to 
abut with DNA sandwiched between. Different complexes emerged later, which might vary 
depending on charge ratio, lipid formulation and mode of preparation. Condensed lipoplexes 
are seen with diameters of 100 – 200 nm, and also elongated, ‘spaghetti’ shaped, lipoplexes, 
which are thought to represent DNA surrounded by a lipid uni and/or bilayer. Large 
aggregates or ‘sphagetti’ lipoplexes are also observed, and thought to comprise numerous 
lipid and DNA molecules (Tros de Ilarduya et al., 2010). X-ray diffraction (XRD) studies 
have revealed that different lipoplex structures exist. Two types of structures were observed 
in plain lipoplexes (Tros de Ilarduya et al., 2010; Nishiyama and Kataok, 2006; Lasic et al., 
1998) viz a multilamellar structure (Figure 1.12A), with DNA monolayer sandwiched 
between the cationic membranes, and an inverted hexagonal structure (Nishiyama and 
Kataok, 2006) (Figure 1.12B), occasionally called the inverted ‘honeycomb’ phase, with 
DNA encapsulated within the cationic lipid monolayer tubes (Tros de ilarduya et al., 2010). 
The lipoplex is perceptive to the cationic to anionic (+/-) charge ratios of the complex and the 
sizes of the liposome and DNA (de Lima et al., 2003).  
 
3.6. Characterization of Liposomes 
3.6.1. Transmission Electron Microscopy 
Transmission electron microscopy with negative staining was used to (outlined in 
section 2.1.6.4) investigate the morphology of cationic liposomes produced by the thin film 
method. The liposomes appeared to vary in shapes (Figures 3.6.1 and 3.6.2). The images 
showed that all liposomes (unPEGylated and PEGylated) were generally discrete and round 
structures (Figures 3.6.1 and 3.6.2), ranging in size from 50 to 100 nm in diameter (Table. 
3.1). For convenient reading purposes, MSO9:DOPE and SGO4:DOPE liposomes will be 
referred as untargeted liposomes, MSO9:2%PEG and SGO4:2%PEG are as PEGylated, 
MSO9:2%PEG:DSPE-PEGFOL and SGO4:2%PEG:DSPE-PEGFOL will be described as 











































Figure 3.6.1:  Transmission electron micrographs of MSO9 cationic liposome. (a,b,c) unPEGylated,
 PEGylated and targeted MSO9 liposomes respectively. (d,e,f) unPEGylated, 
 PEGylated and targeted MSO9 lipoplexes respectively. Lipoplexes at their optimal 
 gel retardation  charge ratios were employed for TEM investigation. Scale bar 










































Figure 3.6.2:  Transmission electron micrographs of SGO4 cationic liposome. (a,b,c) unPEGylated, 
 PEGylated and targeted SGO4 liposomes respectively. (d,e,f) unPEGylated, 
 PEGylated and targeted SGO4 lipoplexes respectively. Lipoplexes at their optimal 
  gel retardation  charge ratios were employed for TEM investigation. Scale bar 






The average size measurements obtained (Table. 3.1) from transmission electron 
microscopy for MSO9 untargeted liposomes was 77.41 nm, MSO9 PEGylated was 73.83 nm 
and MSO9 targeted was 53.49 nm. Sizes obtained for SGO4 unPEGylated, PEGylated and 
targeted liposomes were 73.50 nm, 70.85 nm and 70.70 nm, respectively. From the results, it 
is evident that incorporation of PEG into the liposomes influenced the size of liposomes. The 
presence of PEG molecules at the surface of liposomes has been reported to cause 
disaggregation of liposome assemblies resulting in a gradual reduction of liposome size (Kaur 
et al., 2012). Polyethylene glycol components that are present on the liposome outer surface 
have a tendency to repel each other, which prevents liposomal aggregation during the 
preparation process resulting in the construction of smaller sized vesicles (Vermette and 
Meagher, 2003). Results show that at optimal lipid:DNA charge ratios (+/-), the liposomes in 
liposome:DNA complexes seemed more compressed than those liposomes not complexed to 
the pCMV-luc plasmid DNA (Figures 3.6.1-3.6.2). It is thought that the cationic lipoplexes 
fuse with the negatively charged plasma membrane (Kamiya et al., 2002; Duan et al., 2009) 
subsequently releasing the DNA in to the cytoplasm (Kamiya et al., 2002). 
 




All liposome vesicles used in this study showed spherical, unimodal, relatively 
narrow size distributions in the range of 50 –100 nm. However, no significant differences in 
sizes between untargeted and targeted liposomes were perceived in the transmission electron 
micrographs. Morphology and size distribution of all liposome and lipoplex particles were 
described using TEM. Additionally, size distribution, polydispersity and charge of the 
particles were also confirmed by zeta sizing and zeta potential parameters using the dynamic 





3.6.2. Band Shift Assay/ Gel Retardation Assay 
Band shift or gel retardation assay results of both cationic liposomes and PEGylated 
cationic liposome preparations are shown in Figures 3.7.1 ˗ 3.7.2. In all cases, increasing 
weight ratios of cationic liposomes calculated as per the nitrogen to phosphate proportions 
(N/P or +/-), together with a constant amount of plasmid DNA (pCMV-luc) (0.5 μg) were 
used for all the gel retardation assays.  
 
The purpose of this assay was to investigate the efficiency and effect of binding and 
interaction between the cationic liposomes and the DNA. The gel retardation assay is a 
commonly used method to evaluate the complex formation of DNA to a non-viral vector. 
DNA that is completely bound to the liposome would not travel into the agarose gel matrix, 
since the negative charges on the DNA are completely neutralized by the positive charges on 
liposomes. On the other hand, free DNA and DNA which is not fully complexed with 
cationic liposomes would easily travel in the gel towards the anode (positive charge). 
 
The results presented in Figures 3.7.1 - 3.7.2 show the binding of DNA (-ve charge) 
and the cationic or PEGylated cationic liposomes (+ve charge) as a result of charge 
neutralization. The naked DNA in lane 1, in the absence of liposome, appears as two bands. 
The bottom band is the supercoiled form of the DNA while the top band is the relaxed closed 
circular form. As can be seen in Figures 3.7.1-3.7.2, with the increased charge ratios (N/P), 
the migration of free DNA into the gel was reduced or retarded. The plasmid DNA which 
was completely bound to the cationic liposome via electrostatic interactions did not migrate 
from the wells and remained as deep intensely stained bands. At complete retardation it is 
said that the cationic liposome and DNA form complexes which do not migrate through the 
agarose gel matrix when subjected to electrophoresis, hence remain in the wells (Zuber et al., 
2003). These complexes (lipoplexes) are visualized in the wells due to staining the gel with 
ethidium bromide. Sometimes, the lipoplexes may precipitate in the wells causing them to 
float out of the wells thus avoiding the detection of DNA (Singh, 1998). The optimal 
retardation ratios of all six liposome formulations are indicated by white arrows on the gels 



































Figure 3.7.1: Gel retardation assays of MSO9. Untargeted A. PEGylated B. and targeted C. 
 liposomes were complexed with pCMV-luc at various charge ratios, and then run 
 through a 1% agarose gel. The mobility of pDNA was visualized by ethidium 
 bromide staining. The charge ratio of liposome:DNA was 1:1, 2:1, 3:1, 4:1, 5:1, 
 6:1and 7:1 (lanes  2, 3, 4, 5 , 6 and 7 respectively). Lane 1, 0.5 µg plasmid DNA.  The     



































Figure 3.7.2: Gel retardation assays of SGO4. Untargeted A. PEGylated B. and targeted C. 
 liposomes were complexed with pCMV-luc at various charge ratios, and then run 
 through a 1% agarose gel. The mobility of pDNA was visualized by ethidium bromide 
 staining. The charge ratio of liposome:DNA was 1:1, 2:1, 3:1, 4:1, 5:1, 6:1and 7:1 
 (lanes  2, 3, 4, 5 , 6 and 7 respectively). Lane 1, contained 0.5 µg plasmid DNA. The 





Agarose gel retardation results showed that all the liposomes were able to successfully 
bind the DNA and form lipoplexes. As can be seen from the results (Figure 3.7.1), a lower 
cationic liposome:DNA binding ratio was obtained with the PEGylated MSO9 liposome 
compared to the MSO9 untargeted and folate targeted liposomes. Complete retardations 
obtained for untargeted MSO9, PEGylated MSO9, folate targeted MSO9 cationic liposomes 
were at 6 µg, 4 µg, and 6 µg respectively with the pCMV-luc DNA kept constant (0.5 µg) to 
achieve these end point weight ratios. Charge ratios calculated (N/P) for these liposome 
formulations were 3:1, 2:1, and 3:1 respectively. From the results (Figure 3.7.1) it can be 
noticed that, with the increasing charge ratios the ability of the DNA to bind to the cationic 
liposome increased, thus providing the tight binding of the DNA in the complex. Cationic 
liposomes spontaneously interacted with the negatively charged DNA molecules by 
interaction between the cationic and anionic centers (on phosphate groups of the DNA) 
forming complexes in a self-assembling manner. When all the DNA negative charges are 
neutralized by the positive charges of the cationic liposome surface, the DNA is no longer 
able to migrate into the gel (Lungwitz et al., 2005; Mintzer and Simanek, 2009). As expected, 
a smaller charge ratio was obtained for the PEGylated MSO9 liposome due to the presence of 
the PEG molecule. The PEG coating can cause some adumbration of charge centres, as a 
consequence, the number of positive charges accessible for interaction with the DNA 
negative charges is reduced. 
 
A similar trend was observed with the SGO4 cationic liposome. However, there was 
no difference in charge ratios was noticed between the untargeted, PEGylated and folate 
targeted cationic liposomes. Interestingly, the amount of liposome (6 µg) to fully bind to the 
0.5µg plasmid DNA was the same for all liposome formulations (Figure 3.7.2). The charge 
ratio for all three SGO4 liposomes obtained was 3:1 (N/P) and this charge ratio was 
considered as the optimal end point ratio. Interestingly, the PEG component in the SGO4 
liposome formulation did not influence the charge ratio.  
 
Agarose gel retardation results were taken into account to develop the complexes for 
cell culture studies, such as cytotoxicity and transfection in the different cell lines. Therefore, 
along with the optimal end point charge ratio the infra, supra and optimal liposome:DNA 






3.6.3. Serum Nuclease Protection Assay 
DNA degradation by serum nucleases is one of the most important barriers faced by 
gene delivery vectors (Hashida et al., 1996). A desirable feature of any delivery vector is its 
ability to bind and protect the DNA from degradation by nucleases. The ability of the six 
liposomes prepared with cytofectins MSO9 and SGO4 to protect the DNA from enzymatic 
degradation was studied using the nuclease protection assay. The results obtained are 
presented in Figures 3.8.1-3.8.2. EDTA was added to the complexes to stop the action of the 
enzyme and sodium dodecyl sulphate (SDS) was used to release the bound DNA from the 
liposome:DNA complex. These complexes were then subjected to agarose gel electrophoresis 
where the unbound, negatively charged DNA will migrate into the gel during electrophoresis. 
Protection of DNA from nuclease digestion by cationic liposomes was confirmed by the 
appearance of undigested intense fluorescent bands seen in the agarose gel when compared to 
the naked plasmid DNA that was totally digested with the enzyme where no band was visible. 
 
Figure 3.8.1A shows the serum nuclease protection study on MSO9 untargeted (lanes 
3, 4, 5) and targeted (6, 7, 8) lipoplexes on agarose gels. Interaction of plasmid DNA with 
MSO9 liposome was analyzed by examining the fragmentation of uncomplexed or 
unprotected DNA as a result of the endonuclease activity of serum nucleases. As is evident 
from the results, uncomplexed or intact DNA was completely degraded by the nucleases (lane 
2). In contrast this confirmed the stability of the lipoplex bound plasmid DNA in the presence 
of serum nucleases (lanes 3-8). The detection of intense fluorescence appeared in lanes 3-8 
indicating the tight association between MSO9 untargeted and targeted liposomes and DNA. 
However, diffused fluorescence detected in the lanes 3-8 is attributed to the leaching of small 
amounts of DNA from the liposome particles or the partial DNA degradation by serum 
digestive enzymes. In contrast, the MSO9 liposome:DNA complexes were found to be able to 
partly protect the complexed DNA against serum nucleases as seen in (Figure 3.8.1A and B) 
where the supercoiled form of the plasmid DNA in lipoplexes had virtually disappeared. The 
predominant bands of MSO9 untargeted and targeted lipoplexes, in lanes 3 to 8 (Figure 
3.8.1A), could be due to nicking of the supercoiled DNA to the relaxed closed circular forms. 
From the results it seems that the PEGylated MSO9 liposomes provided greater plasmid 
protection than the untargeted and targeted liposomes (Figure 3.8.1B). Supercoiled and 
closed circular forms of the plasmid DNA are visible from the lanes 3 to 6 which suggest that 































Figure 3.8.1: Serum nuclease protection assay of MSO9 liposomes. Lipoplex stability at infra to 
 supra optimal N/P ratios were studied. A. MSO9 untargeted and targeted lipoplexes at 
 2:1, 3:1, 4:1 ratios (lanes 3, 4, 5 and lanes 6, 7, 8 respectively) B. MSO9 PEGylated 
 lipoplexes at 1:1, 2:1, 3:1, 4:1 ratios (lanes 3, 4, 5, 6). In both gels Lane 1 contained free 
 DNA (1 µg), and Lane 2 shows digested pCMV-luc in the absence of liposome. pCMV-





































Figure 3.8.2:  Serum nuclease protection assay of SGO4 liposomes. Lipoplex stability at infra to 
supra optimal N/P ratios were studied. A. SGO4 untargeted lipoplexes at 2:1, 3:1, 4:1, 
5:1 ratios (lanes 3, 4, 5 and 6) B. SGO4 PEGylated and targeted lipoplexes at 2:1, 3:1, 
4:1 ratios (lanes 3, 4, 5 and lanes 6, 7, 8 respectively). In both gels Lane 1 contains 
free DNA (1 µg), and Lane 2 digested pCMV-luc in the absence of liposome. pCMV-













Results presented in Figure 3.8.2 demonstrate that plasmid DNA in different SGO4 
lipoplexes tested at various ratios was protected partially from nuclease degradation. Figure 
3.8.2 shows the image of free plasmid DNA in the gel after the uncomplexation from SGO4 
liposomes in the presence of 10% serum. The high mobility band in lane 1 (Figure 3.8.2A) 
was attributed to the most compact (supercoiled) form, whereas the other bands were 
considered to contain the non-supercoiled content in the plasmid i.e. circular, linear. The loss 
of the supercoiled form due to nicking was detected for the PEGylated and targeted SGO4 
lipoplexes (Figure 3.8.2B, lanes 3 to 8) respectively. A significant amount of linear DNA is 
noticeable in the gel (Figure 3.8.2B) suggesting that the impact of nuclease attack to further 
degrade the plasmid in lipoplexes from relaxed closed circular to linear form. However, the 
supercoiled form is visible in the case of SGO4 untargeted lipoplexes (Figure 3.8.2A, lanes 3 
to 6). Hence, the results suggested that plasmid DNA complexed with SGO4 liposomes was 
more stable than the free or intact plasmid DNA in lane 2, which was completely degraded by 
nucleases present in the serum. The difference in the protective effects between the cationic 
liposomes studied could be due to the stability, and surface modification, such as the polymer 
coating of the liposomal membranes. 
 
The DNA protection efficacy was achieved by the introduction of liposome carriers 
and subsequent liposome:DNA complex formation. Although some plasmid DNA 
degradation in complexes occurred, it was nevertheless protected partly from nuclease attack 
through the complexation with the cationic MSO9 and SGO4 liposomes.  
 
3.6.4. Ethidium Bromide Intercalation Assay 
Ethidium bromide is an intercalating dye, which is used to study the level of DNA 
condensation. The higher the level of DNA condensation, the lower is the ethidium bromide 
uptake and therefore lower fluorescence intensity is detected. Electrostatic interaction 
between cationic liposomes and anionic DNA causes binding and compaction of 
liposome:DNA complexes. When ethidium bromide is added to a solution of DNA, it 
intercalates between the base pairs of the DNA double helix, emitting an intense 
fluorescence. This fluorescence quenched upon the formation of liposome:DNA complexes. 
In general, as the ratio of cationic lipid to DNA is increased, ethidium bromide fluorescence 
decreased, indicating that less DNA is accessible for ethidium bromide intercalation 




intensity with increasing lipid:DNA ratio were found to be markedly dependent on the 
concentration of ethidium bromide relative to DNA (Hongtao et al., 2006). 
 
Therefore, to assess the interaction of cationic liposomes with DNA, the fluorescence 
intensity of ethidium bromide for MSO9 and SGO4 lipoplexes as a function of the (cationic 
lipid:DNA) +/- charge ratio  was investigated by the addition of increasing amounts of 
liposome to a fixed amount of DNA and ethidium bromide in HBS. In this study, results 
revealed that all liposome formulations successfully displaced the ethidium bromide in the 
HBS-EtBr-DNA suspension and were capable of condensing the DNA. The liposome was 
added in 1 µL aliquots and the point at which the DNA is fully compacted to the liposome 
was established as the inflection point or plateau. Beyond this point, any further addition of 
















Figure 3.9.1: Ethidium bromide intercalation assay of MSO9 cationic, PEGylated cationic liposomes. 
 The incubation mixtures contained 100 μL (HBS), 1.2 μg pCMV-luc DNA. Increasing 
 amount of liposome in 1 µL aliquots (2.8 µg total lipid) was added to the wells 
 containing HBS-EtBr mixtures.  
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Figure 3.9.2: Ethidium bromide intercalation assay of SGO4 cationic, PEGylated cationic liposomes. 
 The incubation mixtures contained 100 μL (HBS), 1.2 μg pCMV-luc DNA. Increasing 
 amount of liposome in 1 µL aliquots (2.9 µg total lipid) was added to the wells 
 containing HBS-EtBr mixtures. 
  
The results represented in the Figure 3.9.1 showed, the gradual decrease in 
fluorescence with the increase in liposome concentration. UnPEGylated MSO9 liposome 
showed an overall fluorescence reduction or displacement of approximately 60%. PEGylated 
and folate targeted liposomes showed 55% and 45% of fluorescence reduction respectively. 
From the results (Figure 3.9.1), it can be noted that the relative fluorescence for the 
unPEGylated MSO9 liposome appeared slightly higher than that for the PEGylated MSO9 
liposome. However, folate targeted MSO9 (also PEGylated) liposomes showed a significant 
decrease of percentage fluorescence when compared to both the MSO9 unPEGylated and 
PEGylated cationic liposomes. The charge ratios (+/-) obtained from this study for MSO9 
unPEGylated, PEGylated and targeted liposomes were 2:1, 2.4:1 and 2.6:1 respectively. The 
quenching of the ethidium bromide fluorescence is due to plasmid DNA condensation by the 
liposomes causing displacement of the ethidium bromide. 
 






































The fluorescence pattern obtained for SGO4 liposomes seemed to be similar to that of 
the MSO9 liposomes. Ethidium displacement or fluorescence reduction percentage for 
untargeted SGO4 liposome was 70%. Approximately 55% fluorescence reduction was 
observed for PEGylated SGO4, and 50% for the folate targeted SGO4 liposome. From the 
results (Figure 3.9.2) it is clear that ethidium bromide dye displacement by the PEGylated 
liposome was reduced slightly compared to the unPEGylated SGO4 cationic liposome. This 
indicates a lower degree of DNA compaction or condensation and a more tenuous binding of 
DNA. In the case of folate targeted SGO4 liposome, it was found that a lower ethidium 
bromide access to DNA than the unPEGylated, PEGylated SGO4 liposome. It should be 
noted that the degree of compaction has a significant role in the overall transfection process. 
In order to be able to attain the best transfection results condensation of DNA in the 
liposome:DNA complex should not be too tight, as the eventual dissociation of the DNA 
from the liposome within the cell is a crucial aspect for successful transfection. However, on 
the other hand, a lower degree of DNA compaction may stimulate premature dissociation in 
the endosome followed by DNA degradation (Grigsby and Leong, 2010; Lechardeur et al., 
2005). Liposome(+):DNA(-) charge ratios obtained at endpoints in this study for SGO4 
untargeted, PEGylated and targeted liposome were 2.7:1, 2.3:1 and 2.4:1 respectively. 
 
 Ethidium bromide dye displacement results obtained are consistent with the agarose 
gel retardation assay results discussed in section 3.5.2. For both MSO9 and SGO4 the degree 
of condensation of DNA by the liposomes was highest in the untargeted lipoplexes, followed 
by the PEGylated and lastly the targeted liposomes. The PEGylated liposomes do show 
higher EtBr accessibility to pDNA, which could be ascribed to a reduction in pDNA 
condensation encouraged by PEG in the lipoplexes. Moreover, Zhang and co-workers (2010) 
suggested that PEGylation reduces the surface charge density of cationic liposomes and show 
a negative effect on nucleic acid binding affinity which may result in weaker pDNA binding 
compared to unPEGylated liposomes.   
 
3.6.5. Size Distribution of the Cationic Liposomes 
The ability of liposome:DNA complexes to enter into the cell via clathrin and 
caveolin-mediated endocytic pathways, which involve the development of coated vesicles 
and flask-shaped invaginations have been investigated and found to depend largely on 
particle size (Khalil et al., 2006). The sizes of liposomes and lipoplexes were measured by 




(Malvern Instrument). Lipoplexes at their optimal binding charge ratios (+/-) were considered 
for the sizing analysis. It can be seen from Table. 3.2 that the profile of the size variation 
appears markedly different for the various complexes studied.  
 
Table 3.2: Particle sizes of MSO9, SGO4 liposome and lipoplex assemblies investigated using zeta-
 sizer (Malvern zetasizer nanoseries). Lipoplex size measurements were done at the 
 optimal charge ratios established from the gel retardation assays.   
 
Formulation Liposome  Lipoplex 
 Mean 
diameter 













MSO9:DOPE 196 ± 2.17 0.22  3:1 695 ± 112.56 0.57 
MSO9:DOPE:2%PEG 121±  1.62 0.23  2:1 106 ± 0.46 0.21 
MSO9:DOPE:2%PEG:DSPEPEG2000FOL 168 ± 2.91 0.33  3:1 191± 11.63 0.47 
SGO4:DOPE 89 ± 0.84 0.19  3:1 1055 ± 166.2 0.64 
SGO4:DOPE:2%PEG 77 ± 0.58 0.17  3:1 195 ± 3.0 0.33 
SGO4:DOPE:2%PEG:DSPEPEG2000FOL 78 ± 0.83 0.21  3:1 147 ± 0.6 0.15 
 
Sizes obtained for untargeted, PEGylated, and folate targeted MSO9 liposomes were 
196 nm, 121 nm, and 168 nm respectively. A clear reduction in size was detected for the 
PEGylated liposomes. It was noted that the PEGylated liposomes appeared much smaller 
than untargeted liposomes (Table. 3.2). The incorporation of DSPE-PEG2000 seemed to 
reduce the particle size of cationic liposomes when compared to the unPEGylated liposomes. 
Yet again; a significant increase is observed for the sizes of PEGylated cationic liposomes 
upon the addition of the ligand, folic acid in the folate targeted liposome preparation (Table. 
3.2). The MSO9 untargeted liposome:DNA complex prepared at a 3:1 charge ratio had the 
largest size of (695) nm, compared to the MSO9 PEGylated, targeted lipoplexes which had 
sizes of 106 nm and, 191 nm respectively. This result suggests that large lipoplexes might 
form when the charge of lipoplex its neutralized, and the size of lipoplex could decrease 
when the charge of lipoplex increases from it’s neutralization point (Zhang et al., 2010). The 
larger liposomal particles tend to be rapidly taken up by the reticulo-endothelial system 
(RES) resulting in rapid clearance and a shorter half-life of the lipoplex. PEG is the structural 
component of lipid vesicles, which is responsible for steric stability. The size reduction 




inhibiting fusion of the liposomes (Kim et al., 2010). The phenomenon of instability in the 
liposome preparation results in an increase in particle size due to the aggregation of unstable 
liposomes during the preparation and/or upon storage. It is critical that liposomes have small 
and uniform sizes in order for them to be effective vectors (Yang et al., 2007). 
 
The mean diameters obtained for SGO4 untargeted, PEGylated and folate targeted 
liposomes were 89 nm, 77 nm and 78 nm, respectively. The hydrodynamic diameter of SGO4 
lipoplexes prepared in the absence or presence of PEG was 1055 nm, 195 nm and 147 nm 
respectively. A similar trend involving the decrease in size of liposomes and lipoplexes upon 
PEGylation was afforded. Lipoplex size is considered essential for influencing the entry 
pathway into the cell, although this may not have a direct correlation on the transfection 
efficiency (Gopal et al., 2011; Arangoa et al., 2003; Kim et al., 2010). Though the correlation 
of size with high transfection efficiency is widely debated (Dai et al., 2011), it is known that 
the size and heterogeneity of the lipoplex increases with increasing lipid to DNA charge ratio 
and depends on the condensing ability of monovalent lipids. 
 
For both MSO9 and SGO4 untargeted lipoplexes an abrupt increase in diameter was 
detected (695 nm, and 1055 nm respectively) at a predetermined charge ratio, however, the 
sizes of the other PEGylated lipoplexes were of the size that is generally found to be suitable 
for cellular uptake (100-200 nm) especially in vivo. Moreover, the poly dispersity index is an 
important parameter when assessing the homogeneity of colloidal dispersions such as 
liposomes, particularly for ensuring predictable therapeutic release prompted by a uniform 
surface area available for diffusion (Pereira- Lachataignerais et al., 2006; Wang et al., 2011). 
A polydispersity index (PDI) of 0.1 is indicative of monodispersity. A PDI >0.1 indicates that 
the liposomal population was polydisperse and heterogenous. In this study, PDI was between 
0.17 and 0.33, indicating that samples were polydisperse. SGO4 liposomes however were 














Figure 3.10: Particle sizing and zeta potential analysis using Dynamic Light Scattering technique 
 (DLS). A. Particle size and distribution is measured by passing a laser beam through 
 the sample. B. Surface charge (zeta potential) of particles in the sample is measured by 
 the moment and velocity of the particles. Adapted from Malvern Material 





3.6.6. Surface Charge of Cationic Liposomes using Zeta Potential Measurements 
The complexation induced by mixing the negatively charged polyelectrolyte DNA 
and the positively charged liposome was studied by means of zeta potential measurements to 
detect the electro neutral points of the liposome:DNA complexes. The presence of a positive 
charge is essential for pDNA:cationic liposome condensation. The charge neutralization point 
of the anionic DNA:cationic lipid complex is considered as one of the most fundamental 
parameters of  a lipoplex, being defined as the cationic lipid:DNA ratio at which the charge 
ratio of the lipoplex equals 1. In these conditions, positive charges of liposomes neutralize the 
negative charges of the DNA stoichiometrically. Theoretically, this charge neutralization 
point should be equal to 1, when the number of negative moles from DNA is equivalent to 
number of moles on the cationic liposome (Cuomo et al., 2012). Though, the glycocalyx in 
the outer cell membrane has a negative charge which is effective in the lipoplex uptake, it 
appears that there is no need for lipoplexes to carry positive charges to transport DNA into 
the cell cytoplasm (Cevher et al., 2012). In fact, the charge ratio value that corresponds to the 
electrostatic neutrality of the surface charge of the particle depends on various factors such as 
the hydrophobic forces on the nanoparticle surface which could play an important role and 
contribute to the charge of the ratio value at neutralization (Vijayanathan et al., 2002). 
 
As seen in Table. 3.3, the zeta potential achieved for the untargeted MSO9 cationic 
liposome was 24.07 mV while PEGylated and targeted liposomes gave values of 22.23 mV 
and 19.33 mV respectively. Here it appears that the zeta potential value for the liposomes was 
reduced when the polymer PEG was introduced in the formulation. This observation may be 
attributed to the PEG steric shield over the surface of the cationic liposomes which could 
partly shield the positive charge centres. Zeta potential established for their lipoplexes were 
8.07 mV, -3.37 mV and -14.31 mV respectively. A drastic decrease of surface charge in 
untargeted lipoplexes was noticeable (Table. 3.3). The comprehensive interaction of DNA 
molecules with the cationic charges present on the liposomal surface led to the complete 
charge neutralization of the DNA anionic forces by the liposome cationic forces. PEGylated 
MSO9 and targeted lipoplexes had negative zeta potential values at optimal charge ratios for 






Table 3.3: Zeta potential (surface charge) of MSO9, SGO4 liposome and lipoplex assemblies 
 investigated using zeta-sizer. Lipoplex size measurements were done at the optimal 












A positive zeta potential (surface charge) value of 36.07 mV was obtained for the 
untargeted SGO4 liposome. In contrast, it was seen that the zeta potential for PEGylated 
SGO4 sharply decreased approaching the surface charge neutralization point and thereafter 
reversed from positive to a negative value to -1.03 mV. The surface charge of the SGO4 
targeted liposome was also found to be negative with a value of -0.38 mV. It is important to 
note that the negative value attained for targeted SGO4 liposome was close to the electro 
neutral point and lower than that for the PEGylated SGO4 liposome, suggesting that 
incorporation of the targeting ligand did not seriously interfere with the charge, resulting in a 
slightly more negative zeta potential value. From the results obtained it can be said that the 
negative zeta potential values correspond to a population of cationic molecules, having the 
surface completely wrapped by the polyethylene glycol. Surface charge values attained for 
untargeted, PEGylated and targeted SGO4 lipoplexes were 1.91 mV, -1.79 mV, and -2.09 
mV respectively. As was seen with liposomes, a trend in decreased in zeta potential value 
from positive to negative was noted for SGO4 lipoplexes. A comparison between the zeta 
potential of untargeted SGO4 liposome and the lipoplexes suggests that the decreased surface 
charge of the lipoplex was due to the shielding effect of the cationic charges of the liposome 
with anionic charges of DNA as a consequence of electrostatic interaction. It is important to 
note that, in the case of the targeted SGO4 lipoplexes, a combination of factors; such as the 














MSO9:DOPE 24.07 3:1 8.07 
MSO9:DOPE:2%PEG 22.23 2:1 -3.37 
MSO9:DOPE:2%PEG:DSPEPEG2000FOL 19.33 3:1 -14.31 
SGO4:DOPE 36.07 3:1 1.91 
SGO4:DOPE:2%PEG -1.03 3:1 -1.79 




them a slight increase in the zeta potential value when compared to their liposome 
counterparts. These results are consistent with previous reports (Ghonaim et al., 2008). 
 
The general trend observed for both the MSO9 and SGO4 liposomes is a decrease in 
zeta potential value upon polyethylene glycol grafting onto the cationic surface of liposome. 
The zeta potential of all cationic liposomes was reduced by the addition of DSPE-PEG. 
 
3.7. Maintenance of Cell Lines 
HEK293, HeLa and KB cells were successfully maintained in complete culture 
medium (EMEM + foetal bovine serum (10%) + antibiotics) throughout the study. Figure 
3.11 shows the images upon successful cell propagation of cell lines utilized in this study. 
Cell growth initially was slow probably due to reconstitution after a long period of 
cryopreservation, but growth increased gradually over time. This increase in proliferation is 
most likely due to the increased levels of growth factor secretions by the dividing/growing 
cells. Once the cells reached the confluent stage, they were trypsinised and subcultured in 1:2 













Figure 3.11: Cells viewed under inverted microscope (100 X) at semi-confluent state. A. KB Cells 
 (human nasopharyngeal carcinoma), B. HEK293 (human embryonic kidney) cells and 






3.8. Cell Viability Assay 
The cytotoxicity of the cationic liposomes was evaluated using the MTT assay at 
charge ratios that encompass their infra and supra optimal retardation end points. The results 
were expressed as the percentage of cell viability with respect to a control corresponding to 
untreated cells. All the cationic formulations showed significantly lower cytotoxicity in the 
presence of 10% FBS. The cytotoxicity of the cationic assemblies was investigated using the 
HEK293, HeLa and KB cell lines. No appreciable cytotoxicity was observed; whilst over 
70% of cells were found to be viable in the presence of each cationic liposome at the charge 
ratios considered for the study. Cells not treated with liposome:DNA complexes were 






Figure 3.12: Diagrammatic representation (not drawn to scale) of MTT dye activity in mitochondria 
 by metabolically active cells. Mitochondrial reductase converts the MTT (yellow) 
 tetrazolium dye into MTT formazan (purple). The absorbance of this purple formazan 
















































Figure 3.13.1: In vitro growth inhibition assay of HEK293, HeLa and KB cells with plasmid DNA 
 complexed to MSO9 cationic liposomes. N/P ratios: A. MSO9 unPEGylated 
 lipoplexes from 2:1, 3:1, 4:1 (4, 6, 8 µg) B. MSO9 PEGylated lipoplexes from 1:1, 
 2:1, 3:1 (2, 4, 6 µg), C.  MSO9 targeted lipoplexes from 2:1, 3:1, 4:1 (4, 6, 8  µg). 
 Control: cells without  liposome or DNA treatment. Cell viability was  measured as 
















































































































Figure 3.13.2: In vitro growth inhibition assay of HEK293, HeLa and KB cells with plasmid DNA 
 complexed with SGO4 cationic liposomes. N/P ratios: A. SGO4 unPEGylated 
 lipoplexes from 2:1, 3:1, 4:1 (4, 6, 8 µg) B. SGO4 PEGylated lipoplexes from 2:1, 
 3:1, 4:1 (4, 6, 8 µg), C. SGO4 targeted lipoplexes from 2:1, 3:1, 4:1 (4, 6, 8  µg). 
 Control: cells  without liposome or DNA treatment were considered as the control. 
 Cell viability was measured as a percentage relative to untreated cells. The data 























































































The results from this assay clearly show that the MSO9 untargeted liposomes at the 
three charge ratios 2:1, 3:1 and 4:1 showed minimal toxicity with 75% to 95% cell viability 
in all three cell lines tested (Figure 3.13.1A). MSO9 PEGylated liposomes had a 75 to 90% 
cell viability rate at charge ratios of 1:1, 2:1 and 3:1 (Figure 3.13.1B). In the case of the 
targeted MSO9 liposomes 80% to 85% of the cells were viable (Figure 3.13.1C). It can be 
noted that HEK293, HeLa, KB cells treated with MSO9 untargeted and PEGylated liposomes 
were more than 75% viable, an indication that these cationic liposomes were relatively well 
tolerated by the cells. A reduction in cell viability was observed with MSO9 PEGylated 
liposomes. It can be seen that lower levels of cytotoxicity was established for the liposomes 
with shorter spacer units. Generally, the hydrophobicity of the lipids, on the liposomal 
surface, would be expected to affect the degree of cytotoxicity since the hydrophobic material 
can facilitate adherence to the cellular membranes by hydrophobic interaction (Obata et al., 
2009). 
 
Figure 3.13.2A-C shows the effects of SGO4 liposomes on cell viability in HEK293, 
HeLa and KB cells. The results show at least 70% to 90% average cell viability (Figure 
3.13.2A) for liposome:DNA complexes formulated with unPEGylated untargeted SGO4 
liposomes at charge ratios of 2:1 to 4:1. For PEGylated SGO4 lipoplexes, cell viability 
increased slightly at charge ratios 2:1, 3:1 for all cell lines, but dropped at charge ratio 4:1 
(Figure 3.13.2B). Cell viability remained high at 70 to 90% for the targeted SGO4 lipoplexes 
(Figure 3.13.2C) at charge ratios 2:1 to 4:1. Cationic lipids themselves have been shown to 
exhibit some cytotoxicity. It is, therefore, possible that the cytotoxicity exhibited by cationic 
liposome:DNA complexes was partly attributed to the effect of a combination of cationic 
lipids and the nucleic acid (Moghimi et al., 2005; Wu et al., 2007; Medvedeva et al., 2009). 
By contrast, no drastic reduction in cell viability was observed for the different liposome 
formulations. The toxicity of liposomes to cells may be related to the presence of different 
cationic compounds such as DOGS or DOSPA. After releasing plasmid DNA, the cationic 
compounds form aggregates with the cellular organelles which lead to cell death (Sarker et 









3.9.  Transfection 
Liposome:DNA complexes are generally taken up by the process of endocytosis and 
transported to the lysosomes, where the complexes are degraded. The DNA must be released 
from the endosome before degradation and enter the nucleus where transcription takes place 
(Ferrari et al., 2002; Hasegawa et al., 2002). Liposomal uptake is considered to be a critical 
rate-limiting step and has a strong influence on the transfection efficiency. The transfection 
efficiency of the different cationic lipoplexes (MSO9 and SGO4) was evaluated on three 
transformed cell lines; HEK293 (human embryonic kidney cell line), HeLa (human cervical 
carcinoma), and KB (human nasopharyngeal carcinoma) cell lines at different charge ratios 
(+/-) as mentioned in section 2.1.9. The gene expression efficiency was quantified by 
determining the luciferase activity after an incubation period of 48 h using a luciferase assay 





















Figure 3.14: Schematic illustration of luciferase assay system used to measure the transgene   




Lipoplexes prepared with MSO9 untargeted liposomes at a 4:1 charge ratio exhibited 
elevated transfection levels whilst lipoplexes at a 2:1 ratio exhibited weaker transfection in 
HeLa cells. For KB cells, untargeted MSO9 lipoplexes prepared and employed at the optimal 
ratio (3:1) had a peak gene expression activity at charge ratios of 4:1 and 2:1 respectively 
(Figure 3.15.1A). On the other hand, PEGylated MSO9 lipoplexes at a 2:1 charge ratio 
revealed an increase in transfection activity over those with the 1:1 and 3:1 charge ratios in 
HeLa cells. This finding suggests that favorable lipoplex size and zeta potential values 
offered the complexes better transfection conditions such as suitability for cellular entry with 
the size <150 nm in diameter (106 nm, Table. 3.2); and low negative zeta value -3.37 mV 
(Table. 3.3) which is important for fusion with cellular membrane. In the case of the KB 
cells, PEGylated lipoplexes with 4:1 and 3:1 ratios achieved almost the same transfection 
levels, while low transfection was measured with the 2:1 charge ratio (Figure 3.15.1B). This 
suggests that although DNA association in the lipoplexes is favourable at these charge ratios, 
any further increase in +/- charge ratio may not afford better transfection activities since the 
plasmid DNA binding in the lipoplex may be too tight. This tight packing may also result in 
poor DNA release in cell cytoplasm from the endosome.  
 
Figure 3.15.1C shows the transfection results obtained with MSO9 targeted 
lipoplexes. The transfection level in HeLa cells at a 2:1 charge ratio was greater than the 
transfection obtained at 3:1 and 4:1 charge ratios. The highest activity measured at a 2:1 ratio 
is in agreement with the EtBr displacement result, which also showed the complete plasmid 
DNA condensation by the liposome at this ratio. Transfection in KB cells by the FR-targeted 
liposomes continued to be dominant with the 3:1 optimal charge ratio similar to the 
untargeted assemblies. Luciferase gene expression activity attained by MSO9 targeted 
lipoplexes was 100 fold higher than the MSO9 untargeted lipoplexes and 10 fold higher when 
compared to the MSO9 untargeted PEGylated lipoplexes (Figure 3.15.1A-1C). These results 
suggest that the reason for the higher transfection efficiency of the MSO9 FR-targeted 
liposome when compared to their untargeted counterparts, is its binding to the folate receptor 
on the membrane via the attachment of folate ligand, and subsequent internalization of 
liposome:DNA complexes in the  endosomes, resulting in higher efficiency of translocation 
of the DNA into the nucleus. These results are consistent with the EtBr intercalation assay 





As can be seen in Figure 3.15.2A, gene expression activity of SGO4 unPEGylated 
liposomes in the HeLa cell line with a charge ratio of 4:1 was significantly higher than those 
at charge ratios of 3:1 and 2:1 (p ˂ 0.05) respectively. Gel retardation results showed that the 
complete binding of DNA to SGO4 untargeted liposome occurred at the charge ratio of 3:1 
(+/-). Therefore, it can be demonstrated that effective DNA binding to the liposome could 
effectively offer improved gene expression activity. However, there seems to be no direct 
correlation with the lipoplex size and transfection efficiency, since it was seen that the 
highest transfection was achieved for the larger of SGO4 untargeted lipoplexes (1055 nm). A 
large lipoplex may form when the charge of lipoplex is neutralized. The non-viral vectors 
producing larger particle sizes with nucleic acids were reportedly effective to protect the 
DNA from nuclease attack, thereby facilitating improved gene transfection (Almofti et al., 
2003). Mok and Cullis, (1997) reported that pDNA encapsulated in the stabilized lipid 
particles inhibited plasmid DNA degradation during intracellular delivery. High gene 
expression efficiency achieved for the same liposome composition in KB cells was at the 
lipid-to-DNA charge ratio of 2:1. Indeed, no significant reduction in gene expression levels 
was obtained with the other charge ratios of 3:1 and 4:1. Transfection activity in HEK293 
cells was found to be low compared to that of the HeLa and KB cell lines. Cationic lipids 
form a stable complex with the fusogenic co-lipid DOPE, which has been reported to have a 
high tendency to form an inverted hexagonal phase (HII) at acidic pH (Hafez et al., 2001). 
Formation of the HII phase by DOPE destabilizes the endosomes, resulting in efficient escape 
from lysosomal degradation and cytoplasmic release of DNA (Chun-Jung et al., 1990; 
Caracciolo et al., 2009).  
  
 In the case of PEGylated SGO4 liposomes (Figure 3.15.2B), maximum gene 
transfection activity in the HeLa cells were observed at a 2:1 (p<0.05) liposome:DNA charge 
ratio, thereafter a slight decrease was perceived for charge ratios 3:1 and 4:1 respectively. In 
the KB cell line, the highest transfection activity was obtained at a 3:1 charge ratio, whilst the 
lowest was achieved at a 2:1 charge ratio. The transfection efficiency of SGO4 PEGylated 
liposomes in both HeLa and KB cell lines was 10 fold greater than that of the untargeted 
SGO4 liposomal formulation which also displayed low activity at all charge ratios (Figure 
3.15.2A). PEG derived liposomes are widely used as long-circulating liposomes (van Vlerken 
et al., 2007) mainly for systemic delivery of nucleic acids. PEGylation enhances the stability 




phagocytic cells of the reticulo endothelial system (RES), therefore contributing to the high 
gene expression activity (Chaudhari et al., 2012; Torchilin, 2012). 
 
In contrast, PEGylated liposomes which are slightly negatively charged (Table. 3.3), 
have reduced clearance rate from the circulation and are able to localize in tumours via the 
enhanced permeability and retention (EPR) effect. Compared to electrostatic interactions, the 
EPR effect depends on extravasations, which is a relatively slow process. Kim et al., (2007) 
reported that PEGylated lipoplexes seemed to increase transfection efficiencies even in the 
presence of serum when compared to liposome mediated transfection methods that lack such 
surface attachments. Additionally, it is thought that PEG forms a steric barrier around the 
lipoplexes, which stifles clearance due to reduced macrophage uptake, which may allow the 
liposome to overcome aggregation problems through mutually repulsive interactions between 
the PEG molecules. These characteristics increase bioavailability, facilitating higher 
transfection efficiencies due to improved tissue distribution and larger available 
concentrations (Barry et al., 1999). 
 
Targeted gene delivery mediated by folate receptors can be evaluated and confirmed 
by comparing the transfection activities of FR-positive cell lines (HeLa, KB) with FR-
negative cell lines (HEK293) (Zhou et al., 2012; Lee et al., 2006). As shown in Figure 
3.15.2C, transfection levels were significantly enhanced for the SGO4 targeted-PEGylated 
lipoplexes (p ˂ 0.001) at all charge ratios and in all cell lines. It is interesting to note that the 
transfection pattern of targeted SGO4 lipoplexes is similar as that of the PEGylated-
untargeted SGO4 lipoplexes, nonetheless transfection activity in targeted lipoplexes was 
increased by 15 %. A charge ratio of 2:1 displayed the highest transfection activity in HeLa, 
followed by 3:1 and 4:1 respectively. High transfection levels seen in the KB cell line were 
obtained at charge ratios 3:1, 4:1 and 2:1 respectively. Gratton et al., (2008) indicated that 
particles with sizes around 150 nm can achieve high internalization levels in HeLa cells. In 
this study, enhanced gene expression levels were achieved in HeLa cells, with lipoplexes of 
approximately 150 nm in size. Transfection mediated by the SGO4 folate targeting lipoplex 
exhibited a 10 fold higher reporter gene activity in both HeLa and KB cell lines when 
compared to the SGO4 un-targeted liposomes (either unPEGylated untargeted or PEGylated 
SGO4 lipoplexes) (Figure 3.15.2A-C). Gene expression levels with the SGO4 targeted 


































Figure 3.15.1: In vitro transfection activity in HEK293, HeLa and KB cells with plasmid DNA 
 complexed with MSO9 cationic liposomes. A. MSO9 unPEGylated lipoplexes from 
 2:1, 3:1, 4:1 (4, 6, 8 µg) B. MSO9 PEGylated lipoplexes from 1:1, 2:1, 3:1 (2, 4, 6 
 µg), C. MSO9 targeted lipoplexes from 2:1, 3:1, 4:1 N/P ratios  (4, 6, 8 µg), 200 µM 
 excess  folate was used for competition study of folate targeted liposomes. C1: cells 
 without liposome or DNA treatment were considered as the control 1. C2: 
 cells treated in the absence of liposome and the presence of plasmid DNA was 
 considered as control 2. The data represent the means ± SD (n=3). Gene  expression
 activity was measured in RLU/mg protein. p< 0.05 was considered statistically 




















































































































































































































































































































Figure 3.15.2: In vitro transfection activity in HEK293, HeLa and KB cells with plasmid DNA 
 complexed withSGO4 cationic liposomes. A. SGO4 unPEGylated lipoplexes from 
 2:1, 3:1, 4:1 N/P ratios (4, 6, 8 µg) B. SGO4 PEGylated lipoplexes from 2:1, 3:1,  4:1 
 N/P ratios (4, 6, 8 µg), C. SGO4 targeted lipoplexes from 2:1, 3:1, 4:1 N/P ratios  
 (4, 6, 8  µg), 200 µM excess folate was used for competition study of folate 
 targeted liposomes. C1: cells without liposome or DNA treatment were  considered 
 as the control 1. C2: cells treated in the absence of liposome and the presence of 
 plasmid DNA was considered as control 2. The data represent the means ± SD 
 (n=3). Gene expression activity was measured in RLU/mg protein. p< 0.05 was 




-gene expression activity of SGO4 FR-targeted lipoplexes compared to that mediated by 
SGO4 untargeted or PEGylated lipoplexes can be explained by the differences in their 
binding and uptake in the cells. Indeed, the surface charge of the lipoplexes and the existence 
of folate can influence the interaction of the lipoplexes with the cell membrane. A net 
positive surface charge on the SGO4 untargeted lipoplexes (Table. 3.3) permits them to 
engage in electrostatic interactions with the negatively-charged cell membrane, thus 
promoting their internalization by the cells. Conversely, FR-targeted SGO4 lipoplexes 
prepared at the charge ratio of 3:1 (+/−) had a negative surface charge (Table. 3.3), indicating 
that the enhanced effect on binding and internalization of complexes in the cells is 
presumably attributed to the presence of the folic acid ligand, and not on the establishment of 
electrostatic interactions with the anionic cell membrane. As a result of these factors (binding 
and uptake), the surface charge of the lipoplexes and the existence or lack of the folate 
moiety, the SGO4 targeted lipoplexes showed higher transfection activity than that of the 
untargeted SGO4, PEGylated lipoplexes (Figure 3.15.2). The transfection enhancement by 
FA-targeted lipoplexes is not only attributed to the receptor mediated binding and uptake of 
the lipoplex but also depends on other factors such as, release of DNA from endosome and its 
translocation into the nucleus. Overall, in all cases (Figure 3.15.2A-C) SGO4 cationic 
liposomes showed the highest transfection activity in HeLa cells followed by KB cells and 
HEK293 cells. Decreased transfection activity was noted with targeted lipoplexes for 
HEK293, as was expected for this folate receptor negative cell line. 
 
Many strategies including receptor mediated endocytosis (Karmali and Chaudhuri, 
2007) and ligands for extra cellular matrices (Remy et al., 1995) have been designed to 
increase the endosomal uptake of the lipoplexes, thus achieving higher transfection levels. 
Success of such therapies based on nucleic acids as drugs critically depend on their delivery 
efficiency. Approaches to enhance delivery of lipoplexes to specific cell types commonly 
employ cell specific ligands as targeting molecules. A number of small molecules such as 
folic acid (Müller and Schibli, 2011), transferrin (Cardoso et al., 2009, Singh et al., 2006b), 
haloperidol (Mukherjee et al., 2005), hyaluronic acid (Park et al., 2010) and short peptides 
(Mäe et al., 2009) have been successfully utilized for targeted transfection. 
 
The results of this study indicate that both (MSO9 and SGO4) folate targeted 
liposomes had enhanced transfection activity compared to the non-targeted liposomes. The 




spacer arms (11, 13 spacer arms respectively). This simple structural variation had a minor 
impact on the overall transfection efficiency with a 10 fold greater transfection activity noted 
for liposomes prepared with MSO9 than those prepared with SGO4. Moreover, TEM and 
zeta sizing investigations (Table. 3.1 and 3.2 respectively) revealed that the relative size 
measurements for the liposomes and lipoplexes containing the cytofectins MSO9 and SGO4 
were not significantly affected as a result of the length of the spacer segment. Furthermore, a 
slight variation in charge ratios was observed for MSO9 and SGO4 lipoplexes for the gel 
retardation studies suggesting that these cytofectins show rather similar functionalities despite 
their structural difference. Therefore, it can be hypothesized from these findings that, the 
cationic liposome formulations (MSO9 and SGO4) grafted with a targeting ligand folate, 
mediated the efficient uptake of lipoplexes into the cells by means of the folate receptors. On 
the other hand, commercially available liposomes e.g. Lipofectamine 2000/3000, DOTAP, 
Fugene were not implemented for the purpose of comparision of transfection results obtained 
with the liposomes used in this study. This is because they are non-targeting, Turbofect  
(Naicker, 2014), FuGene 6 (Singh, 2006) and Lipofectamine  (Singh, 2005) were tested previously 
in our laboratory and showed very comparable results.  
 
3.10. Competition Assay 
In order to establish that the folate is indeed mediating the binding of the ligand 
functionalized stealth liposomes to FR-positive cells, cells were incubated with an excess of 
free folic acid (200 µM) for 20 min prior to incubating them with the liposome:DNA 
complexes as in section 2.2.11 for 48 h at 37 ºC. The FR-positive HeLa and KB cells were 
used to confirm and evaluate that the targeted lipoplexes entered the cell via folate receptor- 
mediated endocytosis. Cell-specific targeted liposomes may achieve better treatment results 
than non-targeted liposomes owing to the tumour cell specific endocytosis and the rate of 
therapeutic (DNA/drug) escape from the endosomes (Xiong et al., 2011). As reported, the 
folate receptor is over expressed in several types of human cancer, such as brain, kidney, 
lung, and breast. The FR ligand, folate (or folic acid), is a vitamin required for nucleotide 
biosynthesis and elsewhere in one carbon metabolism and is utilized in elevated levels to 
meet the needs of proliferating tumour cells (Wang et al., 2010). 
 
For MSO9 folate targeted lipoplexes, a decline in the transfection level was obtained 
for receptor positive HeLa and KB cells at all three charge ratios tested (2:1, 3:1, and 4:1) due 




(Figure 3.15.1C). The decline in transfection activity was highest in the HeLa cells (24%) 
compared to that of the KB cells (28%) in the targeted MSO9 liposomes. Similar results have 
been reported by Xiang et al., (2013) when excess folate molecules were used to compete for 
receptor binding on the cell surfaces. These results support the hypothesis that the targeted 
MSO9 lipoplexes were proficiently recognized by the folate receptors on the cell surface, 
which consecutively facilitated the receptor mediated endocytosis mechanism for the folate 
targeted components. Wang et al., (2010) also showed folate-conjugated nanoparticles were 
taken up selectively by mammalian cells via receptor mediated endocytosis pathway.  
 
As can be seen in Figure 3.15.2C, the luciferase gene expression was significantly 
higher (p< 0.05) in HeLa and KB cells when transfected with targeted SGO4 lipoplexes than 
when the complexes were transfected in the presence of excess/free folic acid. In Figure 
3.15.2C, it appeared that addition of the excess free folate inhibited the stealth liposomes 
from being bound to the folate receptor positive HeLa and KB cells. The transfection 
efficiency of targeted SGO4 lipoplexes in both HeLa and KB cells was extremely low in the 
presence of excess folate. The results obtained in this study suggest that free/excess folate can 
prevent cellular uptake of the lipoplexes by competitively binding to the folate receptors on 
the cell membrane. Therefore, it can be said that folate is mediating the binding of 
functionalized folate targeted lipoplexes to the receptor positive tumour cells. 
 
3.11. Flow Cytometry 
Intracellular uptake of optimized lipoplexes was quantitatively studied using flow 
cytometry. Figures 3.16.1-3.16.2 are the representative GFP fluorescence intensity 
histograms of FR-positive HeLa and KB cells transfected with MSO9 or SGO4 untargeted, 
PEGylated and targeted lipoplexes along with that of the untreated cells as control. Results 
revealed that all lipoplexes produced fluorescence signals. Therefore, the mean fluorescence 
intensities of different lipoplexes were compared in order to establish the lipoplexes 
efficiency in terms of transfection. The results suggested that in general, the fluorescence 
efficiency was higher in the folate targeted lipoplexes than those of the both types of 
untargeted lipoplexes (PEGylated or unPEGylated) in all cell lines which is in agreement 
with the transfection result obtained from the luciferase reporter gene assay.  
 
The GFP fluorescence intensities of MSO9 lipoplexes were significant in both HeLa 




in HeLa cells transfected with various MSO9 lipoplexes was as follows: PEGylated-targeted 
˃ PEGylated-untargeted ˃ untargeted-unPEGylated lipoplexes with the mean fluorescence 
intensity of 40354, 33172 and 32369 respectively. It is apparent from Figure. 3.16.1 that the 
cell uptake of targeted lipoplexes was higher compared to the untargeted lipoplexes. This 
enforces the idea of the targeted lipoplex being receptor dependent, which is not the case for 
untargeted lipoplexes as they lack the receptor specificity. In KB cells, the MSO9 lipoplexes 
showed moderate to stronger fluorescence signals depending on the type of formulation. GFP 
mean fluorescence intensities noted for the MSO9 untargeted, PEGylated and targeted 
lipoplexes were 29258, 31056, 32071 respectively. This result of increased fluorescence 
intensity of the targeted lipoplexes clearly points to the specificity and FR-mediated uptake. 
Glycosaminoglycans (GAGs) or mucopolysaccharides serve as the primary receptors of many 
viral vectors, polyplexes and lipoplexes serve as non-viral vectors (Payne et al., 2007). 
Generally, these early carrier-cell surface GAGs interactions were rather dependent on 
common surface physico-chemical properties of the complexes, markedly, for instance their 
surface charges. These early interactions promote the initial binding of the complexes and 
further cellular internalizations. Subsequent cell uptake (whether caveolin clathrin dependent 
or other pathways) can be improved in target cells by using specific ligands (for instance 
folate) through receptor mediated endocytosis (Russell-Jones et al., 2004; Darvishi et al., 
2013). Tang and co-workers (2014) noted the increased cell uptake efficiencies at increased 
FA densities in HeLa cells, and postulated that it may due to the FR-mediated internalization 
process (Tang et al., 2014). Thus, the results of this study demonstrate the main 
internalization mechanism of the MSO9 targeted lipoplex is reliable to a FR-facilitated 
endocytosis pathway, specific to FR-expressing cells such as HeLa and KB cells.  
 
 Figure. 3.16.2 shows the mean fluorescence intensities of SGO4 lipoplexes in HeLa 
(upper panel) and KB cells (lower panel). As illustrated in the figures, fluorescence 
intensities were significant for the SGO4 targeted lipoplexes in the FR-overexpressed HeLa 
and KB cells in comparison to SGO4 untargeted lipoplexes, irrespective whether they were 
PEGylated or unPEGylated. In the HeLa cells, the mean GFP fluorescence intensities of 
SGO4 lipoplexes were 35284, 37584, and 40678 respectively for untargeted-unPEGylated, 
untargeted-PEGylated and targeted lipoplexes respectively. In KB cells, uptake of lipoplexes 
by means of fluorescence intensity was respectively of 22959, 21407 and 24207 for the 




produced greater fluorescence intensity within the gated cell population area which remained 
constant for all liposome formulations. This is also supported by the luciferase assay result, 
and it can be reasonably concluded that the efficient gene delivery mediated by the FA-
targeted lipoplexes was a result from the synergistic effect of PEG improved transfection and 
the FR-targeted delivery. Literature has suggested that folate functionalized liposomal uptake 
will proceed by receptor-mediated endocytosis in FR-bearing tumour cells; more so, folate 
targeted liposomes have faster clearance compared to non-targeted liposomes probably due to 
direct liposome uptake via the liver FR (Gabizon et al., 2004). The fluorescence observed in 


















Figure 3.16.1: Quantitative cell uptake analysis of MSO9 complexes by flow cytometry. 
 Fluorescence intensities of untreated cells, untargeted, PEGylated and targeted 
 MSO9 lipoplexes respectively in HeLa (upper row images) and KB (lower row 
 images) cells. Results of the flow cytometry are shown in histograms with the X-
 axis indicating the mean fluorescence intensity and Y-axis indicating the cell count.  






























































































































































Figure 3.16.2: Quantitative cell uptake analysis of SGO4 complexes by flow cytometry. 
 Fluorescence intensities of untreated cells, untargeted, PEGylated and targeted 
 SGO4 lipoplexes respectively in HeLa (upper row images) and KB (lower row 
 images) cells. Results of the flow cytometry are shown in histograms with the X-
 axis indicating the mean fluorescence intensity and Y-axis indicating the cell count.  
HeLa 




























Figure 3.16.3: GFP fluorescence intensity of lipoplexes in HeLa and KB cells. Transfection of 
(A) MSO9 untargeted, PEGylated and targeted lipoplexes, and SGO4 (B) untargeted,           
PEGylated and targeted lipoplexes respectively  at ratios at optimum transfection            






 Figure 3.16.3 demonstrates the transfection efficiency of MSO9 and SGO4 lipoplexes 
in terms of percentage range. It can be seen clearly from the results that either MSO9 or 
SGO4 targeted lipoplexes indicated enhanced cell uptake when compared to the untargeted, 
unPEGylated lipoplexes which is in agreement with the flow cytometry histograms where the 
targeted lipoplexes exhibited broader fluorescence distribution.  
 
 At the optimal transfection ratios of the different MSO9 or SGO4 lipoplexes in each 
of two cell lines utilized for study, FA-functionalized lipoplexes displayed higher 
fluorescence intensity than the non-functionalized lipoplexes, corroborating the idea that the 
FA-lipoplexes are targeted to HeLa and KB cells via FR-mediated endocytosis. These results 
indicate that FA-targeted MSO9 or SGO4 liposomes can be used to target FR-positive 
tumour cells to deliver therapeutics of interest. The general transfection efficiency and FR-
specificity of these liposome formulations justifies their potential for in vivo use, where active 
targeting together with passive targeting would play a role in tissue accumulation, though the 










 Gene therapy exemplifies a pioneering approach for the treatment of certain human 
diseases, and is anticipated to have a great impact in the field of medicine in the future. 
Hence, for this purpose safe and effective gene delivery vectors need to be developed. Due to 
several draw backs associated with viral vectors with regards to safety, the non-viral vectors 
are emerging as alternatives for therapeutic applications. However, some non-viral vectors 
undesirably lack the functional complexity to overcome several barriers that impede 
successful gene transfer. Efforts to design the essential functionalities into non-viral vectors 
resulted in modest triumphs, revealing major limitations in our current understanding of non-
viral vectors (Zhang et al., 2012). Cationic vectors (polymers, liposomes etc) have been the 
subject of intensive investigations for researchers in recent years to understand the parameters 
governing the efficiency of transfection (Jean-Michel et al., 2014). The understanding of 
mechanisms, like formation of complexes to the intracellular delivery, has led to the design of 
a plethora of novel non-viral vector systems for gene therapy applications.  
 
  In the current study, cationic liposomes, targeted and untargeted (PEGylated and 
unPEGylated) were successfully formulated with mono-cationic head group containing 
cytofectins MSO9 and SGO4 and the fusogenic co-lipid DOPE through the thin film 
hydration-sonication method. The PEGylated and targeted liposomal formulations 
encompassed a constant amount of two mole percent amino-DSPE-PEG2000 to sustain the 
expedient properties of PEG. Morphological and physicochemical characterization of all the 
liposome preparations by cryo-TEM, and dynamic light scattering techniques revealed 
unilamellar, nano-scaled particles with liposomes appearing as sphere-shaped vesicles and 
lipoplexes as spherical knots. Size distribution as determined by cryo-TEM and dynamic light 
scattering were in unison. Successful lipoplex formation with pCMV-luc DNA was 
confirmed by agarose gel retardation studies, and ethidium bromide dye displacement assay 
which further confirmed the liposomal ability to condense the plasmid DNA. Furthermore, 
serum nuclease protection assays showed that the cationic liposomes partially protected the 
plasmid DNA within the lipoplexes from nuclease degradation. Zeta potential measurements 





 Complexes prepared with the MSO9 and SGO4 liposome formulations and pCMV-
luc DNA were shown to exhibit moderate cytotoxicity levels in HEK293, HeLa and KB cell 
lines at selected concentrations chosen for gene transfection studies. This luciferase reporter 
gene assay showed that transgene activity achieved with PEGylated cationic liposomes was 
tenfold higher than that obtained with the unPEGylated control liposomes for both MSO9 and 
SGO4 preparations in the HeLa, and KB cells. Further investigation is required to validate 
this increased gene expression efficiency by PEGylated liposomes and to establish optimum 
PEG concentrations to achieve even better transfection efficiencies.  
 
 The targeting aspect by the biological ligand, folic acid was successfully established 
to promote liposome-mediated DNA delivery into target tumour cells. Cationic liposomes 
formulated with the folate targeting ligand in this study were shown to specifically bind and 
interact with the folate receptor bearing tumour cells (HeLa and KB) and successfully 
increase the transfection efficiency by 100 fold compared to untargeted formulations. 
Furthermore, folate-tagged PEGylated liposomes in the presence of either MSO9 or SGO4 
cytofectins also showed higher transfection levels compared to their untargeted counterparts. 
Receptor-mediated transfection by targeted liposomes was confirmed using competition 
experiments with free folic acid, where the transfection activity decreased significantly, while 
flow cytometry revealed effective internalization of folate targeted lipoplexes. All these 
findings confirm cell-specific uptake of these targeted cationic liposomes via the receptor-
mediated endocytosis mechanism.  
 
 From the results obtained in this study we can propose that these novel liposomal 
suspensions have the potential to be promising clinical gene delivery vectors. Further 
optimization and investigation of the system in vivo is warranted, given the observed lipoplex 
stability, integrity of the cargo DNA, high folate receptor specification and favorable particle 
size for extravasation into tumour masses. Nonetheless, further derivatisation of the 
formulations may be needed to reduce non-specific uptake and increase gene expression 
efficiency. In summary, these novel targeted cationic liposome formulations were able to 
successfully bind and deliver plasmid DNA to tumour cells in vitro primarily via the process 
of folate receptor mediation. This type of tissue-specific targeting interaction may have broad 
implications for the development of efficient targeted gene delivery systems. Further studies 
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a b s t r a c t
Gene transfer using non-viral vectors is a promising approach for the safe delivery of nucleic acid
therapeutics. In this study, we investigate a lipid-based system for targeted gene delivery to malignant
cells overexpressing the folate receptor (FR). Cationic liposomes were formulated with and without the
targeting ligand folate conjugated to distearoylphosphatidyl ethanolamine polyethylene glycol 2000
(DSPE-PEG2000), the novel cytofectin 3b[N(N1,N1-dimethlaminopropylsuccinamidoethane)-carbam-
oyl]cholesterol (SGO4), which contains a 13 atom, 15 Å spacer element, and the helper lipid, dioleoyl-
phosphatidylethanolamine (DOPE). Physicochemical parameters of the liposomes and lipoplexes were
obtained by zeta sizing, zeta potential measurement and cryo-TEM. DNA-binding and protection capabil-
ities of liposomes were confirmed by gel retardation assays, EtBr intercalation and nuclease protection
assays. The complexes were assessed in an in vitro system for their effect on cell viability using the
MTT assay, and gene transfection activity using the luciferase assay in three cell lines; HEK293 (FR-neg-
ative), HeLa (FR+-positive), KB (FR++-positive). Low cytotoxicities were observed in all cell lines, while
transgene activity promoted by folate-tagged lipoplexes in FR-positive lines was tenfold greater than that
by untargeted constructs and cell entry by folate complexes was demonstrably by FR mediation. These
liposome formulations have the design capacity for in vivo application and may therefore be promising
candidates for further development.
 2014 Elsevier B.V. All rights reserved.
1. Introduction
Gene therapy is a treatment modality for many diseases with a
genetic origin. Thus, the delivery of the appropriate, therapeutic
gene (DNA) into the cells that will replace, repair or regulate the
defective gene that causes the disease is a key step in gene therapy.
DNA, however is a negatively charged polyanion and does not
easily traverse the negatively charged and hydrophobic cell mem-
brane. Consequently, gene delivery carriers (also called vectors or
vehicles) have been developed (Ward and Georgiou, 2011). Antitu-
mor drug delivery systems with nanometric dimensions have
received much attention due to their unique accumulation
behaviour at the tumour site. Various nanoparticulate carriers such
as liposomes, polymer conjugates, polymer micelles, and nanopar-
ticles are utilized for selective delivery of various anti-cancer drugs
to tumours in a passive targeting manner. However, a more effec-
tive and active targeting system is needed to enhance the uptake of
drugs using nanocarriers into cancerous cells at the tumour site
(Kawano and Maitani, 2011). This may be achieved by
ligand–receptor, antigen–antibody and other forms of molecular
recognition for site-specific delivery (Steichen et al., 2013). The
over-expression of receptors such as those for folate and transfer-
rin, by tumour cells, may be exploited for this purpose (Liechty and
Peppas, 2012). Non-viral vectors are generally cationic in nature.
They include cationic polymers such as polyethyleneimine (PEI)
and poly L-lysine (PLL), cationic peptides and cationic liposomes.
Recently, a liposomal preparation LPD (liposomes–protamine–
DNA) has shown transfection efficiency greater than that of
conventional liposome:DNA complexes (lipoplexes) (Tros de
Ilarduya et al., 2010). Physical properties such as size and zeta
potential play a critical role in determining their efficiency.
Selected modifications to these approaches that can produce safe,
efficient and targetable gene carriers are desirable. Although non-
viral vectors are less efficient than their viral counterparts, they
have the advantages of safety, simplicity of preparation and high
gene encapsulation capability (Nasiruddin, 2007).
Although cationic liposomal vectors mediate effective gene
transfer, tissue specific in vivo DNA delivery is still a major
challenge in gene therapy (Zhang et al., 2012; Jin et al., 2014). To
date, tissue-specific targeting of cationic liposomal DNA has been
accomplished by two distinct techniques. The first method
involves transfection of selected tissues, such as nasal epithelium,
arterial endothelium, lung or tumours by locally administering the
complexes within a defined region (Reddy et al., 2002; Alton,
2007). This method has proven to be a viable option for the clinical
http://dx.doi.org/10.1016/j.ejps.2014.04.012
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treatment of several diseases, including cystic fibrosis, and cancer.
A second method used to enhance the specificity of gene delivery is
by the coupling of cell-binding ligands, such as folic acid (FA),
transferrin or carbohydrates to liposomes for the purpose of com-
bining the intrinsic activities of lipids with the receptor-mediated
uptake properties of the attached ligand (Kamaly et al., 2012).
We have been interested in the use of FA as a targeting ligand to
deliver attached therapeutic and imaging agents to cancer cells
that over-express the folate receptors (Kukowska-Latallo et al.,
2005). Because FA-linked cargoes are efficiently bound and inter-
nalized by folate receptor-expressing cells, we have explored the
possibility of using FA to enhance cationic liposomal vector deliv-
ery to FR-enriched tumours (Reddy and Low, 2000). When FA is
linked via a carboxyl group to virtually any molecular construct
(e.g. a drug, imaging agent, proteins, virus, liposome, etc.), folate
receptor binding proceeds unhindered and folate-conjugate uptake
occurs via receptor-mediated endocytosis (Lu and Low, 2012). The
high affinity of folate for its receptors (1010 M), the small size of
FA, and the compatibility of FA with a variety of solvents and solu-
tion conditions also adds to the attractiveness of the targeting
ligand (Reddy and Low, 2000). It has been shown that folate-com-
bined nanoparticles concentrated in tumour cells and liver tissue
over four days longer after administering than non-targeted agents
(Kukowska-Latallo et al., 2005). The role of folate receptors in the
cellular transport of folate is not well understood, although a pot-
ocytosis (caveolin-coated endocytosis) model has been proposed.
After binding to receptors on the cell surface, folate conjugates
have been shown to traffic to endosomes (Lu and Low, 2012).
Recently, it has been reported that folate mediated delivery of drug
loaded nanoparticles can enable binding, promote uptake, and
exhibit increased cytotoxicity to cancer cells in vitro and in vivo
(Zhao et al., 2010). For in vitro applications, lipoplexes are usually
formed with excess positive charge (cationic moiety (+) to nucleo-
tide ()). However for gene transfer applications in vivo, lipoplexes
formed with excess positive or excess negative charge ratios have
been used (Xu et al., 1999). It has been shown that lipoplexes
adsorb a ‘protein corona’ in serum by low affinity and competitive
binding, which may promote the formation of large aggregates of
intact lipoplexes (Caracciolo et al., 2010). This, in turn may affect
the mode of cellular uptake in vitro. The possible effects on
in vivo applications are also far reaching as the nanoparticles per-
ceived by cells may differ considerably from the intended formula-
tion. However, the inclusion of polyethylene glycol (PEG) in
lipoplexes creates a steric hindrance, which greatly reduces protein
adsorption, opsonization and elimination by macrophages (Pozzi
et al., 2014).
The aim of this study was to formulate novel serum-tolerant
folate-decorated stealth lipoplexes for gene delivery to tumour cells
that overexpress the folate receptor. Thus a new cholesteryl cytofec-
tin featuring a 13 atom 15 Å spacer element separating the cationic
head group and the hydrophobic cholesteryl fused ring anchor
element was prepared to facilitate DNA interaction with PEGylated
liposomes displaying folate on the distal end of membrane tethered
polyethylene glycol 2000. Interactions were characterized by cryo
transmission electron microscopy (cryo-TEM), gel retardation and
ethidium displacement assays. Systems were further assessed for
cytotoxicity and transfection activity in folate receptor-positive
(HeLa, KB) and receptor-negative (HEK293) cell lines.
2. Materials and methods
2.1. Materials
Dioleoylphosphatidylethanolamine (DOPE), folic acid and
bicinchoninic acid (BCA) assay reagents were purchased from the
Sigma Chemical Company, St. Louis, USA. Distearoylphosphatidy-
lethanolamine poly(ethylene glycol) 2000 (DSPE-PEG2000) and
amino distearoylphosphatidylethanolamine poly(ethylene glycol)
2000 (DSPE-PEG2000NH2) were purchased from Avanti Polar Lipids,
Alabaster, USA. Cholesteryl chloroformate, 2-[4-(2-hydoxyethyl)-
1-piperazinyl] ethane sulphonic acid (HEPES), ethidium bromide
and silica gel 60F254 thin layer plates were purchased
from Merck, Damstadt, Germany. Cationic lipid, 3b[N(N1,N1-
dimethlaminopropylsuccinamidoethane)-carbamoyl]cholesterol
(SGO4) was synthesized as described below. Ultrapure DNA
grade agarose was purchased from Bio-Rad Laboratories, Rich-
mond, USA. pCMV-luc DNA was purchased from Plasmid Factory,
Bielefeld, Germany. HEK293 cells were supplied by the Univer-
sity of the Witwatersrand Medical School (South Africa). HeLa
cells were obtained from Highveld Biologicals (Pty) Ltd.
(Lyndhurst, South Africa). KB cells were provided by Professor
S.T. Chen, Institute of Biological Chemistry, Academia Sinica
(Taipei, Taiwan). Minimum Essential Medium (MEM) containing
Earle’s salts and L-glutamine, trypsin-versene and penicillin
(5000 units/ml)/streptomycin (5000 lg/ml) were purchased
from Lonza BioWhittaker, Walkersville, USA. The Luciferase
Assay kit was purchased from the Promega Corporation,
Madison, USA. All tissue culture plastic consumables were pur-
chased from Corning Incorporated, New York, USA. All other
reagents were of analytical grade. Milli-Q ultrapure 18 MX cm
water was used throughout.
2.2. Chemistry
2.2.1. Preparation of 3b[N(2-aminoethyl)-carbamoyl]cholesterol
(SGO1)
To a solution of ethylenediamine (2.25 g, 37.5 mmol) in dry
dichloromethane (40 ml) was added a solution of 2.0 g of choleste-
rylchloroformate (4.45 mmol) in dry CH2Cl2 (40 ml) drop wise over
5 min. After 48 h at room temperature the reaction mixture was
extracted with 3  150 ml H2O. The CH2Cl2 layer was dried over
anhydrous Na2SO4 and evaporated to a white powder. Thereafter,
the product was recrystallized from cyclohexane. Next, the product
was purified further by column chromatography on a silica gel 60
column (2.2  23 cm) equilibrated with chloroform (50 ml). Col-
umn elution was with CHCl3:MeOH:conc.NH4OH (95:4:1, v/v/v)
(100 ml) followed by CHCl3:MeOH:conc.NH4OH (90:10:1, v/v/v).
Product fractions were pooled and evaporated and the title com-
pound was obtained in crystalline form from cyclohexane. Yield:
67%; Mp: 168–170 C; 1H NMR (400 MHz, CDCl3): d 0.67 (s, 3H,
H-180), 0.86 (d, 6H, J = 7 Hz, overlapping 2 Hz, H-260, H-270), 0.91
(d, 3H, J = 6.5 Hz, H-210), 1.00 (s, 3H, H-190), 1.0–2.1 (m, 28H, cho-
lesteryl), 2.35 (m, 2H, H-40), 2.85 (m, 2H, H2NCH2), 3.25 (q, 2H,
J = 5.7 Hz, H2NCH2CH2), 4.49 (m, 1H, H-30), 5.37 (d, 1H, J = 4.9 Hz,
H-60) ppm. 13C NMR (100 MHz, CDCl3): 11.9 (C-180), 18.7 (C-210),
19.3 (C-190), 21.0 (C-110), 22.6 (C-260), 22.8 (C-270), 23.9 (C-230),
24.3 (C-150), 28.0, 28.2 (C-20, C-160, C-250 overlapping), 31.9 (C-70,
C-80 overlapping), 35.8 (C-200), 36.2 (C-220), 36.6 (C-1, C-100), 37.0
(C-10), 38.6 (C-240), 39.5, 39.7 (C-40, C-120), 42.3 (C-130), 50.0 (C-90),
56.2 (C-170), 56.7 (C-140), 74.4 (C-30), 122.5 (C-60), 156.5 (NHCOO),
139.8 (C-50). HR-MS (ESI-QTOF +ve): Anal. Calcd. for C30H53O2N2:
(M+H) 473.4113, Found 473.4290.
2.2.2. Preparation of 3b[N(hemisuccinamidoethane)-
carbamoyl]cholesterol (SGO2)
A solution of 3b[N(2-aminoethane)-carbamoyl]cholesterol
(237 mg, 0.5 mmol) in CH2Cl2 (5 ml) was added drop wise to a
solution of succinic anhydride (60 mg, 0.6 mmol) in pyridine
(1 ml). After 24 h a gel-like product was formed. A further aliquot
of succinic anhydride (60 mg, 0.6 mmol) was added and 1 ml of
DMF. A clear solution was obtained. After a further 24 h a
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quantitative yield of product was obtained. The product was
recrystallized from ethanol. Yield: 84%; Mp: 168–170 C; 1H NMR
(400 MHz, C5D5N): d 0.67 (s, 3H, H-180), 0.90 (d, 6H, J = 6.6 Hz, H-
260, H-270), 1.0–2.1 (m, 28H, cholesteryl), 2.56 (m, 2H, H-40), 2.85
(t, 2H, J = 6.9 Hz, H-2), 3.06 (t, 2H, J = 6.8 Hz, H-1), 3.68 (t, 2H,
J = 6.5 Hz, H-5), 3.74 (t, 2H, J = 5.5 Hz, H-6), 4.82 (m, 1H, H-30),
5.38 (bs, 1H, H-60). 13C NMR (100 MHz, C5D5N): 12.0 (C-180), 19.0
(C-210), 19.4 (C-190), 21.3 (C-110), 22.7 (C-270), 23.0 (C-260), 28.2,
28.5, 28.7 (C-20, C-160, C-250), 31.5 (C-5), 32.1, 32.2 (C-70, C-80),
36.1 (C-220), 36.5 (C-100), 36.8 (C-10), 39.2 (C-1), 39.7, 39.9 (C-40,
C-120), 42.5 (C-130), 50.3 (C-90), 56.4 (C-170), 56.8 (C-140), 74.1 (C-
30), 122.6 (C-6), 140.4 (C-5), 157.3 (NHCOO), 172.7 (C-4), 175.5
(C-7). HR-MS (ESI-QTOF +ve): Anal. Calcd. for C34H57N2O5 (M+H)
573.4273, Found 573.4338.
2.2.3. Preparation of 3b[N(N1,N1-
dimethlaminopropylsuccinamidoethane)-carbamoyl]cholesterol
(SGO4)
To a solution of 3b[N(hemisuccinamidoethane)-carbamoyl]cho-
lesterol (114 mg, 0.2 mmol) and N-hydroxysuccinamide (32 mg,
0.28 mmol) in pyridine (2 ml) was added a solution of dic-
yclohexylcarbodiamide (55 mg, 0.26 mmol) in pyridine (0.8 ml).
A catalytic amount of 4-dimethylaminopyridine (2.4 mg,
0.02 mmol) was also included in the reaction mixture. After 24 h,
3-dimethylaminopropylamine (51 mg, 0.5 mmol) was added to
the mixture which was stored in the dark at room temperature
for a further 24 h. Dicyclohexylurea crystals were removed by fil-
tration. The filtrate was concentrated and the product was purified
by silica gel 60 column (2.0  17.0 cm) chromatography. Equilibra-
tion and elution was with CHCl3:MeOH:conc.NH4OH (43:7:1).
Yield: 61%; Mp: 216–218 C; 1H NMR (400 MHz, CDCl3): d 0.68
(s, 3H, H-180), 0.86 (d, 6H, J = 6.7 Hz, overlapping 2 Hz, H-260, H-
270), 0.91 (d, 3H, J = 6.5 Hz, H-210), 1.00 (s, 3H, H-190), 1.00–2.21
(m, 27H, cholesteryl), 2.27 (s, 6H, H-13, H-14), 2.42 (t, 2H,
J = 6.3 Hz, H-4), 2.50 (s, 4H, H-6, H-7), 3.30–3.36 (m, 6H, H-1, H-
2, H-9), 4.48 (m, 1H, H-30), 5.37 (d, 1H, J = 4.9 Hz, H-60) ppm. 13C
NMR (100 MHz, CDCl3): 11.9 (C-180), 18.7 (C-210), 19.3 (C-190),
21.0 (C-110), 22.6 (C-260), 22.8 (C-270), 23.8 (C-230), 24.3 (C-150),
28.0, 28.2 (C-20, C-160, C-250 overlapping), 31.8 (C-10), 31.9 (C-70,
C-80 overlapping), 35.8 (C-50), 36.2 (C-220), 36.6 (C-1, C-100 overlap-
ping), 37.0 (C-10), 38.6 (C-240), 39.5, 39.7 (C-40, C-120), 42.3 (C-130,
C-9 overlapping), 45.2 (C-13, C-14 overlapping), 50.0 (C-90), 56.1
(C-170), 56.7 (C-140), 58.3 (C-11), 74.5 (C-30), 122.5 (C-60), 139.8
(C-50), 156.8 (NHCOO), 172.1 (C-7), 173.0 (C-4). HRMS (ESI-QTOF
+ve): Anal. Calcd. for C39H69N4O4 (M+H) 657.5324, Found
657.5516.
2.3. Synthesis of DSPE-PEG2000FOL
DSPE-PEG2000FOL was synthesized as reported previously
(Yoshida et al., 2006; Liu et al., 2011). Briefly, folic acid (100 mg,
0.226 mmol) was dissolved in 5 ml dimethyl sulfoxide (DMSO).
To this was added an equimolar amounts of N-hydroxysuccinimide
(NHS) (28.8 mg, 0.25 mmol) and dicyclohexylcarbodiimide (DCC)
(51.5 mg, 0.25 mmol). The reaction mixture was incubated over-
night at room temperature. The insoluble dicyclohexylurea (DCU)
was filtered off from the reaction mixture. To a DMSO solution
(44 ll) of the NHS ester of folic acid (NHS-FOL, 2 lmol) was added
DSPE-PEG2000NH2 (2.79 mg, 1 lmol). DMSO (40 ll) and pyridine
(40 ll) were added to the mixture, whereupon a clear solution
was obtained. The solution was left overnight and pyridine was
removed by rotary evaporation. Water (500 ll) was added to the
reaction mixture, which was then dialyzed (MW cut off 2000 Da)
against water (3  500 ml). The dialysate was centrifuged at
12,000 rpm (SANYO MSE) for 5 min at room temperature and the
supernatant was stored at 20 C before use. An aliquot of the
dialysate (30 ll) was diluted to 1000 ll with water and the absor-
bance at 280 was determined (Shimadzu UV-160A). Untargeted
PEGylated liposomes were used as a control. The concentration
of folate was calculated (e280 = 2.582  104 M1 cm1, Kranz
et al., 1995) and the loading onto DSPE-PEG2000NH2 was found to
be 95%. The synthesis of DSPE-PEG2000FOL and the absence of
DSPE-PEG2000NH2 (ninhydrin) was also confirmed by thin layer
chromatography (TLC) on silica gel 60F254 plates, which were
developed in CHCl3:MeOH:H2O (75:36:6 v/v/v) (Kang et al., 2013).
2.4. Preparation of cationic liposomes
Cationic liposomes and PEGylated cationic liposomes were pre-
pared with or without the conjugated lipid DSPE-PEG2000FOL and
DSPE-PEG2000 (Table 1) by a method adapted from Gao and
Huang (1991). Briefly, SGO4 (1 lmol) and the helper lipid DOPE
(1 lmol) were dissolved in chloroform (1 ml) and the solutes were
deposited as a thin film on the inner wall of a test tube by rotary
evaporation of the solvent in vacuo at 25 C (Buchii Rotavapor-R).
Residual chloroform was removed in Büchi-TO drying pistol drier
(200 mTorr, 30 C, 2 h). The dried lipid film was rehydrated over-
night at 4 C in a sterile solution containing 20 mM HEPES and
150 mM NaCl (pH 7.5, 0.5 ml). The resulting liposome dispersion
(4 mM total lipid, 2.9 mg lipid/ml) was briefly vortexed and soni-
cated for 5 min in a Transonic 460/H bath-type sonicator
(35 kHz) at 20 C. Liposome dispersions were routinely stored at
4 C for several months, without visible aggregation, until use.
2.5. Preparation of lipoplex
Lipoplexes were formed by the addition of pCMV-luc DNA
(0.5 lg) to various amounts of cationic liposome dispersions (1–
14 lg) and brought to a final volume of 10 ll with HEPES-buffered
saline (HBS) to achieve specific liposome (+)/pDNA () charge
ratios ranging from 1:1 to 7:1. Lipoplexes were incubated at room
temperature for 20 min prior to use.
2.6. Gel retardation assay
The gel retardation assay was performed to confirm the binding
of cationic liposome to pDNA (Duckett et al., 1996). Lipoplexes
were prepared as described above to achieve (+/) charge ratios
in the range 1:1–7:1. After addition of gel loading buffer (0.05%
bromophenol blue, 40% sucrose, 2 ll) to complexes samples were
subjected to electrophoresis (50 V) on a 1% agarose gel containing
ethidium bromide (EtBr) (1.5 lg/ml) in a buffer comprising 36 mM
Tris–HCl, 30 mM sodium phosphate and 10 mM EDTA (pH 7.5) for
90 min. Thereafter gels were viewed in a Syngene G-box under
transillumination at 300 nm, and images were captured with
GeneSnap software following exposure for 800 ms.
2.7. Serum nuclease digestion assay
For this assay liposome:DNA complexes containing 0.5 lg
pCMV-luc DNA from below to above end point retardation ratios
were incubated in HBS for 20 min at room temperature and there-
after foetal bovine serum (FBS) was added to a final concentration
of 10% (v/v). Samples were incubated for 4 h at 37 C, whereupon
EDTA and SDS were added to final concentrations of 10 mM and
0.5% (w/v) respectively. After a further incubation for 20 min at
55 C, the samples were analysed by electrophoresis on 1% agarose
gel containing ethidium bromide (1.5 lg/ml) and viewed as
described above.
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2.8. Ethidium bromide intercalation assay
Ethidium bromide (EtBr), a DNA-intercalating dye, was used to
examine the association of DNA with the cationic liposomes. Ini-
tially, 2 ll of EtBr solution (100 lg/ml) was added to 100 ll of
HBS in wells of a black 96-well plate and the fluorescence mea-
sured at 580 nm in a Glomax multi+ detector system (Promega)
(excitation wavelength 525 nm) was set to 0% relative fluores-
cence. Thereafter, 2.4 ll (1.2 lg) of pCMV-luc DNA was added to
the solution and the fluorescence reading was set to represent
100% relative fluorescence. Cationic liposome dispersions (1 ll)
(2.9 lg total lipid) were added stepwise to the pDNA-EtBr solution
and the fluorescence intensity after each addition was recorded.
Results are presented graphically as relative fluorescence versus
liposome concentration.
2.9. Cryo-transmission electron microscopy
The morphology and particle size distribution of the liposomes
and lipoplexes were examined using cryo transmission electron
microscopy (cryo-TEM). The cationic liposome dispersions were
diluted to a 1:20 ratio, and the lipoplexes diluted to 1:100 with
sterile HEPES buffered saline (HBS). A 1 ll droplet of the diluted
cationic liposome/lipoplex suspension was deposited on an elec-
tron microscopy carbon coated 400-mesh copper grid. To this,
was added 1 ll of 1% (w/v) uranyl acetate and the grid was allowed
to dry for 2 min. After removing the excess solution with a filter
paper the grid was kept under liquid nitrogen and then transferred
into a GATAN cryo-holder maintained at 170 C, which was then
introduced into the microscope for observation at 150 C. Images
were obtained under cryogenic conditions and at 100 kV using a
JEOL JEM1010 electron microscope (Tokyo, Japan). The micro-
graphs were generated by a MegaView III camera and SIS i-TEM
software facilitated measurements of liposomes on calibrated
images.
2.10. Size and zeta potential measurements
Liposome and lipoplex particle sizes, polydispersity and zeta
potential were measured in a Malvern Zetasizer Nanoseries (Mal-
vern Instrument). All measurements were carried out at 25 C.
The cell types chosen for Z-average measurement were DTS0012
(polystyrene disposable sizing cuvette), and DTS-1061 for zeta
potential measurements. Measurements were performed in
triplicate.
2.11. Cell culture
HEK293 (human embryonic kidney), HeLa (human cervical
carcinoma), and KB (human nasopharyngeal carcinoma) were
maintained in 25 cm2 flasks at 37 C under 5% CO2 in Minimum
Essential Medium (MEM). Cell culture medium was supplemented
with 10% (v/v) heat inactivated foetal bovine serum (FBS), penicil-
lin (100 units/ml), streptomycin (100 lg/ml), and L-glutamine
(4 mM) (Gibco BRL Life Technologies). Cells were split 1:3 every
4–5 days.
2.12. MTT cell viability assay
Cells were seeded at a density of 2.5  104 cells/well in 48-well
plates, and incubated at 37 C in a humidified 5% CO2 incubator for
24 h before treatment. Medium was then removed and the lipo-
some:pCMV-luc complexes (10 ll) containing 0.5 lg pCMV-luc
plasmid DNA were added to each well in a total volume of 0.3 ml
complete medium (with 10% FBS, streptomycin at 100 lg/ml, and
penicillin at 100 U/ml) and incubated for a further 48 h at 37 C.
After incubation, the medium was discarded and equal volumes
of (0.2 ml) fresh complete medium and 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide solution (MTT) (5 mg/ml
PBS) were added to the sample wells and incubated for an addi-
tional 4 h at 37 C. Thereafter, the MTT containing medium was
removed, and 0.2 ml of dimethylsulphoxide (DMSO) was added
to dissolve the formazan crystals produced by the cells. The absor-
bance was measured at 575 nm using a Mindray micro plate reader
(MR-96A). Cell viability was determined as the percentage relative
to the untreated control (100%). Experiments were performed in
triplicate and the results were calculated and expressed as the
mean ± standard deviation.
2.13. Transfection assay
HEK293, HeLa, and KB cells were seeded onto a 48-well plate at
a density of 2.5  104cells/well, in 300 ll complete medium
(MEM + 10% FBS + penicillin (100 units/ml), streptomycin
(100 lg/ml), and L-glutamine (4 mM) at 0.3 ml per well. After
24 h of growth in 5% CO2 at 37 C, the medium was replaced by
0.3 ml complete medium. Lipoplexes, which had been prepared
as described in Section 2.5, were prepared separately to cover a
range from below to above end point charge ratios (2:1–4:1) and
contained 0.5 lg pCMV-luc plasmid DNA in 10 ll HBS, were added
to wells. The plate was incubated for a further 48 h at 37 C in
humidified 5% CO2. In competition experiments free folate (final
concentration 200 lM) was introduced to cells 20 min before addi-
tion of lipoplexes. Thereafter, the cells were washed with phos-
phate buffered saline (PBS) (2  0.5 ml), followed by addition of
100 ll of cell culture lysis buffer (Promega) to each well (25 mM
Tris–phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM 1,2-diaminocy-
clohexane-N,N,N0,N0-tetraacetic acid, 10 % v/v glycerol, 1 % v/v Tri-
ton X-100). The level of luciferase gene expression in the lysates
was evaluated by measuring luminescence using a luminometer
(Glomax Multi+ Detector system). Protein content in lysates was
measured by the BCA Protein Assay reagent (Sigma) using bovine
serum albumin as the standard. The data are expressed as relative
light units (RLU) per milligram of total soluble cell protein. Two
controls were employed i.e. C1: untreated cells, C2: cells with free
DNA, without liposome. All experiments were carried out in
triplicate.
2.14. Statistics
Statistical analysis was performed using one way ANOVA and
Tukey’s Multiple Comparison Test to compare between groups.
Differences were considered statistically significant at p < 0.05.
3. Results and discussion
3.1. Synthesis of the cationic cholesterol derivative SGO4
Cholesterylchloroformate was treated with ethylenediamine
to afford 3b[N(2-aminoethyl)-carbamoyl]cholesterol (SGO1),
which was then succinylated (succinic anhydride/pyridine) to
give 3b[N(hemisuccinamidoethane)-carbamoyl]cholesterol (SGO2).
The hemisuccinate (SG02) was converted to 3b[N(N1,N1
-dimethlaminopropylsuccinamidoethane)-carbamoyl]cholesterol
(SGO4) by activation of the carboxyl function to its N-hydroxy-
succinimide ester followed by treatment with 3,3-dimethylamino-
propylamine (Fig. 1). All the synthesized compounds gave
satisfactory analyses for their proposed structures, which were con-
firmed on the basis of their spectral 1H NMR, 13C NMR, and HR-MS
spectral data (Supplementary Materials Figs. A.1a–c, A.2a–c and
A.3a–c) respectively.
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3.2. Synthesis of DSPE-PEG2000FOL for folate targeted liposome
The delivery of nanoparticles to cancer cells may be facilitated
by folate decoration, as many cancer cells overexpress the folate
receptor, which is rapidly internalized by receptor-mediated
endocytosis (Kularatne and Low, 2010; Xiong et al., 2011). Here
we have linked the ligand folate to DSPE-PEG2000NH2 for inclusion
in a cationic liposome formulation containing a novel cytofectin.
The key intermediate, NHS-folate, was prepared by activating the
carboxyl group on folic acid with N-hydroxysuccinamide (NHS)
according to previously reported methods using a dicyclohexylcar-
bodiimide coupling procedure (Yoshida et al., 2006; Liu et al.,
2011). The product obtained is a mixture of the c carboxylate
(80%) and a carboxylate (20%) esters (Lee and Low, 1994). It is
important to note that for folate to retain its receptor recognition,
it must be appended via the c carboxyl group (Bhattacharya et al.,
2008). The title compound DSPE-PEG2000FOL was obtained by the
reaction of the ester NHS-FOL with the distal amino function on
DSPE-PEG2000NH2 (Fig. 2). Covalent attachment of folate to PEG
was deemed to be advantageous as the ligand would not only be
prominently displayed, but the spacer, PEG2000 enjoys low cytotox-
icity (Ogris et al., 1998), water solubility (Lukyanov and Torchilin,
2004) and low immunogenicity (Tian-Lu et al., 2012). Moreover,
the presence of PEG to form a shell at the outside of the carrier pro-
vides functional end groups for the attachment of the targeting
ligand through a flexible tether. The attachment and stoichiometry
of the folate moiety in the compound were confirmed by UV spec-
troscopic analysis and TLC.
3.3. Zeta sizing
Particle size of non-viral vectors for gene delivery is a key
parameter to be considered in the development of new systems
with the capacity for in vivo application (Pathak et al., 2009;
Nishikawa and Huang, 2001). The extent of nanoparticle uptake
in vivo is variable and also dependent on the size, charge, rigidity,
and other physicochemical properties of the particles (Aranda
et al., 2013). Not only may particle size influence the mode of cel-
lular uptake, it also determines if vectors may successfully extrav-
asate and successfully negotiate the extracellular matrix to access
tumour masses. Particle sizes of complexes were measured by
dynamic light scattering in the absence and presence of the folate
ligand. Results presented in Table 1 show that for all three formu-
lations, liposomes were small and fell within a narrow size range
(78–89 nm) and were monodisperse (PDI < 0.21). Lipoplexes at
end point ratios, however varied in size. Targeted PEGylated
Fig. 1. Synthesis of cationic cholesterol derivative 3b[N(N1,N1-dimethlaminopropylsuccinamidoethane)-carbamoyl]cholesterol (SGO4).
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lipoplexes were the smallest (147 nm) with a low PDI value (0.15)
indicating a monodisperse population. Untargeted PEGylated lipo-
plexes were somewhat larger (195 nm) and more heterogeneous in
size distribution (PDI = 0.33). By contrast, untargeted, unPEGylated
lipoplexes were very large (1055 nm) and polydisperse
(PDI = 0.64). From the above it may be concluded that the steric
repulsion imparted by PEG moieties prevents lipoplex aggregation,
resulting in smaller, more uniform dispersions, while unPEGylated
lipoplexes, with low f potential, aggregate to form ill-defined lar-
ger assemblies (Table 1). Similar trends have been reported by
Zhang et al. (2010) with lipoplexes containing the cholesteryl cyto-
fectin DC-Chol. Targeted lipoplexes prepared in this study with a
mean diameter <200 nm are therefore able to exploit the enhanced
permeation and retention (EPR) effect for delivery of therapeutic
molecules to cancer cells (Malhi et al., 2012). While it has been
shown in vitro that an increase in lipoplex size to >1000 nm is asso-
ciated with improved transfection activity (Ross and Hui, 1999),
particles with diameters >200 nm are more readily cleared by the
reticuloendothelial system in vivo (Alexis et al., 2008). The ‘stealth’
aspect afforded by PEGylation and the associated size reduction
leads to improved pharmacokinetic properties of lipoplexes
(Kesharwani et al., 2012). However the polymer reduces fusion of
lipoplexes with endosomal membranes thereby negatively affect-
ing release of cargo nucleic acid from endosomes.
3.4. Zeta potential
Zeta potential is an indicator of the electric potential in the
interfacial double layer of nanoparticle:DNA complexes and is
affected by the charge density of the cationic moiety at the surface
of the liposomes (Nie et al., 2011). The interaction of cationic lipo-
somes with pDNA is dominated by the electrostatic interaction of
the polyanionic DNA and positively charged liposomal cytofectins
and hydrophobic interaction (Zuidam and Barenholz, 1997). The
positive charges on the surface of the complexes promote tight
binding of the nanoparticles to the negatively charged cellular
membrane, thereby facilitating their entry into the cells by endocy-
tosis (Morille et al., 2008). The charge neutralization point of the
anionic DNA:cationic lipid complex is considered as one of the
most fundamental parameters of a lipoplex, being defined as the
cationic lipid:DNA ratio at which the charge ratio of the lipoplex
equals 1. At this point, positive charges of liposomes neutralize
the negative charges of the DNA stoichiometrically (Cuomo et al.,
2012). It has been shown that positively charged lipoplexes may
also be taken up by cells using a temperature-dependent transport
mechanism, while negatively charged lipoplexes favour an energy
independent transport, which could be driven by lipid mixing
(Resina et al., 2009). The zeta potential of the unPEGylated untar-
geted liposomes in this study reflects a clear positive value, while
that of PEGylated liposomes, whether untargeted or targeted, was
close to zero (Table 1). This may be attributed, in part, to some
shielding of the cationic centres by PEG and the contribution of
negative charges on the appended folate moieties, which are
located closer to the slipping plane than the cationic centres
(Weijun et al., 2004). From the results obtained it may be con-
cluded that the small negative zeta potential values point to a pop-
ulation of cationic liposomes whose charge is substantially
adumbrated by membrane-embedded polyethylene glycol, which
has caused a shift of the slipping plane further away from the lipo-
some bilayer thus reducing the zeta potential (Kim et al., 2009).
While the surface potential on cationic liposomes is positive, the
zeta potential may be somewhat different as is seen in the PEGylat-
ed liposomes prepared in this investigation. Indeed PEGylation has
been shown to reduce zeta potential of cationic liposomes by as
much as 30 mV (Meyer et al., 1998; Zhang et al., 2010). The out-
ward extension of PEG2000 from the liposome bilayer substantially
Fig. 2. Synthesis of DSPE-PEG2000FOL.
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increases drag, thereby reducing the mobility of lipoplexes during
measurement of the electrokinetic (zeta) potential (Kim et al.,
2009), resulting in low readings. In a related study, the introduc-
tion of the folate ligand onto chitosan was shown to be accompa-
nied by a reduction in particle size and a decrease in zeta
potential (Fernandes et al., 2012).
3.5. Gel retardation assay
The ability of the liposomes to bind to DNA was assessed using a
gel retardation assay. The electrostatic interaction between the
cationic liposomes and plasmid DNA neutralizes the negative
charge of the phosphate groups on the DNA backbone, thus retard-
ing the DNA mobility in an electric field. To transport pDNA to
cells, the cationic liposome vectors should be able to complex
pDNA through electrostatic interaction. The partial or complete
charge neutralization of pDNA by the vector results in complete
retardation of pDNA and no migration toward the anode (Simoes
et al., 1999). Incomplete pDNA binding was noted at (+/) ratios
of 1:1, 2:1 (Fig. 3A–C, lanes 2 and 3). At lipoplex (+/) ratios >2,
migration of pDNA was completely prevented, indicating tight
complex formation between the liposome and pDNA. These results
are consistent with previous reports that employed agarose gel
electrophoresis to examine cationic lipid–pDNA binding (Simoes
et al., 1999) and lipopolylysine:DNA complexes (Eastman et al.,
1997).
3.6. Nuclease protection assay
Folate receptor-targeted liposomes in this study have been for-
mulated with PEG2000, anchored to the liposomal bilayer, by
attachment to DSPE. It has been established that PEGylation affords
lipoplexes protection from opsonization and elimination by the
reticuloendothelial system (RES) (Kuai et al., 2011). However, there
remains the possibility that the cargo DNA may not be sufficiently
protected from degradation by serum nucleases during its
extended period in circulation. Therefore, a serum nuclease diges-
tion assay was performed on the lipoplexes to examine the integ-
rity of liposome-bound pDNA after exposure to foetal calf serum
(10% v/v) for 4 h at 37 C. Results presented in (Fig. 4A) confirm
that the DNA underwent some nicking, as evidenced by the
increase in the closed circular form of the plasmid and associated
decline of the super helical species. The naked pDNA in lane 2
was however extensively degraded under the same incubation
conditions. These results demonstrate that the cationic liposomes
in this study have the potential to provide pDNA a high degree of
stability in a nuclease rich environment and therefore may be used
as non-viral vectors for transporting integral pDNA into the cells
(Schatzlein, 2001; Merdan et al., 2002).
3.7. Transmission electron microscopy
The liposome morphology was analyzed by cryo-TEM. At end
point charge ratios established from gel retardation assays, the lip-
osomes in complexes appeared more compacted than those in the
absence of pDNA (Fig. 5). The observed vesicle fusion, twisting and
wrapping on one another was due to the presence of nucleic acid
molecules that induced deformation of the original liposomes.
These findings are in accordance with those of Laura et al.
(2007). A few large aggregates observed in the liposome:DNA
ratios investigated, were probably due to aggregation caused dur-
ing sample preparation. Liposomes, which appeared as unilamellar
vesicles showed spherical, unimodal, relatively narrow size distri-
butions in the range of 50–100 nm, whilst lipoplexes ranged from
100 to 200 nm except for the untargeted-unPEGylated lipoplex
which had a size of approximately 1055 nm in diameter. Otherwise
no significant differences in sizes between targeted and untargeted
liposomes were seen in micrographs.
3.8. EtBr intercalation assay
The ethidium bromide assay was used to evaluate the extent to
which lipoplexes were able to condense and compact the DNA.
Ethidium bromide is a monovalent DNA-intercalating agent whose
fluorescence is dramatically enhanced upon binding to DNA and
quenched when displaced by higher affinity compounds or by con-
densation of the DNA structure (Duarte et al., 2011). Initially
charge neutralization is believed to occur, which is followed by
condensation of the nucleic acid (Geall and Blagbrough, 2000). It
is noted, in Fig. 6, that EtBr fluorescence decreased with increasing
(+/) charge ratio of lipoplexes, indicating that an increase in the
amount of cationic liposomes led to a higher degree of DNA con-
densation. Results presented in (Fig. 6) also show ethidium dis-
placement to be the greatest with untargeted, unPEGylated
liposomes indicating a higher degree of DNA condensation in the
corresponding lipoplexes than in the PEGylated-untargeted lipo-
plexes, whilst DNA in targeted-PEGylated complexes was least
condensed and more tenuously bound (least ethidium displace-
ment). At low grafting density, as is the case in this study, the
PEG chains assume a ‘mushroom’ regime, in which the the polymer
chains protrude 30–50 Å from the liposomal bilayer and do not
interact laterally (Barenholz, 2001). Furthermore the PEG polymer
chains provide ‘steric stabilization’ to liposomes by attracting a
water shell around them (Tirosh et al., 1998). This arrangement
may lead to a reduction in DNA compaction and more tenuous
A B C
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Fig. 3. Gel retardation assays. (A) untargeted, (B) untargeted PEGylated, and (C) targeted PEGylated liposomes. Cationic liposomes were complexed with pCMV-luc plasmid
DNA (0.5 lg) at various weight ratios to achieve the following (+/) charge ratios: 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1 (lanes 2, 3, 4, 5, 6, 7 and 8, respectively). Lane 1 contained
0.5 lg pDNA alone. White arrows indicate endpoint at which the pDNA was completely bound to cationic liposomes.
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binding of the nucleic acid (Narainpersad et al., 2012). Lipo-
some:DNA complex end point (+/) ratios determined for the
unPEGylated, PEGylated and targeted liposomes were 2.7:1, 2.3:1
and 2.4:1 respectively. Although a slight difference was noted




Fig. 4. Serum nuclease protection assay of SGO4 liposomes. Reaction mixtures (10 ll) contained pCMV-luc DNA lipoplex suspensions from below to above end point ratios
(2:1, 3:1, 4:1). Lane 1: naked plasmid DNA; lane 2: plasmid DNA with serum. (A) Lanes 3–6: untargeted-unPEGylated liposomes (4, 6, 8, 10 lg). (B) Lanes 3–5: untargeted-
PEGylated liposomes (4, 6, 8 lg); lanes 6–8: targeted-PEGylated liposomes (4, 6, 8 lg). All lanes contained 0.5 lg plasmid DNA.
Fig. 5. Transmission electron micrographs of liposomes and lipoplexes. (A) Untargeted-unPEGylated, (B) untargeted-PEGylated, (C) targeted-PEGylated liposomes and (D–F):
their respective lipoplexes. The scale bar indicates 200 nm except for (A) (100 nm).
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between these ratios and those obtained in retardation studies, it
can be said that the assays are in good agreement with each other
and corroborative.
3.9. Cell viability assay
Cell viability assays were performed using the MTT assay. All
lipoplexes were generally well tolerated in the HEK293, HeLa and
KB cell lines under transfection conditions. Good cell viability
was obtained, with higher than 75% viability noted (Fig. 7), inde-
pendent of the liposome formulation (targeted or untargeted)
and the cell line used.
3.10. Transfection assay
A reporter gene expression assay was used for evaluating the
in vitro gene delivery efficiency of SG04 lipoplexes in three human
transformed epithelial cell lines (HEK293, HeLa, KB) (Fig. 8A–C), in
the presence of 10% FBS, using the pCMV-luc plasmid vector
encoding the luciferase gene. The incorporation of DOPE into lipo-
somes improves the endosomal release of lipoplexes by promoting
the conversion of the lipoplex lamellar phase to an inverted hexag-
onal micellar arrangement (HII) at endosomal pH, which exposes
hydrophobic acyl chains that interfere with and destabilize endo-
somal bilayers. This, in turn, may contribute to efficient endosom-
olysis and intracellular trafficking of plasmid DNA (Morille et al.,
2008). After endosomal escape within target cells DNA complexes
are believed to fuse to the nuclear membrane followed by the
release of DNA in the nucleus (Kamiya et al., 2002). For the
unPEGylated liposomes, a linear increase in transfection activity
was obtained in HeLa cells with increasing (+/) ratio (2:1–4:1),
while a linear decrease in transfection levels was observed in KB
cells over the same range (Fig. 8A). By contrast the untargeted,
PEGylated liposomes gave the highest transfection activity in HeLa
cells at a (+/) ratio of 2:1 (Fig. 8B), whereas in KB cells peak activ-
ity was achieved at a ratio of 3:1. In a related study by Kim et al.
(2007), it was reported that PEGylated lipoplexes promoted higher
transfection efficiencies than their unPEGylated counterparts in
the presence of serum. In addition, PEGylated lipoplexes display
improved stabilities and longer circulation times in the blood. It
is thought that the PEG forms a steric barrier around the lipoplexes,
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Fig. 6. Ethidium bromide intercalation assay. Incubation mixtures in HBS (100 ll)
contained pCMV-luc plasmid DNA (1.2 lg) and increasing amounts of liposome



















Fig. 7. Cell viability studies on liposome-pCMV-luc plasmid DNA complexes in
HEK293, HeLa and KB cell lines. Incubation mixtures in complete medium (300 ll)
contained plasmid DNA (0.5 lg) complexed to liposomes at different (+/) charge
ratios as indicated. Control: untreated cells. Data are presented as means ± SD
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Fig. 8. Transfection studies of SGO4 cationic liposome:DNA complexes in HEK293,
HeLa and KB cells. Lipoplex mixtures contained 0.5 lg of plasmid DNA and varying
amounts of liposome dispersions to achieve (+/) ratios from below to above end
point ratios were incubated with cells in complete medium (300 ll). Competition
experiments with HeLa and KB cells included 200 lM folate. Luciferase activity is
expressed as RLU/mg protein. Control 1: untreated cells; Control 2: cells with naked
DNA. (A) Untargeted unPEGylated lipoplexes, (B) untargeted PEGylated lipoplexes,
(C) targeted PEGylated lipoplexes. Data are presented as means ± SD (n = 3). A
significant difference was noted in the presence of the competitor (p < 0.001).
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which stifles clearance due to reduced macrophage uptake (Daniel
and Godbey, 2011). PEGylation may also reduce the tendency of
lipoplexes to aggregate through steric repulsion between the PEG
chains. Gene delivery mediated by the folate receptor can be dem-
onstrated by comparing the transfection efficiency between FR-
positive and FR-negative cell lines (Elnakat and Ratnam, 2004;
Hattori and Maitani, 2005). As can be seen in Fig. 8C, transfection
levels attained by targeted-PEGylated lipoplexes for all charge
ratios in HeLa and KB cells in the presence of 10% (v/v) FBS were
an order of magnitude greater than those achieved by either
unPEGylated or PEGylated untargeted lipoplexes (p < 0.01). Nota-
bly, transfection levels obtained by all three lipoplex formulations
in the folate receptor-negative line HEK293 were low. Lipoplexes
formulated for this study have been assembled at (+/) ratios at,
and close to, the ratios that ensure complete binding of DNA by
the respective cationic liposome preparations (Fig. 3A–C). Conse-
quently f potentials of lipoplexes are close to zero (Table. 1) and
electrostatic interaction with the negatively charged plasma mem-
brane is therefore minimized. Under these conditions ligand–
receptor interaction was believed to be the dominant lipoplex–cell
interaction mechanism. During the course of this investigation
Urbiola et al. (2013) have independently shown that lipopolyplex-
es, ornamented non-covalently with folate, transfected HeLa and
B16-F10 cells efficiently in the presence of high levels of FBS. It
has been shown that the transfection potential of the multi-cat-
ionic cytofectin DOSPA, found in lipofectamine, is greatly reduced
in the presence of serum as there is significant competition
between anionic proteins and DNA. By contrast, rigid cholesteryl-
based monocationic cytofectins are less affected by the presence
of serum (Ghosh et al., 2000).
3.11. Competition assay
A competition assay was carried out to validate folate receptor-
mediated transfection of FR-targeted liposomes using the folate
receptor positive HeLa and KB cell lines. The results (Fig. 8C)
demonstrate that pre-treatment with free folate (200 lM) as a
competitor, essentially prevented folate-tagged lipoplexes from
binding to, and being transported into HeLa, KB cells (p < 0.001).
More particularly, transfection activities were reduced by 85%
and 70% respectively.
4. Conclusion
In summary, FA-tagged cationic liposomes containing the novel
cholesteryl cytofectin SGO4, which features a monocationic centre,
a 15 Å spacer and biodegradable amide and carbamate linkages,
displayed very favourable physicochemical and FR-targeting prop-
erties when assembled in DNA lipoplexes. The relatively hydro-
philic spacer element in SG04 is expected to provide improved,
more prominent, display of the cationic centre, which in PEGylated
liposomes is an important consideration due to the shielding effect
of the polymer. All lipoplex formulations exhibited low cytotoxic-
ity in the cell lines selected for this study. These findings suggest
that FR-targeted liposomes, which display the ligand folic acid at
the distal end of liposome-anchored PEG2000 are potentially useful
for delivery of DNA therapeutics. PEGylated lipoplex particles were
<200 nm in diameter, a characteristic which is necessary for whole
organism intravenous applications requiring extravasation of com-
plexes to reach target cells. In addition, we have shown that the
FR-targeted lipoplexes achieved high transfection levels in the
presence of serum and were specifically taken up by FR over-
expressing cells, overwhelmingly by FR-mediation. The results
obtained from this study suggest that, FR-targeted liposomes
containing SG04 might constitute a suitable candidate for future
clinical development of gene/drug delivery vectors. The results
obtained from this study may therefore provide a simple and
promising strategy for the design of efficient lipid-based delivery
systems for practical in vivo application.
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Abstract. Gene therapy is a promising strategy for the treatment of human diseases rooted in genetic 
disorders such as cancer. The success of gene therapy however depends on the efficient delivery of 
therapeutic genes into target cells in vitro and in vivo. Liposomes have shown the potential to be ligand-
conjugated and receptor targeted. Our aim is to develop and test a lipid-based system for efficient targeted 
gene delivery to the folate receptors that are overexpressed in a broad spectrum of malignant tumors viz. 
Hence it represents an attractive target for selective delivery of anticancer agents to folate receptor expressing 
tumors. Novel cationic liposomes were formulated with and without the targeting ligand, folate. Folate 
conjugated liposomes were prepapred using the cationic cholesterol derivative N,N-
dimethylaminopropylamidosuccinylcholesterylformyl-hydrazide (MSO9), the helper-lipid, 
dioleoylphosphatidylethanolamine (DOPE), and distearoylphophatidylethanolamine (DSPEPEG2000) which 
was conjugated to folate.DNA-binding and protection abilities of all liposomes have been confirmed by band 
shift assays, dye displacement assays, and nuclease protection assays. The complexes were evaluated in an in 
vitro system for cytoxicity using the MTT assay, and finally gene regulation using the luciferase reporter 
gene assay. Relatively low cytoxicitieswere observed and encouraging gene expression levels were noted. 
This research will have a significant impact in the targeting of genes or drugs to cancer cells in vivo. 
Keywords: Gene Therapy; Non-viral Vectors; Lipid Nanoparticles; Folate Receptor. 
1. Introduction 
Gene therapy involves the delivery of a specific gene (DNA) to the targeted cells thus combating the 
disease at the level of its origin. Successful Gene therapy relies on devising methods for efficient transport of 
nucleic acids through the cell membrane into the nucleus [1]. Targeted gene delivery systems have been used 
to increase the efficiency of drug/gene delivery to specific tissues as well as to optimize the minimum 
effective dose of the drug and its side effects. Cationic liposomes are good non-viral vectors, since they 
readily form complexes with DNA via electrostatic interactions [2]. Folic acid is involved in essential one 
carbon transfer reactions that are important in DNA synthesis and replication, cell division, growth and 
survival, particularly for rapidly dividing cells. Conjugates of folic acid can be taken up by cancer cells via 
receptor-mediated endocytosis, thus providing a mechanism for targeted delivery to FR+ cells [3]. 
2. Methods 
Cationic liposomes were prepared using the method [4], with or without the conjugated lipid DSPE-
PEG-FA. Briefly, MSO9 and the helper lipid DOPE were dissolved in CHCl3   and deposited as a thin film 
on the inner wall of the test tube by evaporation of the solvent in vacuo. The dried lipid film was rehydrated 
overnight at 4°C in a solution containing 20 mM HEPES and 150 mM NaCl (pH 7.5). The resulting 
liposome suspension was briefly vortexed and sonicated. Size and structure of cationic liposomes and 
lipoplexes were established by Zetasizing, and cryoTEM. Lipoplex formation and DNA protection abilities 
were studied by band shift, nuclease protection and ethidium bromide assays. Growth inhibition studies of 
the complexes were determined using the MTT assay and luciferase gene expression levels were assayed 
using the Luciferase Reporter gene assays (Promega) and expressed as RLU/mg protein. 
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3. Results and Discussion 
3.1. Gel retardation assay 
Agarose gel electrophoresis of cationic lipid:DNA complexes was used to assess the relative amounts of 
DNA that were free or incorporated into the complex as a function of the lipid:DNA ratio. DNA in a lipid 
complex did not migrate out of the well. This was most likely the result of the charge neutralization. The 
Fig.1 shows that the amount of uncomplexed, or free DNA decreased as the ratio of lipid:DNA was 
increased. 
 
Fig 1: Gel retardation assays. Cationic liposomes were complexed with pDNA at various weight ratios. The weight ratio 
of cationic lipid/pDNA (a, b, c) was 1:1, 2:1, 3:1, 4:1, 5:1, 6:1,7:1 (lanes 2, 3, 4, 5, 6, 7 and 8, respectively). Lane 1, 
0.5µg plasmid DNA only. 
3.2. Cytotoxicity assay 
For in vitro toxicity study cells (HeLa, HEK293) were incubated with three formulations (plain and PEG 
coated and folic acid conjugated liposomes) for 48 h in 48-well microtitre plates. Control cells were taken 
without formulations and incubated with medium. Cell viability assay was performed using MTT assay. 
Percent cell viability was determined using control as 100%. Results obtained were, the pegylated liposomes 
were slightly toxic to the cells as compared to plain and FA-targeted liposomes (see Fig.2). 
 
Fig 2: In vitro Growth inhibition studies of liposome:pCMV-luc DNA complexes in HEK293, HeLa cell lines. 
Incubation mixtures (10μL) contained 0.5μg of plasmid DNA. Varying amounts of liposome from its suboptimal to 
supraoptimal ratios were assayed.Control: untreated cells. Data are presented as means ± SD (n= 3). 
3.3. Zeta sizing 
The relevance of the parameter ‘particle size’ in gene delivery by non viral vectors is known. The 
particle size of the vector influences the internalization pathway of particles through the cell membrane. The 
preferred particle size would be 100-200 nm, in theory. This point is specially required for in vivo gene 




























measured by dynamic light scattering in the absence or presence of folate ligand and the folate modification 
did change the sizes of liposomes. The average particle sizes of cationic liposomes (MSO9) used in this 
study were 196 nm (untargeted), 121 nm (untargeted, pegylated), 168 nm (pegylated, targeted) (see Table 1). 
The reason for the smaller pegylated liposomes could be the repulsion feature of PEG molecules that prevent 
the liposomal aggregation. 




  Size (nm) PDI Size (nm) PDI 
MSO9:DOPE 3:1 196 0.22 695 0.57 
MSO9:DOPE:DSPEPEG 2000 2:1 121 0.23 106 0.21 
MSO9:DOPE:DSPEPEG 
2000:DSPEPEGFOL 
3:1 168 0.33 191 0.47 















Fig.3: Transfection studies of liposome-plasmid DNA complexes in HEK293 and HeLa cells in vitro. Incubation 
mixtures (10μL) contained 0.5μg of plasmid DNA. Varying amounts of liposome from slightly below to slightly above 
end pointratios were assayed. Luciferase activity is expressed as RLU/mg soluble protein. Control 1: untreated cells; 
Control 2: plasmid DNA alone. Data are presented as means ± SD (n= 3). 
In Fig.3, the folate:liposome:DNA complexes showed a two-fold increase in transfection activity 
compared to plain (without PEG or FA) liposomes and pegylated liposomes. This suggests that FA presence 
in liposome;DNA complexes facilitates the uptake of the FA-liposome:pDNA into the HeLa cells  via 
receptor mediation. Low transfection levels were achieved for HEK293 cells (receptor negative cells). 
Significant transfection levels for HeLa cells for FR-targeted liposomes were seen at their 3:1 (+/-) ratio or (6 
µg/0.5µg ). These findings also support the notion that the lipoplexes with the sizes range from 100-200 nm 
are suitable to traverse the cell membrane to reach the nucleus. Lipoplexes achieved high transfection levels 
falls in this range. 
4. Conclusions 
FR-targeted liposomes, synthesized using F-PEG-DSPE has been shown previously to effectively target 
FR-expressing tumor cells. It is further shown in this study that FR-targeted lipoplexes had poor cytotoxicity 
and this indicates that FR-targeted liposomes are potentially useful for delivery of therapeutic agents. In 
































taken up by FR over expressing cells. In summary, the cationic liposome (MSO9) containing FA ligand had 
good physical chemical and FR targeting properties. The results obtained from this study suggest that, FR-
targeted liposomes may constitute a better candidate for future clinical development of gene/drug in vivo. 
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